TARGETING THE METAL CHELATOR D-PENICILLAMINE TO EXPLOIT THE ELEVATED COPPER AND OXIDATIVE STRESS ASSOCIATED WITH CANCER by Gupte, Anshul
University of Kentucky 
UKnowledge 
University of Kentucky Doctoral Dissertations Graduate School 
2008 
TARGETING THE METAL CHELATOR D-PENICILLAMINE TO 
EXPLOIT THE ELEVATED COPPER AND OXIDATIVE STRESS 
ASSOCIATED WITH CANCER 
Anshul Gupte 
University of Kentucky 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Gupte, Anshul, "TARGETING THE METAL CHELATOR D-PENICILLAMINE TO EXPLOIT THE ELEVATED 
COPPER AND OXIDATIVE STRESS ASSOCIATED WITH CANCER" (2008). University of Kentucky Doctoral 
Dissertations. 598. 
https://uknowledge.uky.edu/gradschool_diss/598 
This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been 
accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
ABSTRACT OF DISSERTATION 
 
 
 
 
 
 
 
 
 
Anshul Gupte 
 
 
 
 
 
 
 
 
 
 
The Graduate School 
University of Kentucky 
2008 
TARGETING THE METAL CHELATOR D-PENICILLAMINE TO EXPLOIT THE 
ELEVATED COPPER AND OXIDATIVE STRESS ASSOCIATED WITH CANCER 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Pharmacy 
at the University of Kentucky 
 
By 
Anshul Gupte 
Lexington, Kentucky 
 
Co-Directors: Dr. Russell Mumper, Professor of Molecular Pharmaceutics, University of 
North Carolina at Chapel Hill, North Carolina and 
Dr. Michael Jay, Professor of Pharmaceutical Sciences, Lexington, Kentucky 
2008 
 
Copyright © Anshul Gupte 2008 
ABSTRACT OF DISSERTATION 
 
 
TARGETING THE METAL CHELATOR D-PENICILLAMINE TO EXPLOIT THE 
ELEVATED COPPER AND OXIDATIVE STRESS ASSOCIATED WITH CANCER 
 
The significantly increased copper and oxidative stress levels are characteristic 
hallmarks of cancer cells. These differences provide a unique opportunity for selective 
targeting of cancer cells. D-penicillamine (D-pen) has been proposed to generate reactive 
oxygen species (ROS) in presence of copper. Therefore, these studies were aimed at 
investigating the potential application of a currently marketed copper chelator, D-pen, as 
a novel cytotoxic anti-cancer agent.  
D-pen was shown to produce ROS, specifically hydrogen peroxide (H2O2), in the 
presence of cupric sulfate through a copper catalyzed oxidation reaction. During this 
process D-pen was converted to D-pen disulfide. The experimental proof of the H2O2 
generation was conclusively shown with the aid of a novel High Performance Liquid 
Chromatography (HPLC) assay.  
The in-vitro cytotoxicity of D-pen co-incubated with cupric sulfate was examined in 
human beast cancer (MCF-7 and BT474) and leukemia cells (HL-60, HL-60/VCR, and 
HL-60/ADR). D-pen was shown to cause concentration dependent cytotoxicity in both 
leukemia and breast cancer cells. A direct correlation between the detection of 
intracellular ROS and cytotoxicity was established. The treatment of D-pen plus cupric 
sulfate resulted in a significant reduction in the intracellular thiol content.  
D-pen is highly hydrophilic and is rapidly eliminated from the body; therefore to 
improve the intracellular uptake and to protect the thiol group of D-pen, we carried out 
the synthesis and the in-vitro characterization of a novel gelatin-D-pen conjugate. It was 
shown that D-pen alone does not enter cells. Confocal microscopy was employed to 
exhibit the uptake of the novel gelatin-D-pen conjugate by cancer cells.       
As the cancer cells in-vitro do not accumulate the same levels of copper as reported 
for cancer cells in-vivo, cancer cells were pre-treated with cupric sulfate to simulate the 
elevated copper levels. The cupric sulfate pretreatment resulted in reduced thiol level and 
significantly increased cellular copper content compared to untreated cells. Whereas both 
free D-pen and gelatin-D-pen conjugate lacked cytotoxicity in un-treated cells, both 
agents caused concentration dependent cytotoxicity in cupric sulfate pre-treated leukemia 
cells.  
Therefore, it was shown that the administration of D-pen as polymer conjugate 
would potentially provide cytotoxicity and specificity in the treatment of cancer.  
KEYWORDS: D-penicillamine (D-pen), Copper, Reactive Oxygen Species (ROS),  
                         Hydrogen Peroxide (H2O2), Cancer 
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Chapter 1 
 
 
Introduction and statement of problem 
 
 
As we gain better understanding of the factors affecting cancer etiology, we can 
design improved treatment strategies. Over the past three to four decades, there have been 
successful efforts in identifying several important cellular proteins which might be 
involved in cancer growth and hence numerous studies have investigated the targeting of 
these proteins as an anti-cancer strategy. However, studies have shown that targeting one 
or two proteins in the complex cancer cascade may not be sufficient in controlling and/or 
inhibiting cancer growth. Therefore, there is a need to develop ‘smart cancer treatment 
strategies’, which target multiple facets of cancer development.  
Angiogenesis is simply defined as ‘the development of new blood vessels’ [1]. 
While angiogenesis is a normal phenomenon in the body, tumors are known to employ 
this process for their benefit. Tumors can only grow to about 1 to 2 mm in diameter 
without recruiting blood vessels that supply essential nutrients [1]. Cells employ a 
number of endogenous angiogenic stimulators and inhibitors in the process of 
angiogenesis [1]. It is known that in a normal cell there exists a balance between the 
endogenous stimulators and inhibitors, and thus the process of angiogenesis is controlled 
[1]. Copper is an important trace metal needed for the normal physiological and 
biochemical functions in the body, by acting as a co-factor for many important enzymes 
[2, 3]. Copper has also been established to be an endogenous angiogenic stimulator, by 
acting as a co-factor for a number of important pro-angiogenic molecules such as 
Vascular Endothelial Growth Factor (VEGF), basic-Fibroblast Growth Factor (β-FGF), 
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and Angiogenin [4, 5]. Several in-vitro and in-vivo studies have shown that cancer cells 
in high copper environment find it easy to proliferate into a solid tumor [6, 7] and copper 
reduction has been shown to inactivate the functions of structurally diverse angiogenic 
factors, cytokines and prostaglandins [8].  
Both the serum and tumor copper levels have been shown to be elevated in a variety 
of malignancies, including both solid tumor and blood cancer [9-12]. Additionally, the 
copper levels have been shown to be directly correlated to cancer progression [13]. As 
copper has been established to be essential for angiogenesis, copper chelators such as D-
penicillamine (D-pen), tetrathiomolybdate, clioquinol, trientine have been extensively 
examined for their potential use as anti-angiogenic agents [8, 14-16].               
Reactive oxygen species (ROS) can be defined as a collective term that includes 
both oxygen radicals and non-radicals that are oxidizing agent and/or easily converted 
into radicals [17]. ROS has been implicated both in the etiology and the treatment of 
cancer [18]. ROS includes radicals such as superoxide (O2.-), hydroxyl (.OH) radical and 
non-radicals such as hydrogen peroxide (H2O2). Enhanced levels of intrinsic ROS stress 
has been shown in variety of tumors, possibly due to the combination of factors such as 
elevated active metabolism, mitochondrial mutation, cytokines, and inflammation [18, 
19]. The proof of elevated ROS stress in cancer cells has been shown directly with the 
measurements of the increase in ROS production in cancer cells compared to normal 
cells, and indirectly through the accumulation of oxidative products, and the 
overexpression of anti-oxidant enzymes (the consequences of adaptation to the excess 
ROS in cancer cells) [19]. Cellular proliferation, DNA damage, genetic instability, 
cellular injury, cell death, and alteration in drug sensitivity have been known to be 
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associated with the ROS stress in cancer cells [19]. Thus, the cancer cells under sustained 
ROS stress tend to heavily utilize adaptation mechanisms and may exhaust cellular ROS-
buffering capacity [20, 21]. The cellular protection against ROS includes antioxidant 
scavengers such as glutathione, ascorbate, thioredoxin and antioxidant enzymes such as 
superoxide dismutase, catalase, glutathione peroxidase, and thioredoxin reductase [22]. 
D-pen is a highly hydrophilic aminothiol. D-pen has been approved by the Food 
and Drug Administration (FDA) for over 40 years for the treatment of Wilson’s disease 
and Rheumatoid Arthritis. The use of D-pen in the treatment of the aforementioned 
disorders is based on its well known copper chelating ability; however, the exact 
mechanism of copper chelation (specifically its interaction with copper during copper 
chelation) is poorly understood. Additionally, Starkebaum et al. has previously proposed 
that H2O2 and other ROS are produced during the D-pen interaction with copper [23, 24]; 
however, the qualitative and quantitative experimental proof of ROS generation from D-
pen in the presence of copper still remains lacking and further investigation is warranted.  
Therefore, the present research was focused both on the proof of concept of the use 
of widely established copper chelator D-pen as a novel cytotoxic copper chelating anti-
cancer agent and on the investigation of the enhanced intracellular delivery of D-pen with 
the aid of novel delivery strategies including nanoparticles, immunoconjugates, and 
polymer-drug conjugates. These studies are of great potential significance since elevated 
copper levels in an assortment of malignancies have been clearly documented. Therefore, 
D-pen shown to produce ROS in the presence of copper then the ROS production from 
D-pen could be targeted to cancer cells. The use of D-pen in the treatment of cancer may 
potentially provide dual anti-cancer effects: 1) cytotoxic, through the copper catalyzed 
 3
ROS (H2O2) generation from D-pen and 2) anti-angiogenic, through the copper chelation. 
Several in-vitro studies were carried out to experimentally prove the quantitative H2O2 
generation as result of D-pen oxidation. Additionally, direct evidence of intracellular 
ROS generation was shown in human breast cancer and leukemia cells after treatment 
with D-pen in the presence of cupric sulfate. The cytotoxicity resulting from D-pen in the 
presence of cupric sulfate was compared with that caused by H2O2 alone.  
Further, to improve the inherent physicochemical properties of D-pen such as 
hydrophilicity, short in-vivo half-life, and the liability of spontaneous oxidation, a novel 
disulfide gelatin-D-pen conjugate was synthesized. In-vitro studies evaluating parameters 
such as release of D-pen in non-reducing/reducing conditions, qualitative and quantitative 
uptake, and cytotoxicity were conducted with the gelatin-D-pen conjugate. Given the 
significantly elevated copper levels in cancer patients compared to normal individuals 
these studies have important implications for the potential use of D-pen as a novel, 
selective and potent agent in cancer treatment.     
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Chapter 2 
 
 
Plan of research 
 
 
 
The overall goal of this research was to investigate the cytotoxic anti-cancer properties of 
the copper chelating agent, D-penicillamine (D-pen), through the generation of hydrogen 
peroxide (H2O2) and other reactive oxygen species (ROS) and to develop novel delivery 
strategies for enhancing its intracellular uptake in order to potentially improve its in-vivo 
therapeutic efficacy as an anti-cancer agent. This research was guided by four 
fundamental hypotheses: 
Hypothesis 1. Copper catalyzed D-pen oxidation will lead to the concentration dependent 
generation of H2O2.  
 
Hypothesis 2. H2O2 generated from D-pen in the presence of cupric sulfate will cause 
ROS stress in human cancer cells and result in cytotoxicity. 
 
Hypothesis 3. A novel polymer-D-pen conjugate could be synthesized and the conjugate 
would be able to deliver D-pen intracellularly and cause cytotoxicity in cancer cells.  
 
Hypothesis 4. Copper pre-treatment of human cancer cells in culture would simulate the 
elevated in-vivo copper status and augment the cytotoxicity of D-pen. 
 
To evaluate these hypotheses, the research plan described in sections 2.1 to 2.4 was 
carried out. 
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2.1  An in-vitro investigation into copper catalyzed D-pen oxidation and the  
          subsequent hydrogen peroxide (H2O2) generation 
The main objectives of this section were: 1) to develop a simple, sensitive and rapid 
high performance liquid chromatography (HPLC) assay to simultaneously detect and 
quantify D-pen, D-pen disulfide and H2O2 in a single run; 2) to provide experimental 
evidence that concentration dependent H2O2 is generated in-vitro as a result of copper 
catalyzed D-pen oxidation; and 3) to investigate the mechanism of copper catalyzed D-
pen oxidation and simultaneous H2O2 production as a function of time, concentration of 
cupric sulfate or ferric chloride, temperature, pH, anaerobic condition and chelators such 
as ethylenediaminetetraacetic acid (EDTA) and bathocuproinedisulfonic acid (BCS). The 
biological implications of cytotoxic H2O2 generation as a result of chelation of D-pen 
with copper was examined against MCF-7 cells, the human breast cancer cells and 
compared to the cytotoxic effects of D-pen, cupric sulfate and H2O2 alone. 
 
2.2 An in-vitro investigation of D-pen cytotoxicity in human breast cancer and 
leukemia cells as a result of intracellular reactive oxygen species generation 
          The main objectives of this section were: 1) to investigate the in-vitro cytotoxicity 
of D-pen in the presence and absence of cupric sulfate and/or catalase compared to H2O2 
alone in human breast cancer (HER2 positive vs. HER2 negative) and leukemia cells 
(wild type vs. anthracycline resistant cells); 2) to examine if the cytotoxicity of D-pen in 
the presence of cupric sulfate correlated to the in-vitro non-cell based molar ratio of D-
pen oxidized to H2O2 generated; 3) to investigate the intracellular H2O2, superoxide anion 
(O2.-), and total cellular thiol (glutathione) content as result of treatment with D-pen plus 
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cupric sulfate compared to H2O2 alone. Breast cancer cell lines differing in HER2 
expression: MCF-7 (HER2 negative) and BT474 (HER2 positive), and leukemia cell 
lines differing based on their anthracycline sensitivity: HL-60 (wild type), HL-60/VCR 
(P-gp) and HL-60/ADR (MRP-1) were used in these studies to ascertain differences in 
H2O2 and ROS cytotoxic effects. The cell viability was measured using 3-(4, 5-dimethyl-
2-yl)-2, 5-diphenylteraolium bromide (MTT) assay. 2’-7’-dichlorodihydrofluorescein 
diacetate (H2DCFDA) was used as an indicator of intracellular ROS generation. 
H2DCFDA is a cell permeable probe, it enters the cell and is deacetylated to a non-
fluorescent product, 2’-7’-dichlorodihydrofluorescein (H2DCF) by cellular esterases and 
is oxidized by ROS to a fluorescent product, 2’-7’-dichlorofluorescein (DCF). The 
intracellular reduced thiol levels were measured with 5, 5’-dithiobis-(2-nitrobenzoic acid) 
(DTNB). 
 
2.3 Enhanced intracellular delivery of the reactive oxygen species (ROS)-
generating copper chelator D-penicillamine via a novel gelatin-D-
penicillamine conjugate 
          The overall objectives of this study were: 1) to synthesize and characterize a novel 
bioactive disulfide gelatin-D-pen conjugate; 2) to synthesize fluorescein-gelatin 
(fluorescein labeled gelatin), fluorescein-gelatin-D-pen conjugate for cell uptake studies; 
3) to evaluate the biological reversibility of the disulfide bond between gelatin and D-pen 
through the in-vitro release of D-pen from the gelatin-D-pen conjugate in simulated 
physiological conditions in the presence of glutathione; 4) to perform the in-vitro 
intracellular uptake of fluorescein labeled conjugates in human leukemia cells (HL-60) 
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with confocal microscopy; 4) to evaluate the in-vitro cell cytotoxicity of the conjugate 
compared to D-pen, gelatin alone and a physical mixture of D-pen plus gelatin. D-pen 
was covalently coupled with a reversible disulfide bond to gelatin with the aid of a 
heterobifunctional cross linker, (N-Succinimidyl-3-(2-pyridyldithio)-propionate) (SPDP). 
Gelatin was coupled with SPDP through the amino group of gelatin and the amine-
reactive N-hydroxysuccinimide (NHS) ester of SPDP to form a stable amide bond. D-pen 
was then conjugated to the SPDP modified gelatin through thiol exchange with D-pen. 
Thus, D-pen was efficiently conjugated to gelatin with a potentially reversible disulfide 
bond. The conjugate was incubated at pH 6.2 (to simulate the early endosomal pH~5.5-
6.5) and pH 7.4 (to simulate the cytoplasmic pH~7.4) in the presence of various 
concentrations of glutathione for specific time to simulate intracellular release of D-pen 
from the conjugate. Gelatin-D-pen conjugate was fluorescently labeled to determine the 
intracellular uptake of the conjugate with the human leukemia cells. The cytotoxicity of 
the conjugate was evaluated in human leukemia cells and compared to gelatin, D-pen 
alone and also to a physical mixture of gelatin with D-pen.   
 
2.4 Copper pre-treatment of human leukemia cells augments the cytotoxicity 
resulting from D-penicillamine chelation of copper    
          The main objectives of this section were: 1) pre-treat cancer cells for pre-
determined time with various concentrations of cupric sulfate to increase the intracellular 
copper levels and simulate elevated in-vivo copper levels. 2) Assess the total cell number, 
viability, intracellular glutathione status and intracellular copper amounts after the cupric 
sulfate pre-treatment and compare these values to un-treated (naïve) cancer cells. 3) 
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Assess the in-vitro cytotoxicity of free D-pen and the novel gelatin-D-pen conjugate in 
naïve and copper pretreated cancer cells. Leukemia cells were used as model cell line for 
these studies. Cultured cells in-vitro do not accumulate the same levels of copper 
compared to cells in-vivo; therefore, cells were pre-treated with cupric sulfate. The total 
cell number, cellular thiol status, cellular protein status, intracellular copper content was 
analyzed after the copper pre-treatment. Additionally, the in-vitro cytotoxicity of a 
copper chelator, D-pen and novel gelatin-D-pen conjugate on the naïve and the cupric 
sulfate pre-treated cancer cells was investigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Anshul Gupte 2008 
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Chapter 3 
 
 
Background and significance 
 
 
3.1  Copper and cancer 
 
3.1.1 Copper 
  
 Copper (Cu) is an essential trace element that plays a central role in the 
biochemistry of every living organism [3]. In the body copper exists in both oxidation 
states, oxidized Cu(II) and reduced Cu(I) [2, 3]. The unique electronic structure of copper 
allows it to serve as a co-factor in redox reactions of enzymes that carry out fundamental 
biological functions required for normal growth and development such as cytochrome c 
oxidase (involved in the mitochondrial electron transport chain), lysyl oxidase (involved 
in the cross-linking of elastin and collagen), and superoxide dismutase (involved in the 
detoxification of reactive oxygen species (ROS)) [2]. A comprehensive list of the major 
copper dependent enzymes and their physiological functions is listed in Table 3.1.  
The recommended daily copper intake in healthy adults is 0.9 mg/day [25, 26]. The 
absorption of copper into the human body is a complicated process and depends on 
various factors and dietary components [27]. Copper is largely absorbed in the small 
intestine through the amino acid transporters, mainly containing methionine, histidine and 
cysteine. Copper absorbed in the intestine is transported to the liver bound primarily to 
serum albumin, and to some extent transcuprein [28]. During the process of cellular 
copper uptake, Cu(II) is reduced to Cu(I) and copper enters the cell through various 
transmembrane transporters such as human copper transporter (hCtr1), which belongs to 
the family of high affinity copper transporters [29, 30]. The intracellular transport of 
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copper is performed with the aid of either glutathione as the Cu(I)-Glutathione complex 
or a class of small cytosolic proteins known as copper chaperons such as antioxidant 
(Atox 1), cytochrome c oxidase (Cox 17) and copper chaperon for superoxide dismutase 
(CCS) [28, 29, 31, 32]. The Cu(I)-Glutathione complex serves as a vehicle for delivering 
copper to metallothioneins (MT), a family of proteins that serve the purpose of 
intracellular metal detoxification. In contrast, the copper chaperons shuttle the copper to 
specific compartments inside the cell [28, 33, 34]. Copper is mainly excreted via the 
biliary pathway (~80%) [33, 34]. 
Ceruloplasmin is the major copper carrying protein in human plasma and contains ≥ 
75% of total plasma copper [2, 35]. Albumin and transcuprein are known to carry the 
remaining plasma copper. The copper bound to these carriers has been reported to be the 
less tightly bound (exchangeable) copper [36, 37]. The concentration of free copper in 
human plasma is reported to be ~10-13 M [2]. The chemical properties which make 
copper biologically useful can also potentially lead to toxic effects, namely, copper 
induced oxidative stress. Therefore, the metabolism and compartmentalization of copper 
is a highly regulated process [3]. The complex mechanisms of copper transport and 
metabolism in order to maintain copper homeostasis are underscored by two inherited 
disorders, Wilson’s disease and Menke’s disease.    
Wilson’s disease is autosomal recessive disorder resulting from the mutation in the 
ATP7B gene [38, 39]. The Wilson’s protein is encoded by the ATP7B gene. The protein 
is homologous to the P-type ATPases and is predominately expressed in the liver and the 
brain [38]. Wilson’s disease results in copper accumulation mainly in the liver and brain 
causing in liver cirrhosis and neurological degeneration [38, 39]. A characteristic 
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hallmark of the neurological form of Wilson’s disease is the presence of ‘Kayser-
Fleischer ring’ which forms due to copper deposits in the cornea [38]. The clinical 
features of Wilson’s disease include decreased serum copper and ceruloplasmin levels 
and increased liver copper levels [3, 38, 40, 41]. The frequency of the disease has been 
estimated to be around 1 in 30,000 and the carrier frequency to be approximately 1 in 90 
[3]. The Long Evans Cinnamon rat and the toxic milk mouse have been used as the 
animal model to study Wilson’s disease [39]. The current clinical treatment of Wilson’s 
disease includes low copper diet and the use of copper chelators such as 
tetrathiomolybdate and D-pen [38, 39].   
Menke’s disease is an X-linked disorder resulting from the mutation in the ATP7A 
gene [3]. The Menke’s protein is encoded by the ATP7A gene. The Menke’s protein is 
more widely expressed throughout the body compared to its counterpart the Wilson’s 
protein [3, 42]. Menke’s disease is characterized by severe neurodegeneration, 
hypothermia and connective tissue abnormalities due to deficient copper-dependent 
enzyme activity [3, 36]. The clinical features of Menke’s disease include decreased serum 
copper, ceruloplasmin and liver copper levels [3, 36]. The frequency of the disease has 
been estimated to be around 1 in 300,000 [3]. The mottled mouse has been used as the 
animal model to study Menke’s disease [42, 43].          
Although copper is known to play an important functional role in the brain as a co-
factor of enzymes, it is also known to contribute to brain disorders such as Alzheimer’s 
disease and Parkinson’s disease. Alzheimer’s disease is a neurodegenerative disorder 
with no effective cure or treatment [44]. The distribution of copper has been reported to 
be severely altered in Alzheimer’s disease patients, copper levels are significantly 
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elevated (~400 µM) compared to healthy brain (~70 µM) [45, 46]. Additionally, the β-
amyloid protein, which has been proposed to be responsible for the formation of the 
damaging plaques in Alzheimer’s disease, is known to avidly bind copper [47-50].  
As discussed earlier, copper is highly regulated in the biological system. Excess 
copper has been known to be a potent oxidant causing the generation of ROS in the cells. 
The role of copper in both the etiology and growth of tumors has been extensively 
studied for the past two decades [4, 51-53]. This was based on reports that copper 
distribution was altered in studies of tumor bearing mice [54, 55], rats [54] and in humans 
[56-58]. Additionally, serum and tumor copper levels have been reported to be 
significantly elevated in cancer patients compared to healthy individuals [9, 59, 60].  
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Table 3.1 Copper-dependent enzymes in mammals. (Adapted from Tapiero [2]) 
 
Enzyme 
 
Function 
 
Cytochrome c-oxidase 
 
Cu/Zn-SOD 
 
Metallothioneins 
 
Ceruloplasmin (extracellular) 
 
Lysine-6-oxidase 
 
Tyrosinase 
 
Dopamine-β-monoxygenase 
 
Diamine oxidase 
 
Amine Oxidase 
 
Angiogenin 
 
Electron transport in mitochondria 
 
Free radical detoxification 
 
Storage of excess Cu 
 
Ferroxidase 
 
Cross-linking of collagen and elastin 
 
Formation of melanin 
 
Catecholamines production 
 
Inactivation of histamine 
 
Inactivation of histamine and dopamine 
 
Induction of blood vessel formation 
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3.1.1.a Ceruloplasmin  
 The protein ‘ceruloplasmin’ was first isolated from plasma and characterized as a 
copper containing protein by Holmberg and Laurell in 1948. Ceruloplasmin belongs to a 
family of multicopper oxidases [61]. This group of proteins is characterized by the 
presence of three types of spectroscopically distinct copper sites [35]. The structural 
model of human ceruloplasmin based on X-ray crystallographic data has confirmed the 
presence of three type I copper sites (charge transfer between copper and the sulfur in 
cysteine results in strong absorption at 600 nm conferring intense blue color to the 
protein), combined with the type II and III coppers it forms a trinuclear copper cluster 
that is the site of oxygen binding [35, 61]. Ceruloplasmin contains six integral copper 
atoms together with an additional (loosely bound) copper atom. This loosely bound 
copper atom has been suggested to be responsible for the pro-oxidant nature of 
ceruloplasmin [62-64].     
Ceruloplasmin is a 1046 amino acid serum glycoprotein normally synthesized in the 
liver [65]. The normal human plasma concentration of ceruloplasmin is between 18-35 
mg/dL [35]. Ceruloplasmin is a multifunctional protein; 1) It is involved in copper 
transport to various tissues and its subsequent incorporation in copper containing 
enzymes, 2) It has ferroxidase activity (based on its ability to oxidize Fe(II) to Fe(III) and 
its subsequent incorporation into transferrin, 3) It is involved in the oxidation of aromatic 
phenols and amines, and 4) It aids in the antioxidant defense as a result of the removal of 
superoxide anion [66]. Due to the above stated multifunctional aspect of ceruloplasmin, it 
has been suggested to be a ‘moonlighting’ protein. This implies that ceruloplasmin has 
the capacity to switch between functions in response to changes in the concentration of its 
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ligand/substrate, to be differentially localized and/or be differentially expressed [66]. This 
might be the reason for conflicting reports about anti-oxidant and pro-oxidant effect of 
ceruloplasmin in literature [35, 62-64].     
In Wilson’s disease, the levels of ceruloplasmin and plasma copper levels are 
reduced, despite the excess copper levels in various organs such as liver and brain [3, 40]. 
Aceruloplasminemia is an autosomal recessive disorder, which causes the lack of 
ceruloplasmin generation. The symptoms of aceruloplasminemia include dementia, 
dystonia, and retinal degeneration [35]. The absence of ceruloplasmin does not produce 
marked changes in copper metabolism; however this absence does affect iron levels. This 
is due to the previously mentioned ferroxidase activity of ceruloplasmin. Iron levels in 
the liver are gradually reduced leading to liver degeneration [35].  
The levels of ceruloplasmin have also shown to be elevated in various forms of 
cancers such as lymphoma [67], breast cancer [68], and gastrointestinal tract cancer [69]. 
Ceruloplasmin has also been proposed to be an endogenous angiogenic stimulator used 
by the cancer cells for development of new blood vessels [4].         
  
3.1.2 Copper levels in the serum and tumor tissue of cancer patients 
Several reports in the literature have shown that both serum and tumor copper levels 
in cancer patients are significantly elevated. A comprehensive literature review of copper 
levels reported in serum and tumor tissue of cancer patients compared to that in the 
healthy individuals is documented in Table 3.2 and 3.3, respectively. A major percentage 
of these studies have focused on determining the concentrations of four important 
elements; copper, zinc, iron and selenium. The studies showed that while the zinc, iron 
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and selenium concentrations where significantly lower in cancer patients, the copper 
concentrations were almost always found to be either elevated or significantly elevated 
(upto 2-3 fold) compared to age matched samples from normal tissue [9, 70]. 
Furthermore, it has also been shown that the Cu/Zn, Cu/Se and Cu/Fe ratios are almost 
always higher in malignant patients compared to normal individuals [9]. It should be 
noted that the elemental concentration in these studies were determined with highly 
specific and sensitive elemental techniques such as atomic absorption spectroscopy or X-
ray fluorescence (XRF).    
Additionally, these elevated copper levels documented in cancer patients have been 
reported i) in a wide spectrum of tumors including breast [9, 12, 59, 60], cervical [71], 
ovarian [71], lung [69, 72], prostate [73], stomach [10, 11, 69, 74], reticulo-endothelial 
system [75] and leukemia [70, 76], ii) in different age groups of patients (10-50 and >50 
years), iii) in both gender (male and female) [75, 77], iv) patients in different 
geographical location (Asia, Europe, and Americas) [9, 59, 60, 70, 72, 78], and most 
striking  v) to correlate with cancer stage and/or progression. [9, 72, 79].  
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Table 3.2 Copper levels in serum of cancer patients  
 
 
 Cancer 
 
Healthy 
(µg/dL ± SD) 
 
Patients 
(µg/dL ± SD) 
Number 
of subjects 
(significance 
compared 
to control) 
Carpentieri  
et al. 1986 
[76] 
Acute 
lymphocytic 
leukemia 
 
114 ± 29 
 
 
328 ± 74 
 
21  
(p<0.01) 
Huang et al. 
1999 [12] Breast cancer 115 ± 20 131 ± 20 
35  
(p<0.01) 
Chan et al. 
1993 [71] Cervical 92.9 129.3 
19  
(p<0.001) 
Chan et al. 
1993 [71] Ovarian 92.9 139.5 
4  
(p<0.001) 
Cohen et al. 
1994 [80] 
Non-hodgkin’s 
lymphoma 120.4 ± 23.3 
134.9 ± 42.4  
(Stage I) 
176.1 ± 66.3  
(Stage II) 
176.9 ± 37.5  
(Stage III) 
157.7 ± 49.6  
(Stage IV) 
 
Yucel et al. 
1982 [60] Breast cancer 122.4 ± 15.8 
222.7 ± 44.4  
(Stage I) 
203.9 ± 31.3  
(Stage II) 
238.1 ± 36.8  
(Stage III) 
228.4 ± 38.0 (Total) 
35 
Diez et al. 
1989 [72] Lung cancer 100  ± 18.2 
125 ± 20.2  
(Stage I and II) 
150 ± 33.8  
(Stage III) 
65 
(p<0.001) 
Habib et al. 
1980 [73] Prostate cancer 84.1 ± 6.27 124 ± 8.3 
44 
(p<0.01) 
Rajput et al. 
1975 [75] 
 
Reticulo-
endothelial 
system 
115.8 ± 13.9 
(males) 
118.9 ± 17.1 
(females) 
228.0 ± 52.4  
(males) 
225.4 ± 61.8 
(females) 
 
70 
(p<0.001) 
 
Scanni et al. 
1977 [69] 
 
 
1) Lung cancer 
 
143.0 ± 3.2 
 
188.2 ± 14.8 (Lung) 
 
 
20 (p<0.01) 
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2) Stomach 
cancer 
3) Large intestine 
171.9 ± 7.3 
(Stomach) 
164.7 ± 13.4  
(Large intestine) 
33 (p<0.01) 
 
22 (p<0.05) 
Gupta et al. 
1993 [81] Colorectal cancer 98.8 ± 24.3 165 ± 33.9 30 (p<0.001)
Zuo et al. 
2006 [70] Leukemia 86.7 ± 25.3 
132.8 ± 50.6 
(acute leukemia) 
129.1 ± 49.8 
(acute lymphoid 
leukemia) 
139.9 ± 51.2 
(acute nonlymphoid 
leukemia) 
109.2 ± 45.4 
(chronic 
myelogeneous 
leukemia) 
41  
(p<0.01)   
 
 
7  
(p<0.01) 
      
34 
 (p<0.001) 
 
8  
(p<0.05) 
Jayadeep et 
al. 1997 [77] 
 
1) Oral 
leukoplakia 
 
2) Squamous cell 
carcinoma 
 
66.9 ± 22.0 
(male) 
 
66.8 ± 14.0 
(female) 
1) Oral leukoplakia 
89.6 ± 19.0 (male) 
95.2 ± 17.0 (female) 
2) Oral cancer 
108.9 ± 17.0 (male) 
107.8 ± 12.0 
(female) 
21 
25 (p<0.001) 
 
22 (p<0.001) 
20 (p<0.001)
Lightman et 
al. 1986 [79] Ovarian cancer 
133 ± 17.0 
(Benign, 
n = 42) 
160 ± 17.0 (Stage I) 
190 ± 6.0 (Stage II) 
179 ± 18.0  
(Stage III) 
210 ± 23.0  
(Stage IV) 
2 
4 
19  
(p<0.001) 
11 
 
Kuo et al. 
2002 [9] Breast cancer 
 
96.5 ± 7.3 
(control)  
n=26 
 
103.8 ± 8.3 
(Benign) 
n=43 
 
125.2 ± 15.0 
 
25 (p<0.01) 
Sharma et al. 
1994 [59] Breast cancer 100.7 ± 40.5 172.8 ± 12.2 50 (p<0.01) 
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Table 3.3 Copper levels in the tumor tissue of cancer patients  
 
 
 Cancer Healthy (µg/g ± SD) 
Patients 
(µg/g ± SD) 
Number 
of subjects 
(significance 
compared to 
control) 
Kuo et al. 2002 [9] Breast cancer 
6.13 ± 4.32 
(normal) 
 
6.51 ± 5.33 
(benign) 
11.08 ± 4.98 
(Stage I) 
10.10 ± 5.61 
(Stage II) 
17.18 ± 11.83 
(Stage III) 
 
 
25 
Rizk et al. 1984 
[82] Breast cancer 9.3 ± 2.3 21.0 ± 10.7 
22  
(p<0.0001) 
Yaman et al. 2007 
[74] 
Ovarian 
cancer 0.2-0.9 0.4-2.8 10 
Gupta et al. 1991 
[81] 
Colorectal 
cancer 1.79 ± 0.57 2.78 ± 0.84 
30  
(p<0.001) 
Santoliquido et al. 
1976 [83] Breast cancer 2.38 3.25 20 
Geraki et al. 2002 
[84] Breast cancer 
0.29 ± 0.29 
Ppm 
0.89 ± 0.56 
ppm 40 
 
 
 
 
Margalioth et al. 
1983 [11] 
Large bowel 
Stomach 
Ovarian 
Breast 
Kidney 
Bladder 
Testis 
Hodgkin’s 
Total cases 
1.53 ± 0.35 
1.44 ± 0.38 
1.26 ± 0.45 
1.58 ± 0.62 
1.80 ± 0.42 
1.54 
1.48 ± 0.7 
1.42 ± 0.44 
1.42 ± 0.44 
1.90 ± 0.6 
2.09 ± 0.52 
2.16 ± 0.63 
1.91 ± 0.56 
1.61 ± 0.25 
2.80 ± 0.3 
1.43 
3.18 
2.08 ± 0.76 
24 (p<0.05) 
7 (p<0.02) 
5 (p<0.01) 
8 
3 
2 
1 
1 
53 (p<0.001) 
Mulay et al. 1971 
[85] Breast cancer 1.47 ppm 5.12 ppm 
15  
(p<0.01) 
Yaman et al. 2007 
[10] 
Stomach 
cancer 
1.1 ± 0.4 
 1.7 ± 0.1 
18  
(p<0.01) 
Lightman et al. 
1986 [79] 
Ovarian 
cancer 1.95 ± 0.64 2.17 ± 0.64 40 
Carpentieri et al. 
1986 [76] Leukemia 
15 ± 4  
µg/106 cells 
52 ± 16 
µg/106 cells 
12 
 (p<0.01) 
 
 20
3.1.3 Copper and angiogenesis 
 ‘Angiogenesis’ is defined as the process of development of new blood vessels. The 
concept that ‘tumor growth is dependent on angiogenesis’ was pioneered by Judah 
Folkman in the 1970-80’s. Tumor cells cannot grow more than 1-2 mm in diameter 
without angiogenesis, which supplies the tumor with oxygen and nutrients [1]. 
Angiogenesis in a normal cell involves a complex interaction and balance between 
endogenous stimulators and inhibitors [1]. Cancer cells have developed ways to either 
synthesize their own angiogenic stimulators or to recruit endothelial cells to synthesize 
them [51-53]. These endogenous angiogenesis stimulators include growth factors such as 
the Vascular Endothelial Growth Factor (VEGF), Angiogenin, Fibroblast Growth Factor 
(β-FGF), Tumor Necrosis Factor (TNF-α), Epidermal Growth Factor (EGF), cytokines 
such as Interleukin (IL) 1, 6 and 8, trace elements such as copper. The endogenous 
angiogenesis inhibitors include cytokines such as Interleukin 10 and 12 and modulators 
such as Angiotensin, Endostatin and Angiopoietin-2 [4, 5, 86, 87].  
 Based on the discoveries regarding the importance of angiogenesis in tumor 
development, the concept of anti-angiogenic therapy has gained tremendous interest, and 
several antiangiogenic agents are currently in clinical trials [4, 86]. These antiangiogenic 
agents in clinical trials belong to the following categories: i) protease inhibitors, ii) 
endothelial cell proliferation/migration inhibitors, iii) antagonists of angiogenic factors, 
iv) endothelial cell specific integrin/survival signaling inhibitors, v) copper chelators and 
vi) agents with unspecific mechanism [86]. Bevacizumab, a monoclonal antibody against 
the angiogenic stimulator VEGF, is currently on the market for the treatment of colorectal 
cancers. Although, anti-angiogenic agents targeted to one specific angiogenic stimulator 
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such as Bevacizumab (anti-VEGF) have shown improvements when used in combination 
with chemotherapeutic agents such as Paclitaxel, 5-Fluorouracil, and Doxorubicin against 
certain tumors such as colorectal, but their effectiveness seems to decrease in other 
cancer types namely breast cancer and non-small cell lung cancer [51, 53]. This might 
simply be due to the availability of a host of other angiogenic factors (as described 
above) to the tumor cell (by either synthesizing themselves or by recruiting endothelial 
cells) for angiogenesis. Therefore, a successful anti-angiogenic therapy would either 
target multiple angiogenic factors or an angiogenic factor which is critical to 
angiogenesis or specifically controls a host of other angiogenic factors.  
In 1980, McAuslan and Reilly, in an attempt to isolate a peptide ‘endothelial 
stimulating growth factor’, noted that copper salts were the simplest angiogenic 
component of the tumor extract, stimulating the migration of endothelial cells [52, 53, 88, 
89]. It has been reported that rabbits fed with copper deficient diets, caused the reduction 
of their serum copper levels by half and resulted in the inability of an angiogenic 
response regardless of the angiogenic stimulus in the rabbit cornea angiogenesis model 
[90, 91]. Copper ions have been shown to stimulate the motility of endothelial cells in-
vitro [91]. Copper salts in-vitro have been shown to induce the synthesis of fibronectin, a 
matrix glycoprotein associated with angiogenesis [92, 93]. The copper levels have been 
shown to locally regulate the growth or regression of new blood vessels [94, 95]. Copper 
has also been shown to stimulate angiogenesis in chick embryo chorioallantoic models 
[94]. In addition, structurally diverse but vital angiogenic cytokines/growth factors such 
as IL-1, 8 and 6, β-FGF, TNF-α and VEGF have been shown to be inactivated with 
copper withdrawal [5, 86]. Further proof of the involvement of copper in tumor growth is 
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suggested from the elevated copper levels in the serum and tumor of cancer patients 
compared to healthy individuals [73, 84]. Serum copper levels have been correlated to 
tumor burden, progression, incidence, regression, and reoccurrence [51]. Ceruloplasmin 
expression has also been reported to be elevated in tumors [68, 69]. Ceruloplasmin levels 
have been reported to be increased four to eight fold during malignant progression and 
return to normal levels after tumor regression [86, 96]. Further, X-ray fluorescence 
microscopy (XFM) has recently revealed large scale relocalization and extracellular 
translocation of cellular copper during angiogenesis [97]. 
All these findings suggest that copper plays a central role in angiogenesis and 
therefore controlling copper levels with the aid of chelators would result in anti-
angiogenic activity.        
 
3.1.4 Copper chelators as anti-angiogenic agents 
 
         Copper reduction as an anti-cancer strategy is currently under intense investigation 
[98, 99]. Copper chelators such as D-pen [5], tetrathiomolybdate (TM) [100, 101], 
clioquinol [102], and trientine [103, 104] have been shown to inhibit angiogenesis both 
in-vitro and in-vivo. Several animal studies have supported the hypothesis of employing 
copper chelators as anti-angiogenic agent. Pan et al. [105] reported a synergistic tumor 
growth reduction effect of tetrathiomolybdate plus doxorubicin in a SUM149 murine 
xenograft. Khan et al. [106] showed a reduction in tumor mass and synergistic effects of 
radiotherapy with tetrathiomolybdate in a murine lung cancer model. Moriguchi et al. 
[107] described a decrease in tumor growth and IL-8 production with trientine treatment 
in hepatocellular carcinoma. Yoshida et al. [108] reported a reduction in the tumor weight 
and vascular density after low copper diet plus D-pen treatment of gliosarcoma 
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xenografts. Brem et al. [109] described the reduced tumor growth and vascularization 
after low copper diet and D-pen treatment in glioma implanted intracerebrally in rabbits. 
Additionally, Pan et al. [100] published that copper deficiency induced by 
tetrathiomolybdate resulted in impairment of tumor growth and angiogenesis in two 
animal models of breast cancer; an inflammatory breast cancer xenograft model in nude 
mice and HER2/neu cancer prone transgenic mice.          
Some clinical trials with copper chelators such as D-pen and tetrathiomolybdate to 
determine their antiangiogenic activity have been conducted. A phase II trial of copper 
depletion and penicillamine therapy as antiangiogenesis therapy for glioblastoma 
reported an effective ceruloplasmin depletion (ceruloplasmin levels decreased from 130 
µg/dL to <50 µg/dL) after two months of combination therapy of penicillamine and a low 
copper diet, but the achievement of hypocupremia was reported not to significantly 
increase survival in glioblastoma patients [8]. A phase I clinical trial to investigate 
tetrathiomolybdate as an anticopper antiangiogenic agent against metastatic cancer 
reported the reduction of ceruloplasmin without added toxicity, with five of six patients 
with stable disease [14]. A phase II trial with tetrathiomolybdate in patients with 
advanced kidney cancer concluded that tetrathiomolybdate was well tolerated and 
consistently depleted copper in all patients and 31% patients exhibited stable disease for 
at least 6 months [110]. Other phase II clinical trials are currently underway to further 
investigate use of copper chelators are anti-angiogenic agents.             
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3.2 D-penicillamine (D-pen) 
D-penicillamine (D-pen) is an aminothiol, which was first identified as a product of 
penicillin hydrolysis in 1943 by Abraham [111]. D-pen was introduced in the clinic as a 
copper chelating agent for the treatment of Wilson’s disease by Walshe in 1956 [112, 
113].  After more than 50 years of clinical use in the treatment of Wilson’s disease, D-
pen is currently also used in the treatment of cystinuria, rheumatoid arthritis and heavy 
metal intoxication. D-pen is currently approved by the Food and Drug Administration 
(FDA) and is marketed as Cuprimine® (250 mg capsules) and Depen® (250 mg tablets). 
D-pen (3-mercapto-D-valine, 3,3-dimethylcystiene or D-(-)-2-amino-3-mercapto-3-
methylbutyric acid; m.w. 149.2) is the S enantiomer of the racemic DL-penicillamine 
[114]. The L-isomer is not used due to toxic effects [114]. D-pen possesses three 
prominent functional groups: an amine, a carboxyl and a sulfhydryl (as shown in Figure 
3.1) [30]. The pharmacokinetics and pharmacology of D-pen is regulated by the reactions 
of these functional groups with endogenous compounds [115]. The pKa of D-pen 
functional groups (amino, sulfhydryl and carboxyl) are 10.5, 7.9, and 1.8, respectively 
[116]. D-pen is known to react with, i) metals to form complexes and/or chelates, ii) with 
carbonyl compounds to form thiazolidine rings, iii) thiols or disulfides to form mixed 
disulfides [116, 117].  
Several initial pharmacokinetic studies with D-pen had reported a problem of 
incomplete D-pen recovery. For example, only between 47 to 85% of D-pen was 
recovered after oral administration in a short term (5 day) human study [118, 119].  
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Figure 3.1 Structure of D-pen and D-pen disulfide 
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D-pen in-vivo is known to be rapidly transformed into: i) low molecular weight 
disulfides (through the interaction of D-pen with the endogenous thiols), ii) S-
methylpenicillamine, and iii) form disulfide with plasma albumin [119-121]. The low 
molecular weight disulfides have relatively short plasma half life. It is now believed that 
the incomplete recovery for D-pen is mainly due to its stable binding with plasma 
albumin [116]. It has been estimated that in-vivo upto 80% of D-pen is bound to plasma 
proteins, 7% of D-pen exist as cysteine-D-pen disulfide, 5% as D-pen disulfide and only 
6% as free D-pen [116]. Orally administered D-pen is rapidly absorbed by the small 
intestine, with drug detectable in the plasma within 20 min after administration [116, 
122]. The peak plasma concentrations of D-pen have been reported to range from 4 µM 
after 150 mg to 27.5 µM after 800 mg oral administration. The time to peak plasma 
concentration ranges between 1.5-4 h after oral administration. While the oral 
bioavailability is 50-70%, and the volume of distribution is between 57-93 L. The 
terminal elimination half life has been shown to be 1 h (monoexponential) and 7.5 h 
(biexponential) and the clearance rate between 561-727 mL/min (independent of dose) 
has been published [114, 116, 122-125]. D-pen has very low lipid solubility owing to the 
ionization of its functional groups. Additionally there is no established or known 
mechanism of active uptake of D-pen into cells [114, 126]. It has been shown that the 
cellular uptake of D-pen is very limited in mucosal cells [127], lymphocytes, 
macrophages [128] and several mammalian cell lines [126]. Lodemann et al. reported that 
while L-Pen was able to accumulate into cells to some extent and also compete with most 
of the natural amino acids (valine, leucine, alanine, threonine, phenylalanine, methionine, 
praline, arginine, and histidine) and reduce their cellular uptake between ~20-60%, D-pen 
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did not accumulate in cells and did not compete with natural amino acids for cell uptake 
[126]. Despite the limited entry into cells, the volume of distribution of D-pen exceeds 
the total body water volume, which can be explained by its binding to tissues such as skin 
and aorta and to plasma proteins (such as albumin). Binding to albumin occurs rapidly 
but is only slowly reversible [129]. The reaction of poorly soluble cystine (cysteine 
disulfide) with D-pen to form a more soluble mixed disulfide is the basis of the use of D-
pen in the treatment of cystinuria [114, 117].       
 
3.2.1 D-pen in the treatment of Wilson’s disease and rheumatoid arthritis 
 The treatment of Wilson’s disease has two main aims: i) minimize the dietary intake 
and absorption of copper and ii) to promote the excretion of copper deposited in tissues. 
D-pen is an orally effective copper chelating agent, which is used in combination with 
reduced copper diet as a treatment of Wilson’s disease [38]. The optimum dose of D-pen 
is generally determined by measurement of the urinary copper excretion and the 
determination of free copper in the serum [115]. The actual doses of D-pen range 
between 250 mg to 1.5 g/day [39]. The side effects of chronic D-pen use have been 
reported to be as aplastic anemia, agranulocytosis, thrombocytopenia, goodpasture’s 
syndrome and myasthenia gravis [39, 115]. D-pen as a new oral therapy in the treatment 
of Wilson’s disease was introduced by Walshe et al. in 1956. D-pen essentially replaced 
2, 3-dimercaptopropanol (BAL) and became the gold standard in the treatment of 
Wilson’s disease [112, 130]. Although new copper chelators such as tetrathiomolybdate 
have been introduced, D-pen still remains one of the primary choices in the treatment of 
Wilson’s disease [38].  
 28
 Gooneratne et al. investigated the copper excretion capacity of established copper 
chelating agents such as EDTA, BAL, D-pen and TM from sheep following a high and 
low copper diet [131]. D-pen administration was shown to increase the urinary copper 
excretion by 266% and 196% in the low and high copper diet sheep respectively, 
compared to 254, 11, 46% and 354, 13, 20% excretion in low and high copper diet sheep 
after administration of TM, EDTA, and BAL, respectively. Therefore, the authors 
concluded that TM and D-pen were the most efficient decoppering agents in the group of 
copper chelating agents examined. However, it was also reported that TM and D-pen 
actually remove copper through different excretion sites (TM through bile, while D-pen 
through urine) [131].   
 Rheumatoid arthritis is an autoimmune disorder and is characterized by chronic 
inflammation of the synovial tissues [132, 133]. The goals of treatment of rheumatoid 
arthritis are to prevent or control joint damage, prevent the loss of function, and decrease 
the pain [132]. D-pen has been used in the treatment of rheumatoid arthritis for over 40 
years [115, 134]. D-pen belongs to the second line treatment group, known as the disease 
modifying anti-rheumatic drugs (DMARD). The mechanism of action of D-pen against 
rheumatoid arthritis is still largely unknown. A number of potential mechanisms have 
been proposed such as dissociation of immunoglobulin (IgM) in-vivo [134], interference 
with the collagen cross-linking in the synovial junctions [135, 136], an anti-inflammatory 
agent [137, 138], interference with the chemotaxis of the leukocytes [139, 140], and that 
D-pen might express immunosuppressive activity [24]. The property of D-pen to produce 
hydrogen peroxide (H2O2) in the presence of copper has been investigated as an 
additional mode of action in its activity in rheumatoid arthritis [141]. It is interesting to 
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note that D-pen shares a reactive thiol group with other DMARD’s like captopril, 
thiopyridoxine, and thiopronine [114]. D-pen has been shown to suppress human 
fibroblast proliferation in the presence of cupric sulfate in-vitro [142], and inhibit the T-
cell function in-vitro in the presence of cupric sulfate [24] Also, the pre-incubation of D-
pen with cupric sulfate was shown to directly effect the ability of the T lymphocytes to 
respond to mitogens and their subsequent proliferation [133].    
 
3.2.2 Copper chelation by D-pen 
Although the copper chelating ability of D-pen has long been established, the exact 
mechanism of copper chelation by D-pen has remained the focus of immense 
controversy. The copper chelation mechanism of D-pen has revolved around the in-vivo 
formation and existence of the multivalent cluster complex (CuII6CuI8(D-pen)12Cl)5-
shown to be formed between D-pen and copper in-vitro [143, 144]. The multivalent 
cluster complex has been shown to be formed in-vitro under simulated physiological 
conditions, but it has never been found in the urine of patients due to its apparent 
instability in urine [144].   
Walshe et al. [112] proposed several possible mechanism of copper chelation by D-
pen, i) a single copper being bound to a single thiol group (C-S-Cu+), ii) a copper atom 
bound on both sides with the thiol groups of two D-pen molecules (D-pen-Cu-D-pen), or 
iii) a ring compound between a copper atom and the thiol and amino groups of D-pen. It 
should be noted that the hypothesis of a ring compound involving both the thiol and 
amino groups was put forth specifically because it was known that ethylmercaptan does 
not function as a copper chelator [112].  
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In 1976 Birker et al. [145] isolated and described the crystal structure of a purple 
color multivalent cluster complex, (CuII6CuI8(D-pen)12Cl)5-. D-pen in the cluster complex 
was reported to bind copper in both oxidation states, Cu(II) and Cu(I) [143]. The Cu(II) 
was described to be in equilibrium with the surrounding media although strongly chelated 
with the nitrogen and sulfur group of D-pen, while Cu(I) was proposed to be removed 
from equilibrium [143]. The methyl groups provided steric hindrance to the complex, 
thus protecting the Cu(I) against oxidation [143]. The solubility of the complex was 
proposed to be due to the presence of ionized carboxyl groups on the surface of the 
complex. The complex was reported to degrade in urine at aerobic conditions, but to be 
highly stable in-vitro in the simulated physiological pH and saline conditions [143].  
In 1977 May et al. [146] introduced the term, plasma mobilization index (PMI), 
which was defined as the relative ability of chelating agent to compete for a metal ion. 
Based on the computer modeling with the aid of PMI, May et al. predicted that D-pen 
would be unable to compete with plasma proteins for Cu(II) chelation. It was instead 
proposed that D-pen could liberate copper from metalloproteins by reduction to Cu(I). 
Other copper chelating agents such as EDTA and Trien were shown to effectively chelate 
Cu(II) [146].  In 1977 Tran-Ho et al. [147] with the aid of the PMI showed that D-pen 
had much lower capacity to remove copper compared to another copper chelator, trien 
[147]. Thus, the authors proposed that the mobilization of copper by D-pen in Wilson’s 
disease is unlikely to be explained by complexation of D-pen with Cu(II) alone [147]. 
These studies agree with the initial observation by Walshe et al. that trien and D-pen 
might act on different copper pools within the body [130].    
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In 1979 Laurie et al. [148] showed that D-pen is unable to compete for copper 
bound to albumin. The authors showed that the rate of formation of the D-pen-copper 
cluster complex was dependent on a host of different factors including copper 
concentration, Cu-D-pen ratio, chloride ion concentration, pH and temperature [148], and 
thus the authors concluded that the multivalent cluster complex might not be the 
mechanism of copper removal by D-pen [148].  
In 1999 Kato et al. [144] with the aid of the 1H-NMR studied the reactions of Cu(I) 
and Cu(II) with D-pen in the presence of glutathione. The data supported the existence of 
the cluster species (Cu6IICu8I(D-pen)12Cl)5-. Kato et al. concluded that the coexistence of 
D-pen, D-pen disulfide, Cu(II), and/or Cu(I) leads to the formation of the stable cluster 
species regardless of the presence or absence of other thiols such as glutathione [144]. 
The cluster species was proposed to be thermodynamically favored compared to other 
copper-containing complexes such as D-pen-Cu+, Glutathione-Cu+, D-pen disulfide-Cu2+, 
and Glutathione disulfide-Cu2+ [144].     
The stability constant (log Kapp) for EDTA with Cu(II) at pH 7.0 has been reported 
to be 15.5, while that of D-pen with Cu(I) is 18.8 [47, 48]. It has been shown that D-pen-
Cu(I) complexes have very poor aqueous solubility in the pH range 1.9-7.6, due to the 
formation of neutral complexes [147]. However, the D-pen-copper cluster complex which 
is proposed to be formed in-vivo would have enhanced solubility due to the earlier 
described negative charge on the complex [144].  
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3.2.3 Metal catalyzed D-pen oxidation 
Thiol oxidation to disulfides is a two electron oxidation process, where the electron 
donor and acceptor in this process typically are other thiols, disulfides, or oxygen: 
2RSH  ↔  RSSR + 2e- + 2H+ 
The reversible thiol/disulfide exchange reactions are typically initiated by the thiolate 
anion [149]. Glutathione is the major biological intracellular thiol and therefore the 
interaction of any other thiol and glutathione is one of the pathways for thiol oxidation 
with simple thiol exchange reaction  
   Kmix = (PSSG) (GSH) / (PSH) (GSSG) 
where PSH is D-pen, GSH is glutathione, GSSG is glutathione disulfide, and PSSG is the 
D-pen-glutathione mixed disulfide. The equilibrium constant (Kmix) for the formation of 
glutathione mixed disulfides of D-pen has been reported to be 3.0, which is higher than 
other thiols such as cysteine (Kmix: 1.1), cysteamine (Kmix: 2.4) [150].  
The direct oxidation of thiols by oxygen is very slow; however the rate of oxidation 
is increased in the presence of some transition metals, as these metals act as efficient 
electron carriers between thiols and oxygen [151, 152]. Copper and iron are the 
biologically relevant transition metals which are known to catalyze thiol oxidation [152]. 
The oxidation of thiols is generally initiated by the electron transfer from the thiolate 
anion to metal, a subsequent transfer of electron from the metal to oxygen results in the 
formation of superoxide radical and hydrogen peroxide [151]. The superoxide radical and 
hydrogen peroxide can then react to form the extremely harmful hydroxyl radicals 
through the well known Haber-Weiss reaction [153]. Thus, the formation of the thiolate 
anion is the rate limiting step in the autoxidation reaction of thiols, implying that thiol 
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oxidation would be highly dependent on the ionization of the thiol group [154]. The pKa 
of the thiol group of some important endogenous and exogenous thiol compounds are as 
follows: D-pen (pK-SH: 7.9), cysteine (pK-SH: 8.3), cysteamine (pK-SH: 8.3), glutathione 
(pK-SH: 8.8), dithiothreitol (pK-SH: 9.1), N-acetylcysteine (pK-SH: 9.5), captopril (pK-SH: 
9.8) [154]. As can be seen, the pKa of D-pen is physiologically significant compared to 
other exogenous thiols. Therefore, D-pen would undergo the highest rate of oxidation in 
the presence of transition metals compared to the other listed thiol compounds. However, 
it should be noted that at sufficiently high concentrations, the thiolate anion of D-pen can 
also react with the H2O2 which is present in the surrounding solution or that has been 
generated in the autoxidation process. The rate of reaction of thiolate anion with H2O2 
and superoxide radical has been shown to be inversely proportional to the pKa of the 
thiol group [154]. Thus, at sufficiently high concentrations (millimolar) D-pen could act 
as antioxidant compared to its oxidative nature at low concentrations (micromolar). D-
pen like other thiols also reacts with free radicals to form thiyl radical (PS.). The 
interaction of two thiyl radicals forms disulfides. Listed below are some of the possible 
reactions of D-pen [155, 156]  
The possible reactions of the thiolate anion of D-pen with other radical and non-
radical species: 
                    (Radical). + PSH   ↔  Radical-H + PS.                                                          (a) 
                              PS. + PS.  ↔  PSSP                                                           (b) 
                                 PSH  ↔ PS- +H+                                                                                          (c) 
                             PS. + PS-  ↔  (PSSP).-                                                                                   (d) 
                          (PSSP).- + O2  → PSSP + O2.-                                                                      (e) 
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                           PS- + H2O2   → PSOH + HO-                                                                      (f) 
                           PSOH + PS-  → PSSP + HO-                                                                      (g) 
where D-pen (PSH), D-pen radical (PS.), D-pen disulfide (PSSP), D-pen disulfide radical 
(PSSP)., superoxide radical (O2.-), hydroxyl radical (HO.). 
 
3.2.4 Quantitative analysis of D-pen 
 
Compounds containing thiol functional group are usually difficult to assay due to 
the rapid oxidation of the thiol group to the respective disulfide in-vitro and the formation 
of mixed disulfides in-vivo. Several methods have been reported in the past for the 
quantitative analysis of thiols such as ion exchange chromatography, gas 
chromatography, capillary electrophoresis and high performance liquid chromatography 
(HPLC) with fluorescence (FL), electrochemical and ultraviolet (UV) detection.  
HPLC with either pre or post-column derivatization of the endogenous thiols and 
thiol containing drugs such as Homocysteine, N-acetyl-cysteine, Cysteine, Glutathione, 
Bucillamine, Cysteamine, Captopril, and D-pen have been assayed with the aid of 
fluorescence compounds such as 5,5’-dithio-(bis-2-nitrobenzoic acid) [157], ammonium 
7-gluorobenzo-2-oxa-1,3-diazole-4-sulfonate (SBD-F) [158-163], 4-(aminosulfonyl)-7-
fluoro-2,1,3-benzoxadiazole (ABD-F) [164], N-(p-(2-benzoxazolyl)-phenyl) maleimide 
(BOPM) [165], o-phthaladehyde [166], monobromobimane [167], and N-(1-
pyrenyl)maleimide) (NPM) [168-171]. The derivatization of thiol compounds with these 
derivatizing agents results in the formation of fluorescent adducts, which are then 
detected using fluorescence chromatography. The formation of these adducts usually 
employ the sulfhydryl functional group of the thiol compounds also resulting in the 
protection of these thiols from oxidation. However, this strategy also restricts the 
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detection of only reduced thiols and not their disulfides. Thus, there is often the problem 
of a lack of mass balance of the thiol compound. The solution to this problem is to 
employ a reduction step before the derivatization process to convert the disulfides to 
thiols that may then react with the derivatizing agent.   
The quantitative analysis of D-pen in biological samples (plasma, tissue 
homogenates) is complicated given the occurrence of D-pen in various forms such as free 
D-pen, mixed disulfide with cysteine or glutathione, D-pen disulfide, and S-methyl-D-
pen, and also D-pen bound to plasma proteins [171]. A number of methods have been 
reported in the literature in order to analyze D-pen such as HPLC-electrochemical 
detection [172-174], gas chromatography [175, 176], radioimmunoassay [177], cation 
exchange chromatography [178, 179], capillary electrophoresis [180-182], 
chemiluminescence [183], and HPLC-Fluorescence detection [165, 171, 184]. Almost all 
of these methods detect D-pen only in the reduced form, as the reduction of D-pen 
disulfide to D-pen has been shown to be very limited even in the presence of high 
concentrations of reducing agents such as dithiothreitol (DTT) and tris (2-carboxyethyl) 
phosphine (TCEP) [185, 186]. Therefore, the D-pen assay methods have to account for 
D-pen conversion to its disulfide or mixed disulfides either by detecting D-pen disulfide 
or with inhibiting D-pen oxidation. We have recently reported on a HPLC-UV assay for 
the simultaneous detection and quantitation of both D-pen and D-pen disulfide in a single 
run [187]. This is the first assay method that can quantify both D-pen and D-pen disulfide 
together in a single run. This assay method provides the simple, sensitive, accurate and 
simultaneous determination of D-pen and D-pen disulfide concentration in samples.                
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3.2.5 D-pen as an anti-angiogenic agent 
 
As reviewed earlier, copper has been established as an endogenous angiogenic 
stimulator. As copper is now known to control a variety of other endogenous stimulators 
by acting as a co-factor, strategies to chelate copper and thus cause anti-angiogenesis are 
being extensively investigated. D-pen and Tetrathiomolybdate are two copper chelators 
currently being investigated as anti-angiogenic agents in clinical trials.   
D-pen is an effective copper chelator and has been shown in in-vivo studies to 
remove copper, Goonerante et al. have shown that D-pen is as effective as 
tetrathiomolybdate in removing excess copper through urinary excretion in both low and 
high copper diet sheep [131]. D-pen has been shown to cause inhibition of the human 
endothelial cell proliferation and neovascularization in-vitro [6]. D-pen was also shown 
to suppress the growth of 9L gliosarcoma tumor implanted in rats [7]. Yoshida et al. 
published that D-pen caused copper depletion and the reduction in the copper/zinc ratio 
in a rat tumor model which might have lead to the reduction in the tumor weight [7, 108]. 
Brem et al. concluded that treatment of D-pen resulted in the inhibition of pseudopodial 
protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain [188]. Hourani 
et al. have shown the inhibition of S-91 mouse melanoma metastases and growth by D-
pen [13].  
In addition, D-pen has also been shown to have properties other than copper 
chelation for it to be an effective anti-angiogenic agent, such as the inhibition of several 
important growth factors (VEGF, FGF) that require copper as a co-factor, dose dependent 
inhibitor of urokinase-type plasminogen activator [189], and activator of angiostatin [86]. 
A phase II clinical trial was recently conducted to investigate the anti-angiogenic activity 
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of D-pen against glioblastoma [8]. D-pen was able to remove copper and reduced the 
ceruloplasmin levels from 130 µg/dL to <50 µg/dL [8] after two months of oral D-pen 
administration.  
 
3.2.6 D-pen as cytotoxic anti-cancer agent  
As described earlier, thiols can generate hydrogen peroxide (H2O2) and other ROS 
through a metal (copper or iron) catalyzed oxidation process. The incubation of D-pen 
with copper in the presence of endothelial cells [6] and lymphocytes [23] have been 
previously reported to result in cell death proposed to be due to the generation of ROS. 
Starkebaum et al. had proposed a mechanism of a copper catalyzed H2O2 generation from 
D-pen and cytotoxicity in lymphocytes [23].  
The mechanism of copper catalyzed D-pen oxidation and subsequent H2O2 
formation is thought to be a free radical based process [23, 190]. As shown in Figure 3.2 
Starkebaum et al. postulated that D-pen initially reduces Cu(II) to Cu(I) presumably 
during copper chelation, and that this process leads to the generation of D-pen radical. 
The Cu(I) then reduces oxygen to superoxide anion followed by reduction of superoxide 
anion into H2O2. During this reduction of oxygen and superoxide anion, Cu(I) is oxidized 
back to Cu(II). The D-pen radicals are proposed to react to form D-pen disulfide. The net 
reaction mechanism shows the reduction to 2 moles of D-pen by 1 mole of O2 leading to 
the formation of 1 mole H2O2 and 1 mole of D-pen disulfide [23, 190].   
Kato et al. [144] has recently performed 1H-NMR studies which support the H2O2 
formation during D-pen interaction with copper during copper chelation and the 
formation of the multivalent cluster complex. It should also be pointed out that these 
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studies were conducted in the presence of glutathione. Additionally, we have recently 
conducted both non-cell based and cell based studies to conclusively show the generation 
of H2O2 and subsequent oxidation of D-pen to D-pen disulfide using a novel HPLC assay 
[187, 190].  
We have also shown that D-pen was able to cause concentration dependent 
cytotoxicity only in the presence of copper in human breast cancer and leukemia cells 
[187, 190]. The D-pen cytotoxicity was inhibited in the presence of catalase. Intracellular 
generation of H2O2 was shown in both breast cancer and leukemia cells [190].  
Thus as shown in Figure 3.3, D-pen targeted to the tumor in presence of the excess 
copper in the tumor microenvironment and/or cells would cause cytotoxicity. The 
elevated oxidative stress in cancer cells compared to normal cells would result in 
selective cytotoxicity in cancer cells compared to normal cells. D-pen could thus be 
employed as a dual anti-cancer agent exhibiting both anti-angiogenic properties due to 
copper chelation and cytotoxic properties due to generation of ROS.      
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2PSH + 2Cu2+ 2PS. + 2Cu+ + 2H+
Cu+ + O2 Cu2+ + O2. -
Cu+ + O2. - + 2H+ Cu2+ + H2O2
PS.  + PS. PSSP
2PSH + O2 PSSP + H2O2  
 
Figure 3.2 Mechanism of copper catalyzed D-pen oxidation and hydrogen peroxide 
generation. Adapted from Starkebaum et al. [23] 
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Figure 3.3 Mechanism of action of D-pen as a cytotoxic anti-cancer agent. The 
mechanism of D-pen activity selectively against cancer cells is based on the difference in 
the oxidizing-reducing balance in cancer vs. normal cells.  
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3.3 Cancer and oxidative stress 
Each cell in the human body maintains a homeostasis between the oxidant and 
antioxidant species. Both of these species are very important for the normal metabolism, 
signal transduction and regulation of cellular functions [191]. Oxidative stress could be 
simply defined as the disturbance in the oxidant-antioxidant balance, favoring the oxidant 
environment [192]. Oxidative stress associated cellular damage has been indicated in a 
range of disorders such as cancer [193, 194], diabetes mellitus [195], atherosclerosis [21, 
196], neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease 
[197, 198], autoimmune disorders such as arthritis [21, 199] and aging [200-202]. The 
relationship between cancer and oxidative stress has been the subject of intense debate; 
mainly due to the well documented fact that the cancer cells are under high levels of 
oxidative stress compared to normal cells [203, 204]. In the past decade oxidative stress 
has been linked both in the etiology and the potential treatment of cancer [203, 204].   
The elevated oxidative stress in cells can lead to modification of number of cellular 
targets and cause cell damage and death. The most important of these targets include: i) 
DNA (nuclear and mitochondrial) leading to single strand breaks, ii) mitochondrial inner 
membrane leading to the loss of cellular stores of ATP, and iii) membrane phospholipids 
by means of lipid peroxidation [205]. The cell damage and the subsequent lack of cellular 
repair processes due to the constant oxidative damage have been associated with 
carcinogenesis [206-208].  
The oxidation of guanine nucleotide base in DNA, through reaction with oxidative 
species results in the formation of 8-hydroxy-2-deoxyguanosine (8-OHdG) [193, 200, 
209]. The interaction of ROS with DNA has been reported to result in fragmentation of 
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DNA with the loss of bases and leading to strand breaks [205, 210, 211]. These DNA 
strand breaks can accumulate in mammalian cells leading to oncogenic transformation 
and/or cell killing, depending on the capacity of cellular repair processes to overcome 
them [206]. Mammalian cells in culture when exposed to ROS have been shown to have 
a direct relationship between accumulation of strand breaks and cell killing [212].   
Lipid peroxidation takes place in the polyunsaturated fatty acids; the process is 
generally initiated by the extraction of hydrogen from a methylene carbon by ROS such 
as hydroxyl radical [209]. Under aerobic conditions, the fatty acid with unpaired electron 
undergoes oxidation to form the peroxyl radical. This radical can then extract hydrogen 
from the adjacent fatty acids to form lipid peroxides and thus a chain reaction is initiated 
and propagated. The simple schematic example of the mechanism of lipid peroxidation 
with hydroxyl radical is shown below [209]: 
             LH + .OH               L. + H2O                                         (a) 
             L. + O2                   LOO.                                                                               (b) 
             LOO. + LH                  LOOH + L.                                                        (c)  
where LH: polyunsaturated fatty acid, L.: alkyl radical, LOOH: lipid hydroperoxide 
Fruehauf et al. has proposed a model of transformation of normal cells into 
malignant cells based on the exposure to ROS. The model is shown in the Figure 3.4 and 
depicts that low level of ROS stress (normally observed in all cells) could cause DNA 
damage, this damage is normally fixed with the aid of specialized DNA repair enzymes 
present in the nucleus. However, constant ROS stress results in loss of efficiency of the 
repair process and may lead to the initiation of malignant state. At this stage, if these cells 
are exposed to further ROS stress, they should normally undergo apoptosis but in some 
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cases the cells start to proliferate and thus are irreversibly transformed into malignant 
cells. Thus, according to this model, the malignant cells would innately have high 
intracellular ROS stress compared to normal cells [213] and maintain a increased level of 
ROS stress compared to normal cells due to increased metabolism. Also as proposed in 
the model further ROS stress in these malignant cells could result in cell death either 
through apoptosis or necrosis and thus the strategy of producing further ROS stress in 
malignant cells could be successful.       
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Figure 3.4 Reactive oxygen species (ROS) exposure and cancer cells. Adapted from 
Fruehauf et al. [213] 
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3.3.1 Reactive oxygen species (ROS) 
ROS can simply be defined as oxygen containing oxidizing agents. It has been 
reported that upto 1-3% of the pulmonary intake of oxygen by humans is converted into 
ROS [214]. ROS are generally divided into two subgroups; free radicals such as 
superoxide radicals (O2.-) and non-radical such as hydrogen peroxide (H2O2). A list of 
biologically relevant radicals and non-radical ROS is shown in Table 3.4. Both radicals 
and non-radical ROS share the presence of an oxygen atom, which differentiates them 
from the reactive nitrogen species (RNS). Free radicals contain one or more unpaired 
electron and are highly reactive chemical species, with the half life generally ranging in 
seconds or minutes. Non-radicals on the other hand can exist for longer period of time, 
but can be converted to radical species by reacting with other radicals.  
ROS are products of normal cellular metabolism. It has been reported that in an 
average adult approximately 10,000-20,000 free radicals attack every cell in the body per 
day [194]. Although high concentrations of ROS are known to be harmful to the cells, 
low concentrations of ROS are known to serve a variety of important cellular functions 
including both the activation and modulation of the signal transduction pathways [191, 
215, 216], modulation of the activities of the redox sensitive transcription factors such as 
NF-κB, AP-1, p53, NFAT, and HIF-1 [215, 217], regulation of apoptosis [218, 219], and 
the regulation of mitochondrial enzyme activities [215, 220]. A complete list of these 
functions of ROS is shown in Table 3.5.  
The formation of ROS is a consequence of aerobic metabolism [221]. In normal 
conditions, the balance in the intracellular ROS levels is maintained with the aid of 
scavenging systems such as glutathione, superoxide dismutase, catalase, and other 
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antioxidant defense components. However, in certain disorders such as cancer, the 
balance between the ROS and the antioxidant species is disturbed. The most important 
source of cellular ROS is the mitochondria, where a continuous production of ROS takes 
place. This is the result of the electron transport chain located in the mitochondrial 
membrane which is essential for the energy production inside the cell [20, 222]. Another 
source of ROS production is in the cytosol, the arachadonic acid cascade involved in the 
production of prostaglandins and leukotrienes is known to produce ROS when the 
released lipid is metabolized [223]. Additionally some cytochrome 450 enzymes are also 
known to produce ROS [224].           
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Table 3.4 Classification of biologically important ROS. Adapted from Halliwell [17] 
 
Reactive Oxygen Species 
Free radicals Non-radicals 
Superoxide anion (O2.-) 
Hydroxyl (.OH) 
Hydroperoxyl (HO2.) 
Peroxyl (RO2.) 
Alkoxyl (RO.) 
Hydrogen peroxide (H2O2) 
Hypobromous acid (HOBr) 
Hypochlorous acid (HOCl) 
Singlet oxygen (O21) 
Organic peroxides (ROOH) 
Peroxynitrite (ONOO-) 
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Table 3.5 Intracellular functions and targets of ROS. Adapted from Seifried [225]  
Target Name Function Effect of ROS or oxidation 
Caspase 8  
Family of cytosolic 
aspartate-specific 
cysteine proteases 
involved in the 
initiation and 
execution of 
apoptosis 
Activated by ROS 
NFκB 
Nuclear factor of 
kappa light chain 
gene enhancer in B 
cells 
 
Activated by ROS 
as κB inhibitor and 
is degraded by 
oxidation 
p53  Tumor suppressor protein 
ROS increases the 
accumulation of the 
protein but 
decreases binding 
to DNA 
VEGF 
 
Vascular Endothelial 
Growth Factor 
Increases the 
permeability of 
capillary blood 
vessels 
Decreased by ROS 
SOD Superoxide Dismutase 
Catalyzes the 
conversion of 
superoxide anion to 
hydrogen peroxide 
Accumulation of 
ROS can damage 
lipids, proteins and 
DNA 
JNK 
 
c-Jun N-terminal 
kinase 
A member of 
MAPK family, 
promotes 
phosphorylation 
and activation of 
AP-1, leads to 
apoptosis or 
necrosis 
 
ROS leads to 
activation following 
dissociation of the 
Trx-apoptosis 
signal-regulating 
kinase 1. 
 
IL6 
 
Interleukin 6 or 
Interleukin beta 
A multifunctional 
protein that plays 
important role in 
host defenses, acute 
phase reactions, 
immune responses 
ROS decreases 
activity 
ASK1 Apoptosis signal-regulating kinase 1 
 
 
ASK1 activates 
 
Causes dissociation 
of the Trx-ASK1 
complex leading to 
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JNK and P38 and 
inactive when 
complexed with Trx
 
ASK1 activation of 
JNK and P38 
 
EGFR Epidermal Growth Factor Receptor 
A member of the 
EGFR family of 
receptor tyrosine 
kinases, which 
activates Raf and 
MAPKK leading to 
the activated ERK 
Activated by ROS 
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3.3.1 a Hydrogen peroxide (H2O2) 
H2O2 is a pale blue colored liquid, freely miscible with water and most importantly 
it is known to freely diffuse through cell membranes [226]. H2O2 is less reactive than its 
radical counterpart such as the superoxide and the hydroxyl radical, but due to the above 
mentioned ability to diffuse through membranes, H2O2 is a potent cellular oxidant 
species. The toxicity of H2O2 is largely based on its conversion to hydroxyl radical (.OH) 
either through ionizing radiation (as shown in reaction a below), by interaction with 
transition metals such as iron and copper through Fenton chemistry (as shown in reaction 
b below), or by interaction with superoxide anion radical through Haber-Weiss reaction 
(as shown in c below) [226]. The superoxide radical, through combination of reaction d 
and the Fenton reaction, results in the recycling of transition metal between their oxidized 
and reduced states and results in the formation of hydroxyl radical at an appreciable rate.  
              H2O2              2 (.OH)                                                                            (a) 
        H2O2 + Fe 2+ or  Cu+                   Fe 3+ or Cu 2+ + .OH + -OH                     (b) 
          O2.- + H2O2                       O2 + .OH + -OH                                               (c) 
       Fe3+ or Cu2+ + O2.-                    Fe2+ or Cu+  + O2                                       (d) 
Fenton type reactions are one of the most important metal mediated reaction, where 
the oxidation of a metal (usually transition metals such as iron (II), copper (I), chromium 
(III), cobalt (II), nickel (II), vanadium (V) by H2O2 leads to the generation of a hydroxyl 
radical.  
          Mn+  + H2O2              Mn+1 + .OH + -OH 
The Haber-Weiss reaction is a metal catalyzed reaction which also leads to the formation 
of hydroxyl radical. However, the metal purely acts as a catalyst in this process. 
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       Mn+1 + O2.-               Mn+ + O2 
       Mn+ + H2O2              Mn+1 + .OH + -OH 
Mn+1/Mn+Overall reaction: O2.- + H2O2                          .OH + -OH + O2 
The hydroxyl radical (.OH) is the most oxidizing radical generated in the human 
body [227]. The aqueous half life hydroxyl radical is reported to be <1 ns [20]. The redox 
potential of hydroxyl radical at pH 7.0 has been reported to be approximately +2.31 V 
[228]. Hydroxyl radical is known to react with DNA and lipid to cause damage and 
peroxidation, respectively [227]. 
H2O2 can also be formed by the direct two electron reduction of oxygen, a reaction 
which is catalyzed by a number of oxidases present in the cell cytoplasm [210]. 
Antioxidant enzymes are involved in the reduction of H2O2 to water: catalase in 
peroxisomes and glutathione peroxidase in the mitochondria and in the cytosol [210, 
229]. Inspite of the high permeability of H2O2 across cell membranes, the actual gradient 
of H2O2 acts by the consumption of H2O2 inside the cell by catalase and glutathione 
reductase (as shown in Figure 3.5) [230]. Therefore, increased activity of catalase and/or 
glutathione peroxidase leads to a concentration gradient where more H2O2 diffuses inside 
the cell. Antunes et al. following a H2O2 exposure to Jurkat T-cells, calculated the 
following gradients: (H2O2)extracellular/(H2O2)cytosol = 7 and (H2O2)cytosol/(H2O2)peroxisome = 3 
[230], which support the suggestions that H2O2 diffusion from outside the cell would 
depend on the activity of the antioxidant enzymes involved in H2O2 consumption [230].  
H2O2 is considered the key component in the ROS toxicity to cells because it can 
accumulate in the cell at relatively high concentrations owing to its apparent stability and 
the likely conversion to radical ROS [229]. H2O2 has been reported to exist in cells at a 
 52
concentration of 1×10-8 M [231]. H2O2 at submicromolar concentrations is known to act 
as intracellular messenger capable of promoting cell growth responses in molecules such 
as protein kinases, phosphatases, transcription factors, or transcription factor inhibitors 
[232]. The concentration of H2O2 shows a biphasic cell effect where low concentrations 
(50 nM) of H2O2 have been shown to be stimulate in-vitro cell growth of some cell lines 
such as human smooth muscle cells [232], rat fibroblast [233], and hamster fibroblast 
[234]. However, medium concentrations (1 µM- millimolar) of H2O2 have been known to 
cause cytotoxicity in cancer cells [190].          
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Figure 3.5 Kinetics of hydrogen peroxide (H2O2) entry into cells. Adapted from 
Antunes [230]   
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3.3.1 b Superoxide radical (O2.-) 
Mitochondria is the source of most of the O2.- present in cells. The intracellular 
concentration of superoxide radical is reported to be about 1 ×10-11 M [201]. Superoxide 
radical is less reactive compared to hydroxyl radical, but is known to cause considerable 
damage to the DNA [194]. As mentioned above, superoxide radical reacts with H2O2 
through the Haber-Weiss reaction to produce the toxic hydroxyl radical. Superoxide 
dismutase (SOD) is a cellular enzyme responsible for the dismutation of superoxide 
radical into the less reactive H2O2 through the reaction shown below. 
                        O2.- + O2.- + 2H+           H2O2 + O2 
Superoxide anion toxicity is seen in the neurodegeneration accompanied with amyotropic 
lateral sclerosis (ALS), mainly due to the SOD levels being low [201]. Superoxide radical 
can also react with glutathione, the major cellular antioxidant to produce damaging 
glutathionyl radical, as shown below: 
                 O2.- + GSH + H+                      GS. + H2O2 
Jones et al. showed that the rate constant of reaction between superoxide and glutathione 
is around 200 M-1s-1. Thus SOD would be able to compete with glutathione for reaction 
with superoxide radical preventing formation of the glutathionyl  radical [235]. 
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3.3.2 Antioxidants 
As ROS are normally being produced inside the cells, there has to be a mechanism 
through which the cells are able to counteract the toxic effects of ROS and able to 
survive. Antioxidants are chemical compounds present inside the cells which protect 
them from the oxidative damage. In Table 3.6, antioxidants are classified into four broad 
categories: 
i) ROS scavenging agents 
Glutathione is one of the major antioxidant compounds present in the cells and 
plays vital role for cellular protection against ROS [236-240]. The role of glutathione as 
an antioxidant is further discussed in section 3.3.2 a. 
Thioredoxin (Trx) is a 12 kDa cysteine rich protein containing thiol-disulfide active 
sites that act as antioxidants by facilitating the reduction of other cellular enzymes by 
cysteine thiol-disulfide exchange reactions [241]. The reduction of the oxidized 
thioredoxin is done by the NADPH-dependent flavin adenine dinucleotide contaning 
flavoenzyme, thioredoxin reductase. Thioredoxin/thioredoxin reductase system forms one 
of the main redox couple in mammalian cells [242, 243 244]. There have been three 
mammalian thioredoxins shown to be located in the cytoplasm, mitochondria and 
spermatozoa [243]. The low pKa of the cysteine thiol group leads to its existence as 
thiolate anion which acts as the attacking group in the reduction of disulfides.          
             Trx-(SH)2 + X-S2                  Trx-S2 + X(SH)2                 
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ii) Dietary antioxidants 
Vitamin E: α-Tocopherol is the major constituent of the fat soluble vitamin E. α-
Tocopherol is known to inhibit lipid peroxidation by reacting with the peroxyl radical 
intermediates formed during the chain reaction of lipid peroxidation [22] as shown in the 
reaction below,  
     α-Tocopherol   + LOO.                   αT.   + LOOH 
The resulting tocopherol radical is much less reactive compared to the peroxyl radical, 
and thus causes the slowing of the lipid peroxidation cascade [245].   
Vitamin C: Ascorbate or ascorbic acid is one of the important dietary water soluble 
radical scavenging antioxidant. The antioxidant activity of ascorbic acid on redox 
dependent biological function is due to the direct redox role of ascorbic acid and its 
metabolites as well as due to the generation of the ascorbate free radical [241]. Ascorbic 
acid is known to regulate transcription factors such as NF-κb, AP-1, GST-pi, MLH1 and 
is known to regulate apoptosis through IL-1 down regulation and changes in the adhesion 
molecules [246, 247]. Vitamin C protects the body against oxidative stress and is a 
cofactor for the biosynthesis of number of important compounds [248]. Several in-vitro 
and in-vivo studies have been investigated the antioxidant function of ascorbic acid and 
have been shown to reduce DNA damage [249-251]. A positive relationship between the 
Vitamin C and E deficiency and lipid peroxidation has also been shown [252]. 
Selenium in the form of selenocysteine, is an important part of many antioxidant 
enzymes known as selenoproteins [241, 253]. Glutathione peroxidases and thioredoxin 
reductase are also well known selenium containing enzymes, which play a critical role in 
intracellular antioxidant activities [241].  
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Carotenoids: β and α-carotene are known to protect the cells against oxidative stress 
caused by radiation and UV exposure. Carotenoids carry out their antioxidant activities 
through a number of mechanisms [241]. Carotenes are known for their ability to scavenge 
free radicals such as singlet oxygen (1O2) species [254], alkoxyl, and peroxyl radicals 
[255]. However, carotenoids can also act as electron donors (by transferring electrons) 
and reducing the free radicals to nonradical species. Thus sub-optimal uptake of 
carotenoids has been linked to carcinogenesis through increased DNA damage [241, 
253].        
Antioxidant activity of carotenoids [194]: 
       ROO. + Car                    ROO-Car. 
       ROO-Car.   + ROO.                         ROO-Car-ROO (non-radical product) 
        Pro-oxidant activity of carotenoids [194]: 
       Car + R.                   RH + Car.  
       Car. + O2                   Car-OO. 
       Car-OO. + RH                 Car-OOH + R.  
       where Car represents carotenoids and Car-OO. is the carotenoid-peroxyl radical 
Flavonoids are plant derived polyphenolic antioxidant compounds. There has been 
extensive research on the in-vitro free radical scavenging properties of flavonoids in the 
last decade [256]. However, their role in-vivo as antioxidant has been unclear [257]. The 
beneficial properties of flavonoids have been largely linked to their antioxidant property 
but also to their ability to interact with basic cellular mechanism such as modulation of 
the signal cascade, interaction with membrane receptors, interaction with nucleoproteins, 
and with nucleic acids [258].       
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iii) Metal sequestering agents 
These compounds are responsible for sequestering free transition metal ions such as 
copper and iron from the blood. As these transition metals are known for catalyzing the 
production of ROS, the metal sequestering agents are very important antioxidants. 
Ceruloplasmin is the major copper carrying protein in the plasma. As copper is known to 
be involved in both Fenton type and Haber-Weiss reaction, the availability of free copper 
in the presence of ROS such as H2O2 and superoxide could cause the generation of the 
highly toxic hydroxyl radical.  
Transferrins are an important class of iron binding proteins widely distributed in the 
human body [259]. The transferrins belong to a family of proteins which includes the 
serum transferrin, lactaferrin, ovotransferrin and metallotransferrin [259]. Iron is well 
known to participate in one electron transfer reactions leading to the formation of ROS 
through either the Fenton or Haber Weiss reaction. Therefore, sequestering of iron by 
transferrins provides for the safe transport of iron to the cells [260]. Transferrin is known 
to bind to the transferrin receptor that is then internalized via receptor-mediated 
endocytosis [259, 261]. Transferrin is known to bind to the transferrin receptor with high 
affinity (Kd = 5×10-9 M) [259, 261, 262].  
Metallothioneins are small sulfhydryl rich peptides [263, 264]. These intracellular 
peptides are cysteine rich compounds which bind trace metals such as cadmium, mercury, 
silver, platinum [263]. Due to their binding of the metals they are known to protect cells 
from potential oxidative stress caused by these metals. The enhanced expression of 
metallothioneins in cells has been shown to cause anti-apoptotic processes and the lack of 
 59
metallothioneins has been reported to increases the susceptibility of cells to apoptosis 
[263, 265].      
 
iv) ROS protective enzymes 
Superoxide dismutase (SOD) and catalase work together to protect the cells against 
superoxide anion and hydrogen peroxide toxicity.  
     O2.- + O2.- + 2H+                H2O2 + O2        reaction catalyzed by SOD 
            2H2O2                2H2O + O2              reaction catalyzed by catalase 
Superoxide dismutases (SOD) are the only mammalian antioxidant enzymes 
converting superoxide into H2O2 [266]. In humans, three different kinds of SOD have 
been discovered, CuZnSOD is mainly located in the cytoplasm, however it has also been 
located in cell organelles [267, 268], MnSOD is synthesized in the cytoplasm but 
transported to the mitochondria [266, 269, 270]. ECSOD is synthesized in the cytoplasm 
but acts mainly as an extracellular enzyme. Due to its location in the mitochondria, 
MnSOD has been identified as the SOD which plays an important role in rapidly growing 
cancer cells [266]. The CuZnSOD and ECSOD contain copper/zinc, while the MnSOD 
has manganese in their reactive sites [271]. The importance of SOD in normal physiology 
has been conclusively shown with the recent studies performed in genetically engineered 
mice. The mice lacking MnSOD died after several days of birth, due to massive oxidative 
stress [271]. In addition, mice lacking CuZnSOD have been shown to develop hepatic 
cancer, accelerated muscle loss, and have a reduced lifespan. While the mice lacking 
ECSOD did not show any signs of oxidative stress and survive to a normal lifespan [272, 
273]. SOD has been shown to be overexpressed in malignant cells [266, 274]. The SOD 
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overexpression in-vivo is associated with poor prognosis of some tumors such as breast 
cancer [275, 276], lung cancer [274, 277], brain tumors [278-280], and leukemia [281] 
Catalase (H2O2 oxidoreductase) is present in almost all aerobic cells and is 
responsible for reducing H2O2 by catalyzing its decomposition without the production of 
ROS. Catalase exist as dumbbell shaped tetramer of four identical subunits (250-350 
kDa), wherein each monomer contains an iron atom at the catalytic center [282]. Catalase 
mainly exists in the peroxisomes and to some extent is also present in the cytoplasmic 
fraction [283]. The catalase levels have been shown to be decreased in both the serum 
and tumor tissue of various malignancies [284].    
Glutathione peroxidase (GP) is an enzyme that catalyzes the detoxification of H2O2 
by glutathione as shown in the reaction below. The enzyme is responsible for detoxifying 
H2O2 in addition with catalase. GP is selenium containing tetrameric glycoprotein.     
                    2GSH + H2O2                 GSSG + 2H2O 
Glutathione reductase (GR) catalyzes the reduction of glutathione disulfide to 
reduced glutathione as shown in the reaction below.   
                  GSSG + NADPH + H+                  2GSH + NADP+  
1, 3-bis (chloroethyl)-1-nitrosourea (BCNU) is a known specific inhibitor of glutathione 
reductase. 
Thioredoxin reductase (TrxR) is responsible for reducing thioredoxin [283]. Three 
different thioredoxin reductase proteins in human cells have been described. TrxR1 is 
present in all compartments in the cells. TrxR2 and TrxR3 are present in the 
mitochondria. Thioredoxin reductase has selenocysteine in its active site and has been 
shown to be essential for its activity [243, 283].    
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             Trx-S2 + NADPH                Trx-(SH)2 + NADP 
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Table 3.6 Classification of antioxidants in the human body  
 
I. ROS scavenging agents 
 
Glutathione 
Thioredoxin 
 
II. Dietary antioxidants 
 
Vitamin E 
Vitamin C 
Selenium 
Carotenoids (β and α carotene) 
Flavonoids 
 
III. Metal sequestering agents 
 
Ceruloplasmin 
Transferrin 
Metallothioneins 
 
IV. ROS protective enzymes 
 
Copper/zinc superoxide dismutase (CuZnSOD) 
Extracellular superoxide dismutase (ECSOD) 
Manganese superoxide dismutase (MnSOD) 
Catalase 
Glutathione peroxidase 
Glutathione reductase 
Thioredoxin reductase 
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3.3.2.a Glutathione 
The major cellular antioxidant, glutathione (γ-Glu-CysH-Gly, γ-
glutamylcysteinylglycine) is a tripeptide, containing glutamate, cysteine, and glycine 
amino acids [237]. It is the most widely distributed intracellular thiol and low molecular 
weight peptide [237]. The γ-peptide bond between glutamate and cysteine in glutathione 
prevents its hydrolysis by most peptidases [236]. There is a sharp contrast in the 
concentration of glutathione inside and outside the cells which is important in creating 
the reductive and oxidative environments inside and outside the cells, respectively. The 
concentrations of glutathione in mammalian cells are in the millimolar ranges (1-11 mM), 
whereas only micromolar concentrations are found in the blood [237, 241]. A small 
proportion of the total cellular glutathione (10-15%) is found in the mitochondria, where 
it reaches a concentration similar to the cytosol [285]. Glutathione is converted to 
glutathione disulfide during the reduction of H2O2 and other peroxides by the selenium 
containing glutathione peroxidase [237]. The intracellular concentration of reduced 
glutathione is maintained by glutathione reductase, a NADPH-dependent enzyme which 
reduces glutathione disulfide to glutathione [236, 237]. Glutathione is synthesized 
intracellularly with the sequential action of γ-glutamylcystiene synthetase and glutathione 
synthetase in a series of six enzyme catalyzed reactions [237]. The physiological role of 
glutathione is multifaceted and is responsible for multiple cellular functions such as 
transport of amino acids, synthesis of proteins and nucleic acids, maintenance of enzymes 
in their active form, and protection against radiation and endotoxin exposure [286]. As 
the human brain cells are known to utilize about 20% of the oxygen consumed by the 
body although it only comprises 2% of body weight, the brain generates large quantities 
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of ROS during this process. Glutathione acts as the first line of defense against the ROS 
generated in the brain cells and cells in other parts of the body [286].     
The ratio between the reduced glutathione (GSH) and the oxidized glutathione 
(GSSG) forms the very important redox couple inside the cells and serves as an 
intracellular redox buffer. In a normal cell, the molar ratio of GSH/GSSG of 30:1 to 
100:1 has been measured [287]. This ratio is known to maintain the intracellular reduced 
conditions and is mainly responsible for the reduction of the oxidative species generated 
inside the cell. The change in this ratio on the other hand is seen in conditions of 
oxidative stress such as cancer [286], where the GSH/GSSG ratio could be greatly 
reduced upto 10 and 1 [286, 288]. Glutathione depletion in humans have been linked to 
many disorders such as HIV, Wilson’s disease, chronic pancreatitis, chronic pulmonary 
disease (COPD), acute respiratory distress syndrome (ARDS), neonatal lung damage, and 
asthma [286]. In addition, GSH depletion has been associated with aging through 
processes such as reduced responsiveness of T lymphocytes to mitogens, decreased 
cognitive capacities [289]. Several selective inhibitors of glutathione redox cycle have 
been developed to study the effect of these components in the glutathione associated 
antioxidant defense mechanism. For example, the activity of glutathione reductase is 
inhibited by 1,3-bis (chloroethyl)-1-nitrosourea (BCNU), the activity of glutamylcystiene 
synthetase is inhibited by buthionine sulfoximine [290], and the activity of glutathione S-
transferase inhibited by 1-chloro-2, 4-dinitrobenzene (CDNB) and diethylmaleate (DEM) 
[291]. Increasing cellular glutathione levels might be beneficial in certain disorders where 
the levels of glutathione are decreased. Cysteine and N-acetylcysteine have been used to 
increase the glutathione concentration [236]. Cysteine is usually the limiting amino acid 
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in the glutathione biosynthesis and therefore its administration has been shown to 
increase the glutathione concentration [240, 292]. N-acetylcysteine is deacetylated to 
cysteine before being used for glutathione biosynthesis [240]. Glutathione itself is not 
taken up by cells to a significant degree [237, 240]. Moreover, orally administered 
glutathione is degraded into amino acids extracellularly and the products are then 
transported inside the cells for subsequent glutathione biosynthesis [236, 238].              
Schafer et al. has described the redox potential inside the cell using the intracellular 
GSH/GSSG couple. As shown in Figure 3.6, the authors have reported that there is a 
correlation between the redox potential of the GSH/GSSG couple and the biological 
status of the cells: proliferation: -240 mV; differentiation: -200 mV; or apoptosis: -170 
mV [244]. Therefore, the GSH/GSSG provides an overview of the cellular homeostasis.          
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Figure 3.6 Redox couples in the human body. Adapted from Schafer [244] 
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3.3.3 ROS and cancer 
In a normal cell, there exists a balance between the free radical generation and the 
antioxidant defense [293]. It has long been documented that cancer cells are under 
increased and persistent oxidative stress due to elevated levels of intracellular ROS 
generation. The direct proof of oxidative stress in the cancer cells is shown through the 
analysis of significantly elevated levels of ROS such as H2O2, superoxide radical, while 
the indirect proof is shown through the existence of increased levels of lipid oxidation 
products in the cancer cells compared to surrounding normal cells. The existence of 
increased ROS induced oxidative stress in cancer cells is also a result of the lower levels 
of antioxidant enzymes such as SOD, glutathione peroxidase, glutathione reductase, and 
catalase in these cells.  
This increased intrinsic ROS stress in cancer cells has been speculated to be due to 
a number of factors such as oncogenic stimulation, increased metabolic activity, and 
mitochondrial malfunction [19]. Cancer is associated with rapid cell growth and 
differentiation. The rapid cell growth rate requires excessive energy from the 
mitochondria subsequently resulting in the production of excessive amounts of ROS. This 
excessive ROS being generated cannot be neutralized by cellular antioxidants and 
oxidative stress pursues [294]. As a result, cancer cells under sustained ROS stress 
conditions tend to heavily utilize adaptation mechanisms and may exhaust ROS-buffering 
capacity while normal cells have low levels of ROS stress and reserve a higher capacity 
to cope with further oxidative insults [19, 294]. The intracellular redox state which is 
directly related to the production of intracellular ROS in cancer cells has also been 
indicated to control the aggressiveness of cancer cells. Chaiswing et al. and colleagues 
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reported that the difference in the redox status of two prostrate cancer cell lines showed 
remarkable differences in the degree of aggressiveness [295].   
Recently, Kondo et al. examined three important questions about oxidative stress in 
cancer cells, i) is the oxidative stress limited to cancer cells and not to other surrounding 
nontumorous cells, ii) is there a difference between the oxidative stress in benign and 
malignant tumor cells, and iii) is there a correlation between oxidative stress in-vivo and 
the level of tumor cell proliferation [296]. The authors observed persistent oxidative 
stress in human colorectal carcinoma (malignant tumor), which was significantly higher 
as compared to the corresponding nontumorous epithelial cells. The authors also showed 
that the level of oxidative stress in cancer cells appears to be maintained high to promote 
cell proliferation, but concluded that this amount of oxidative stress is insufficient to 
cause apoptosis or necrosis [296]. Over the past decades numerous studies have shown 
the existence of higher or significantly higher oxidative stress in various types of 
malignancies compared to the corresponding normal subjects. The studies supporting the 
presence of elevated oxidative stress in oral and stomach cancer is shown in Table 3.7 
and Table 3.8. We further discuss some studies showing the existence of elevated 
oxidative stress in various malignancies below.    
Senthil et al. reported the evidence of oxidative stress in the circulation of the 
ovarian cancer patients. The SOD and catalase levels were analyzed to be 0.9 ± 0.1 and 
4.4 ± 0.4 (U/mg hemoglobin (Hb)), which were significantly (p<0.001) lower as 
compared to control individuals levels of 1.9 ± 0.3 and 5.7 ± 0.6 (U/mg Hb), respectively. 
Also the levels of antioxidants such as Vitamin C and E were 0.4 ± 0.03 and 1.4 ± 0.1 
(mg/dL), which were significantly (p<0.001) lower compared to control individual levels 
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of 1.0 ± 0.1 and 2.8 ± 0.2 (mg/dL), respectively [297]. Additionally, the authors reported 
that the plasma Thiobarbituric Acid Reactive Substances (TBARS) levels (nmoles 
malondialdehyde (MDA)/mL of plasma), which is generally employed as an assay for 
oxidative stress (lipid peroxidation), were significantly higher (p<0.001) in ovarian 
cancer patients compared to normal individuals (5.6 ± 0.5 compared to 2.1 ± 0.2 in 
controls) [297].   
Aydin et al. investigated the alteration of oxidant/antioxidant status in the 
circulation of benign and malignant prostrate cancer patients [298]. The authors report a 
very interesting pattern of the levels of glutathione peroxidase and SOD. The 
concentrations of both the antioxidant enzymes were significantly lower in malignancy 
compared to benign disease, and the levels in benign disease levels were significantly 
lower than in control subjects. The enzyme concentrations were control > benign > 
malignant. The concentrations of glutathione peroxidase were 9.1 ± 1.8, 8.3 ± 1.4 and 7.1 
± 1.4 (p<0.001 compared to control) (U/mL) in the control, benign and malignant 
prostrate cancer patients, respectively. While the concentrations of SOD followed the 
same trend, the concentrations were 168.0 ± 33.3, 144.4 ± 30.1, and 115.2 ± 20.2 
(p<0.001 compared to control) (U/mL) in control, benign and malignant prostate cancer 
patients, respectively [298]. The concentrations of catalase also followed the same trend 
although there were no significant differences between control, benign and malignant 
patients. [298]. 
Ho et al. reported alterations in the antioxidant status in the erythrocytes of patients 
with Non Small Cell Lung Carcinoma (NSCLC) [299]. The authors reported catalase and 
SOD concentrations to be lower than in control subjects. The catalase and SOD 
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concentrations were 7.6 (mU/g Hb) and 13.4 (U/g Hb) in NSCLC patients compared to 
20.9 and 48.7 in control subjects, respectively. The glutathione peroxidase concentrations 
however was shown to be increased in NSCLC patients, 175.2 (mU/g Hb) compared to 
49.2 (mU/g Hb)  in control subjects [299].      
Recently Beevi et al. investigated the antioxidant status in the cervical squamous 
cell carcinoma patients. SOD, catalase, and the glutathione peroxidase concentrations 
were shown to be significantly (p<0.001) lower in cervical cancer patients compared to 
normal subjects [300]. The erythrocyte SOD, catalase, and glutathione peroxidase 
concentrations were 14.2 ± 2.6, 18.9 ± 2.3, 6.7 ± 1.3 in cervical cancer compared to 18.2 
± 3.8 (U/100 mg protein), 29.3 ± 6.4 (U/mg protein), and 11.3 ± 1.8 (U/mg protein) in 
control individuals, respectively [300].    
Baticioglu et al. recently reported presence of increased oxidative stress in stomach 
cancer patients [301]. The SOD and catalase concentrations were shown to be 
significantly (p<0.001) lower compared to control subjects. SOD and catalase 
concentrations (U/mg protein) were 5.1 ± 1.9 and 6.6 ± 3.2 compared to 8.7 ± 2.6 and 
17.6 ± 8.3 in control individuals [301].  
Guven et al. investigated the lipid peroxidation and the antioxidant status in patients 
with Hodgkin’s disease [302]. Selenium and glutathione peroxidase concentrations were 
shown to be significantly (p<0.001) lower in the erythrocytes of cancer patients 
compared to controls. While the SOD levels were shown to be higher in cancer patients 
[302]. The marker for lipid peroxidation (nmol MDA/ g Hb) was significantly increased 
in the erythrocytes of cancer patients [302].   
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Navarro et al. examined the changes in glutathione status and the antioxidant 
system in blood and in cancer cells associated with tumor growth in-vivo [303]. The 
GSH/GSSG ratio was reduced, which was mainly due to increase in the GSSG levels. 
The authors explained the higher GSSG levels were due to the increase in the H2O2 
production by tumor as well as to the changes in the activity of the glutathione related 
antioxidant enzymes [303].   
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Table 3.7 Lipid peroxidation and antioxidant system status in plasma of oral cancer 
patients vs. control [304] 
 
Parameters Controls (n=16) Oral Cancer Patients 
  Stage II (n=16) 
Stage III 
(n=16) 
Stage IV 
(n=16) 
Glutathione 
peroxidase 
(U/L) 
223.8 ± 17.7 204.1 ± 13.7** 190.2 ± 12.5*** 175.1 ± 13.9*** 
SOD 
(U/mL) 4.2 ± 0.3 3.6 ± 0.7
** 3.2 ± 0.2*** 2.9 ± 0.2*** 
Catalase 
(U/L) 0.5 ± 0.03 0.5 ± 0.03 0.5 ± 0.06 0.4 ± 0.04
*** 
GSH 
(mg/dL) 50.6 ± 5.2 44.1 ± 5.6
** 37.6 ± 4.9*** 31.5 ± 4.9*** 
Vit.E 
(mg/dL) 1.2 ± 0.1 1.1 ± 0.10
** 0.9 ± 0.07*** 0.8 ± 0.1*** 
 
** p<0.01 compared to controls, *** p<0.001 compared to controls 
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Figure 3.8 Lipid peroxidation and antioxidant system status in tissue of stomach 
cancer patients vs. control [301]. 
 
Parameters Controls (n=18) 
Stomach cancer 
(n=18) 
SOD 
(U/mg protein) 8.7 ± 2.6 5.1 ± 1.9
*** 
Catalase 
(U/mg protein) 17.6 ± 8.3 6.6 ± 3.2
*** 
Glutathione peroxidase 
(U/mg protein) 0.2 ± 0.1 0.2 ± 0.1 
MDA 
(µmol/g tissue) 13.5 ± 4.7 21.8 ± 5.7
*** 
 
***p<0.001 compared to controls 
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3.3.3.a Leukemia and oxidative stress 
All forms of leukemia including Acute Lymphocytic Leukemia (ALL), Acute 
Nonlymphocytic Leukemia (ANLL), Chronic Myeloid Leukemia (CML) have been 
reported to have significantly increased levels of various ROS such as superoxide radical, 
H2O2, and alteration in the levels of enzymes such as SOD, glutathione peroxidase, 
glutathione reductase, and catalase compared to healthy individuals [70, 293, 305-308]. 
Additionally there have been studies showing that trace metals such as copper levels are 
significantly higher in leukemia patients as compared to healthy individuals [70]. 
Devi et al. reported significant increase in the superoxide anion, SOD, glutathione 
peroxidase in leukemia patients compared to that of controls [293]. The superoxide anion 
levels were shown to be significantly increased (p<0.01) at 8.0 ± 3.4 in leukemia patients 
compared to 5.1 ± 2.8 (nmoles/106 cells/30 min) for controls, while the SOD levels were 
also reported to significantly elevated (p<0.001), 3464.1 ± 1999.4 in leukemia patients 
compared to 1413 ± 243 (U/g Hb) in control individuals. Additionally, the glutathione 
peroxidase levels were shown to be significantly elevated (p<0.001) in leukemia patients, 
231.6 ± 203.3 compared to 62.1 ± 17.5 (U/g Hb) in control individuals [293]. The authors 
also reported on increase in the H2O2 generation in leukemia cells: however, the levels 
were not significantly different compared to controls [293]. The authors concluded that 
the increased free radical generation by leukemia leukocytes, increased antioxidant 
enzyme activities, and normal MDA levels indicated the existence of transient oxidative 
stress in-vivo in leukemia patients [293]. Other studies supporting the presence of 
oxidative stress in leukemia patients are shown in Table 3.9 and Table 3.10. 
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Table 3.9 Antioxidant levels in leukemia patients compared to controls [70]. 
 
Parameters 
 
Controls 
(n=20) 
Acute 
Leukemia 
(n=41) 
 
Acute 
nonlymphoid 
leukemia 
(n=34) 
 
Acute 
lymphoid 
leukemia 
(n=7) 
 
Chronic 
myelogeneous 
leukemia 
(n=8) 
Cu-Zn 
SOD 
(U/mL) 
59.8 ± 8.8 67.9 ± 9.5* 67.6 ± 10.4* 68.3 ± 8.7* 65.1 ± 14.7 
T-SOD 
(U/mL) 76.7 ± 9.8 
86.4 ± 
11.2** 85.5 ± 11.9
** 83.1 ± 10.2* 85.5 ± 14.3 
Mn-SOD 
(U/mL) 16.9 ± 1.8 17.5 ± 1.9 17.9 ± 2.0 17.2 ± 1.9 17.9 ± 2.1 
LPO 
(nmol/L) 1.9 ± 0.6 2.5 ± 0.8 2.4 ± 0.6 2.4 ± 0.7 2.3 ± 0.9 
GPx 
(U/g Hb) 11.8 ± 2.6 
27.8 ± 
9.9** 28.1 ± 10.5
** 27.1 ± 9.9* 17.6 ± 5.4 
*p<0.05 and ** p<0.01compared to controls 
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Table 3.10 Oxidants and antioxidants in leukemia patients compared to controls 
[305] 
 
 Controls (n=10) Leukemia patients 
  Chronic Myelogeneous Leukemia (n=11) 
Chronic Lymphocytic 
Leukemia (n=9) 
GSH 
(mM) 5.4 ± 0.4 9.1 ± 0.9
* 8.2 ± 0.6* 
Ascorbic acid 
(mg/dL) 9.5 ± 0.6 6.5 ± 0.7
* 5.93 ± 0.5* 
H2O2 
(µM) 51.5 ± 4.9 75.1 ± 7.0
* 79.8 ± 7.2* 
MDA 
(mmol/mL.h) 157.7 ± 13.8 401.3 ± 40.1
* 368.9 ± 40.1* 
Total 
Antioxidant 
capacity 
(mM) 
2.57 ± 0.25 4.02 ± 0.41* 3.7 ± 0.5* 
 
*p<0.05 compared to control 
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3.3.3.b Breast cancer and oxidative stress 
Analogous to leukemia, there has been accumulating evidence in support of 
significantly higher oxidative stress in breast cancer patients [284, 309-314]. The 
excessive oxidative stress in breast cancer has been correlated to the severity of the 
disease e.g. Stage IV patients have been shown to have higher levels of oxidative stress 
compared to III, who have been shown to have higher levels of ROS stress compared to 
Stage II patients and so on for Stage I and control subjects [309, 310, 313, 314]. Table 
3.11 and 3.12 shows changes in the glutathione and antioxidant status in breast cancer 
patients. 
Khanzode et al. investigated the levels of antioxidant enzymes and lipid 
peroxidation in different stages of breast cancer patients [309]. The serum SOD and 
MDA concentrations were show to be significantly increased (p<0.001), in the various 
stages IV > III > II > I > control. The plasma ascorbic acid concentrations were 
significantly lowered (p<0.001), stage IV < II < II < I breast cancer patients compared to 
control individuals [309].    
Kumaraguruparan et al. examined the antioxidant profile in the circulation of 
patients with fibroadenoma and adenocarcinoma of the breast [310]. The concentration of 
plasma glutathione (mg/dL), vitamin C and E (mg/dL) were significantly lower (p<0.05) 
in both fibroadenoma and adenocarcinoma patients compared to their age matched 
control subjects [310]. The concentrations of antioxidant enzymes such as SOD, catalase, 
glutathione peroxidase, glutathione S-transferease in the erythrocyte lysate of 
fibroadenoma and adenocarcinoma patients were also found to be significantly lower 
(p<0.05) compared to age-matched control subjects [310].     
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Sener et al. explored the lipid peroxidation and total antioxidant status in breast 
cancer patients [312]. The authors reported significantly lower (p<0.05) total antioxidant 
capacity in breast cancer patients compared to control subjects, while the serum MDA 
levels (indicator of oxidative stress) were significantly higher (p<0.05) in cancer patients 
[312]. However, the author did not find any differences between the lipid hydroperoxide 
levels in breast cancer patients [312].   
Polat et al. compared the oxidant/antioxidant status in the blood of patients with 
malignant tumor and begin breast disease [311]. The MDA levels were significantly 
higher (p<0.05) is both benign and malignant patients. The levels of SOD, catalase, 
glutathione peroxidase were found to be significantly lowered (p<0.05) in malignant 
cancer patients compared to both the benign disease and control individuals [311].  
Ray et al. examined the lipid peroxidation, free radical production and the 
antioxidant status in breast cancer patients [284]. The authors reported that the rate of 
production of ROS such as superoxide and H2O2 in the plasma were significantly 
increased (p<0.001)  in all stages of breast cancer, while the concentration of antioxidant 
such as SOD, glutathione peroxidase were significantly lower (p<0.001) in all stages of 
breast cancer patients, while the concentrations of catalase was decreased in all stages of 
breast cancer [284].        
It should be noted that these and other documented studies suggesting the existence 
of oxidative stress in cancer patients have been performed: i) in different geographical 
locations, ii) with completely different patients and control populations, and iii) the 
studies have been reported over the last three to four decades. Therefore, these well 
documented differences in the levels of oxidative stress in cancer cells and lower 
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concentrations of the antioxidant enzymes provide us with the unique opportunity to 
selectively target cancer cells by designing therapies which employ these differences as a 
mechanism to kill tumor cells.       
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Table 3.11 Glutathione status in breast cancer patients [314] 
 
 Stage I (n=19) 
Stage II 
(n=86) 
Stage III 
(n=112) 
Total 
(n=112) 
 
 
Tumor 
tissue 
 
Adjacent 
tissue 
 
Tumor 
tissue 
 
Adjacent 
tissue 
 
Tumor 
tissue 
 
Adjacent 
tissue 
 
Tumor 
tissue 
 
Adjacent  
tissue 
GSH  
(µM/g) 
498 ± 
862 
164 ± 
476 
902 ± 
2084* 
82.9±  
236 
230 ±  
285 
38.3 ± 
70.8 
792 ±  
186* 
93.9 ± 
284 
GSSG 
(µM/g) 
109 ± 
108* 
52.2 ±  
143 
167 ±  
320* 
56.4 ± 
97.8 
89.8 ± 
112 
31.4 ±  
40.5 
152 ±   
286* 
54.1 ± 
104 
Total 
Glutathione 
(µM/g) 
716 ± 
1010* 
269 ± 
747 
1236 ± 
2644* 
196 ± 
385 
409 ±  
474 
101 ±  
150 
1096 
± 
2367* 
202 ± 
455 
GSH/Total 
Glutathione 
(%) 
36.4 22.2 49.1* 36.1 31.9 31.8 45.9* 33.5 
 
*p<0.05 compared to adjacent tissues 
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Table 3.12 Antioxidant status in breast cancer patients [313] 
 
Parameters Controls (n=117) 
Breast cancer patients 
(n=117) 
Superoxide anion 
(counts/10 s × 103 WBC) 434 ± 209 664 ± 563
* 
MDA (µmol/L) 2.7 ± 0.9 3.3 ± 1.5* 
GSH (µmol/L) 1289 ± 317 506 ± 222* 
GSSG (µmol/L) 103 ± 51.1 81 ± 60* 
GSH/GSSG 16.3 ± 11.5 9.2 ± 7.0* 
SOD (U/g Hb) 806 ± 149 895 ± 350* 
GPX (U/g Hb) 46.8 ± 13.0 53.5 ± 21.4* 
GRX (U/g Hb) 7 ± 3 9.78 ± 2.9* 
Vit C (mg/L) 7.8 ± 2.9 6.5 ± 2.9* 
Vit A (µg/dL) 245 ± 86 240 ± 86.5 
Vit E (µg/mL) 15.5 ± 9.8 12.7 ± 4.6 
 
*p<0.05 compared to controls 
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3.3.4 ROS in cancer treatment 
In the last two decades ROS has been shown to be involved in each step of cancer 
development namely, initiation, promotion and progression [219, 315]. Additionally, the 
levels of antioxidant enzyme such as catalase and SOD have been shown to be altered in 
tumor cells [316]. It has been clearly documented that tumor cells are under persistent 
oxidative stress and the antioxidant system in the cancer cells are under constant attack, 
as they have to cope up with this excessive ROS being produced. Thus, there have been 
suggestions for exploiting this condition in cancer cells as a potential treatment strategy 
for cancer [317-321]. Two main strategies have been proposed: 
i) Inhibition of the antioxidant enzymes and the antioxidant system in general in 
cancer cells 
ii) Production of ROS (H2O2 and/or superoxide) in cancer cells resulting in 
apoptosis and or necrosis.  
Additionally, the higher ROS stress in cancer cells compared to normal cells also 
provides conditions for selectively targeting the cancer cells with agents that can generate 
further ROS and result in apoptosis and/or necrosis, while the normal cells should possess 
enough antioxidant enzymes to combat the extra ROS production. The above strategy is 
also schematically shown in Figure 3.7. The use of ROS in potential treatment of cancer 
was investigated as early as the 1950’s. Green et al. [322] and Sugiura et al. [323] in 1958 
reported the use of H2O2 for treating tumors in animal tumor models. H2O2 has been the 
ROS of choice for anti-cancer therapy due to its apparent stability compared to other 
radical species such as hydroxyl and superoxide radical. However, due to the presence of 
high concentrations of catalase in the blood and the ability of H2O2 to diffuse through 
 83
membranes, it is extremely difficult to achieve any biological effect in-vivo with the use 
of H2O2 alone [219, 322-325]. The first use of an agent which would act as a precursor to 
ROS generation in-vivo was reported by Nathan et al. in 1981. The authors employed 
glucose oxidase as a H2O2 generating agent and this resulted in significant anti-tumor 
activity in an animal tumor model [326]. Since then several H2O2 and superoxide radical 
generating agents have been investigated as potential anti-cancer agents [327-329]. Also, 
many chemotherapeutic agents such as doxorubicin, vinblastine, vincristine, 
camptothecins have been shown to exhibit their anticancer activity through the generation 
of either H2O2 itself or through the activation of H2O2 dependent apoptotic pathways 
inside the cells [330]. Alexandre et al. reported that the accumulation of H2O2 is an early 
and crucial step for paclitaxel-induced cancer death both in-vitro and in-vivo [331]. The 
authors showed that H2O2 was in fact generated both in-vitro in A549, human lung cancer 
cells and in the LLC1 lung cancer cells implanted in-vivo in mice [331]. Studies over the 
last decade both in-vitro and in-vivo with a number of agents which produce ROS such as 
H2O2 or superoxide radical have shown that their administration leads to anti-cancer 
effects and the cytotoxic effect is limited to the cancer cells and there was limited or no 
toxicity in the surrounding normal tissue [332].  
Procarbazine, Buthionine sulfoximine, and Motexafin gadolinium are some of the 
anti-cancer agents whose anti-cancer activity is known to be dependent on production of 
ROS or their interaction with ROS scavenging enzymes.   
Berneis et al. proposed that procarbazine as a new class of tumor inhibiting 
compound based on its generation of ROS (H2O2), as an intermediate during its anti-
tumor activity [333]. The oxidation of procarbazine in aqueous solution was shown to 
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generate H2O2 [316, 333]. Procarbazine has been approved for the treatment of 
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and primary brain tumors to enhance 
the effect of radiation [316]. 
Buthionine sulfoximine is a specific inhibitor of glutamyl synthetase and thus can 
inhibit glutathione synthesis. Several in-vitro and in-vivo studies have shown that the 
depletion of glutathione with the aid of BSO increases the sensitivity to cancer cells to 
the chemotherapeutic agents [334-336]. In addition, with the aid of BSO the resistance 
towards cytotoxic drugs such as paclitaxel was shown to be directly correlated to total 
antioxidant capacity in the cells [337]. A phase I study has shown that BSO lowered 
glutathione to 10% of its pretreatment values in tumor samples and blood lymphocytes 
[338, 339]. Maeda et al. and colleagues recently reported that the combination of BSO 
with arsenic trioxide resulted in the effective treatment of advanced solid tumor [340]. 
The cytotoxicity of arsenic trioxide has been reported to be due to the generation of ROS 
[341], and has been shown to cause clinical remission in patients with acute 
promyelocytic leukemia [342]. The combination of arsenic trioxide with a glutathione 
synthesis inhibitor, BSO resulted in inhibition of in-vitro growth in cell lines of breast, 
prostate, lung, colon, cervix, bladder, and kidney cancer [340, 343].   
Xcytrin® (Motexafin gadolinium) selectively accumulates in the tumor due to the 
increased rates of metabolism of the tumor [344, 345]. Motexafin gadolinium is currently 
being investigated in several phase  II and III clinical trials in the treatment of brain 
metastases, and non-small cell lung cancer [346, 347]. Once inside the cells, Motexafin 
gadolinium induces apoptosis by disrupting the redox dependent pathways [345].  The 
drug has been suggested to have multiple mechanisms of action which leads to the 
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disruption of the intracellular redox pathways such as the potential to inhibition of the 
enzyme thioredoxin reductase, generate ROS, deplete reducing compounds such as 
protein thiols, thioredoxin, ascorbate and glutathione [316, 348, 349].  
Toshikazu et al. have demonstrated that the production of oxidative radicals with 
the aid of a hypoxanthine and xanthine oxidase reaction resulted in anticancer effect in an 
experimental rabbit model wherein VX2 carcinomas were implanted [332]. The authors 
reported that the parenteral administration of xanthine oxidase and hypoxanthine resulted 
in increased production of superoxide radical in the VX2 carcinoma tissue compared to 
the muscle tissue surrounding the tumor region [332]. Recently, Fang et al. employed 
polyethylene glycol (PEG) to conjugate superoxide and H2O2 generating enzymes such as 
xanthine oxidase (XO) and D-amino acid oxidase (DAO) to deliver these enzymes to 
potentially increase their intra-tumor accumulation [350].  
We have recently proposed the use of D-penicillamine (D-pen), a potent copper 
chelator, as an anti-cancer agent based on its production of ROS (H2O2) during the 
copper chelation [187]. We proposed this strategy because it potentially exploits two 
crucial differences between cancer cells and normal cells: 
i) Copper levels have been documented to be significantly higher in a variety of 
malignancies including breast, leukemia, stomach, colon cancers. We have 
shown that D-pen co-incubated with cupric sulfate resulted in cytotoxicity in 
human breast cancer and leukemia cells [190]. We propose that D-pen 
administered in-vivo would interact with the excess copper in tumor tissue and 
results in anti-cancer effect. 
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ii) Cancer cells in comparison to the normal cells are under elevated levels of 
persistent oxidative stress and therefore they may have exhausted or have 
limited antioxidant defense mechanisms against any further ROS production. 
We have recently shown that the in-vitro copper pre-treatment of human 
leukemia cells in culture resulted in D-pen cytotoxicity, while D-pen 
treatment of copper un-treated (naïve) human leukemia cells did not result in 
any toxic effects [351].         
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Figure 3.7 Mechanism of ROS based anti-cancer therapies. Adapted from Nicco 
[321] and Lopez-Lazaro [319]   
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3.4 Intra-tumor delivery of hydrophilic anticancer drugs  
Chemotherapeutic agents belong to various classes of chemical compounds and 
thus they have varied physicochemical properties. The majority of the anti-cancer drugs 
are lipophilic molecules, which mean they generally have very good permeability through 
biological membranes, but they exhibit poor to limited aqueous solubility. Several novel 
delivery forms such as nanoparticles, liposomes and microparticles have been developed 
to mask the lower aqueous solubility of these agents and improve their biological activity.   
There are however, some examples of anti-cancer drugs which belong to the other 
side of the physicochemical spectrum, the biological activity of these molecules limited 
by their low lipophilicity. Over the years, several novel strategies have been proposed to 
effectively deliver these agents to the tumor site. Novel delivery systems such as 
nanoparticles, microspheres, liposomes and polymer-drug conjugates have all been 
employed to mask the physicochemical properties of hydrophilic drugs in order to 
increase their intracellular concentration.           
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3.4.1 Polymer drug conjugates 
The polymer-drug conjugates have been classified by Vincent and Duncan to be in 
the umbrella of polymer therapeutics, which also includes polymer-protein conjugates, 
polymer micelles, multicomponent polyplexes [352, 353]. Polymer-drug conjugates are 
generally composed of two components: a bioactive agent that is attached to a water 
soluble polymer. The main goal of this delivery system is to transport high amounts of 
drugs such as cytotoxic agents to the tumor site and into tumor cells [353, 354]. There are 
some critical properties which have to be considered when selecting water soluble 
polymers. The ideal polymer is biocompatible, biodegradable, non-immunogenic, and has 
a high capacity of loading active agent. Based on the above properties polymers such as 
poly(ethylene glycol) (PEG) [355, 356], N-(2-hydroxypropylmethacrylamide) (HPMA) 
copolymer [357-359], polyglutamic acid (PGA) [360-362], gelatin [363, 364], chitosan 
[365, 366] have been investigated as potential polymer candidates for the synthesis of 
polymer-drug conjugates. 
Several polymer-drug conjugates are in phase I, II, and III clinical trials as listed in 
Table 3.13 [352, 354]. The polymer conjugates in clinical trials mostly include polymer 
linked to well established chemotherapeutic agents such as paclitaxel [359], doxorubicin 
[367] and camptothecins [355, 356]. These conjugates have been shown to increase the 
amount of drug reaching the tumor site mainly through passive targeting by the Enhanced 
Permeability and Retention (EPR) effect. The EPR effect has been cited as the 
mechanism of passive tumor targeting of the polymer drug conjugates [352, 354]. One of 
the unique features of the tumor vasculature is their leakiness as a result of the 
discontinuity of the endothelium [368]. The pore size of these microvessels has been 
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reported to be in the range of 100 to 750 nm depending largely on the tumor location 
[369, 370]. The leaky vasculature of the tumor allows extravasations of the circulating 
molecules resulting in the accumulation of these delivery systems. Once in the tumor 
vasculature, the conjugates can either enter the cancer cells or release the cytotoxic agent 
outside the cell [370].   
Other than the selection of the suitable polymer, another important property which 
needs investigation is the potential bond formed between the drug and the polymer. For 
bioconjugates, the nature of the linker between the active moiety and the polymer has 
been described to dictate the successful delivery [371]. Both covalent and non-covalent 
interactions have been used for polymer-drug conjugate synthesis. The non-covalent 
interactions include high affinity ligand-receptor interactions and the electrostatic 
complexation [371, 372], while the covalent interactions include amide, ester, disulfide, 
malonate, and carbamate [352, 354]. The choice of the bond between the polymer and the 
active moiety is largely dependent on two important properties: biological stability and 
reversibility. When the release of active moiety from the polymer conjugate is necessary, 
the disulfide bond is the ideal choice due to its potential reversibility in the cell [371]. 
The relative stability in the plasma and the reversibility of the disulfide bond is based on 
the difference between glutathione concentration in the plasma (10 µM) versus in the cell 
(1-11 mM) [149, 240]. Saito et al. have described this high redox potential difference 
between the oxidizing extracellular space and the reducing intracellular space makes the 
disulfide bond most desirable as a potential delivery tool [371].  
However, there are certain restrictions in the successful delivery of drugs with the 
aid of disulfide conjugates, as polymer conjugates have low diffusivity due to their size 
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and higher aqueous and therefore low lipid solubility. The cell membrane restricts the 
entry of these conjugates in the cytosol [372]. The process by which the polymer-drug 
conjugate is taken up by the cell is generally thought to be through endocytosis. The pH 
of the early endosomes and the lysosomes have been described as acidic and oxidative in 
nature compared to the cytosol, and therefore, the reduction of the disulfide conjugates is 
slow and limited process [371-373]. In addition, the reduction in acidic environment is 
known to be inefficient as it requires the deprotonation of thiols [373]. Cysteine has been 
known to be the major reducing agent in lysosomes [374, 375], but the presence of other 
cysteine and glutathione containing enzyme has been recently discovered. Gamma-
interferon-inducible lysosomal thiol reductase (GILT) could also aid in the disulfide 
reduction [371, 376, 377].  GILT is a 30 kDa soluble glycoprotein which is expressed in 
the lysosomes and endosomes of antigen presenting cells in humans [377, 378]. GILT has 
a pH activity optimum at 4.0-5.5, compared to thioredoxin whose activity is optimal at 
pH 7.3 [377, 379].       
The synthesis of disulfide conjugates depend on the presence of thiol moieties on 
both the polymer and the active agent. Most of the polymers described above do not have 
endogenous thiol moiety. Therefore, the addition of thiol moiety to these compounds 
(either polymer of active agent or both) has to be accomplished. The modification of 
primary amines has been a popular choice for introducing thiol moieties [371]. 
Heterobifunctional cross-linkers, which have amino reactive group on one end and a thiol 
reactive group on the other end, have been commonly employed for modification of the 
amine compounds. Heterobifunctional cross-linkers such as N-succinimidyl-3-(2-
pyridylthio) propionate (SPDP), N-succinimidyl S-acteylthioacetate (SATA), 4-
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succinimidyl oxy-carbonyl-2-pyridylthio toluene (SMPT) have been used in the synthesis 
of disulfide conjugates [380-382].       
Mylotarg® (anti-CD33, antibody-S-S-calicheamicin) is a chemotherapeutic agent 
composed of recombinant humanized antibody conjugated to the cytotoxic agent, 
calicheamicin with the aid of a disulfide bond. Mylotarg is one of the fist disulfide 
conjugates recently approved by the FDA for the treatment of acute leukemia [371, 383].    
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Table 3.13 Polymer-drug conjugates in clinical trials. Adapted from Vincent [352] 
 
 
Compound 
Commer- 
cial 
Name 
Status Polymer characteristics Linker 
Drug 
(loading) Cleavage 
   Polymer Mass (g/mol)    
Polyglutamate
-paclitaxel 
 
XYOTAX 
Phase 
II/III PGA 40,000 Ester 
Paclitaxel 
(37% w/w) Esterase 
Polyglutamate 
Camptothecin CT2106 
Phase 
I PGA 40,000 Ester 
Camptothecin 
(33-35% 
w/w) 
Esterases 
HPMA 
copolymer-
doxorubicin 
PK1 Phase I HPMA 30,000 Amide 
Doxorubicin 
(8.5% w/w) Cathepsin B
HPMA 
copolymer-
doxorubicin-
galactosamine 
PK2 Phase I/II HPMA 25,000 Amide 
Doxorubicin 
(7.5% w/w) Cathepsin B
HPMA 
copolymer-
carboplatin 
palatinate 
AP5280 Phase I/II HPMA 25,000 Malonate 
Platinum 
(7% w/w) Hydrolysis 
HPMA 
copolymer-
DACH-
platinate 
AP5346 Phase I/II HPMA 25,000 
 
Malonate
-DACH 
Platinum 
(7% w/w) Hydrolysis 
PEG-
Camptothecin 
PROTHE
CAN 
Phase 
I PEG 40,000 Ester 
Camptothecin 
(1.7% w/w) Esterases 
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3.4.1.a Gelatin conjugates 
Gelatin is a commonly used natural polymer which is derived from collagen [384]. 
Two kinds of gelatin can be produced based on the extraction process from collagen. 
Gelatin A and B are the acid and base derived forms of gelatin, respectively. In the 
pharmaceutical industry, gelatin is used as a suspending agent, encapsulating agent, and 
tablet binder [384, 385]. Gelatin is considered as Generally Regarded As Safe (GRAS) by 
the FDA. The characteristic properties of gelatin which make it an ideal polymer 
candidate are low level of immunogenicity and cytotoxicity, biodegradability, and the 
capacity for modification (mainly due to the presence of large number of amino groups 
which could be used for conjugation) [384-387]. Gelatin has been successfully 
investigated as a vehicle for gene delivery [388, 389], as a vehicle for the release of 
bioactive molecules [390-392], and in the generation of scaffolds for tissue engineering 
[393, 394]. Novel delivery formulations employing gelatin have been previously 
described such as conjugates [390, 392, 395], nanoparticles [363, 388, 389, 396, 397], 
microparticles [363, 398, 399], and tissue scaffolds [400, 401]. Gelatin conjugates with 
cytotoxic agents have been shown to be successful in delivering these agents to cancer 
cells. Ofner et al. recently described the synthesis of a gelatin-methotrexate conjugate for 
the increased intracellular delivery of methotrexate in cancer cells [390]. Chung et al. 
have earlier described the enzymatic synthesis and antioxidant property of gelatin-
catechin conjugates [395]. The conjugate was shown to be a good scavenging activity 
against superoxide radical. Additionally, the conjugate was also shown an amplified 
effect on human low density lipoprotein oxidation [395].   
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Chapter 4 
 
An investigation into copper catalyzed D-penicillamine oxidation and subsequent 
hydrogen peroxide generation 
 
4.1 Summary 
 D-penicillamine (D-pen) is a potent copper (Cu) chelating agent.  D-pen reduces 
Cu(II) to Cu(I) in the process of chelation while at the same time being oxidized to D-pen 
disulfide (D-pen-S-S-D-pen). It has been proposed that hydrogen peroxide (H2O2) is 
generated during this process. However, definitive experimental proof that H2O2 is 
generated remains lacking. Thus, the major aims of these studies were to confirm and 
quantitatively assess the in-vitro production of H2O2 during copper catalyzed D-pen 
oxidation, and to determine the reaction kinetics. The biological effect of the proposed 
cytotoxic H2O2 generation was also investigated in-vitro against MCF-7 human breast 
cancer cells.  Cell cytotoxicity resulting from the incubation of D-pen with copper was 
compared to that of D-pen, copper and H2O2. The mechanism of copper catalyzed D-pen 
oxidation and simultaneous H2O2 production was investigated as a function of time, 
concentration of cupric sulfate or ferric chloride, temperature, pH, anaerobic condition 
and chelators such as EDTA and bathocuproinedisulfonic acid (BCS). A simple, sensitive 
and rapid HPLC assay was developed to simultaneously detect D-pen, its major oxidation 
product D-pen disulfide, and H2O2 in a single run. H2O2 was shown to be generated in a 
concentration dependent fashion as a result of D-pen oxidation in the presence of cupric 
sulfate. Chelators such as EDTA and BCS were able to inhibit D-pen oxidation. The 
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incubation of MCF-7 human breast cancer cells with D-pen plus cupric sulfate resulted in 
the production of reactive oxygen species (ROS) within the cell and cytotoxicity that was 
comparable to free H2O2.  
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4.2 Introduction 
Thiol containing compounds such as glutathione and cysteine play an important role 
in protecting biological systems against oxidative stress [154, 402, 403]. However, it is 
recognized that these endogenous thiols can also be oxidized to disulfides in the presence 
of transition metals such as copper and iron [404-406].  This oxidation process is known 
to generate hydrogen peroxide (H2O2) which leads to oxidative stress [152, 407, 408]. 
The interaction of copper and endogenous thiols has received considerable focus since 
the ratio between the oxidized and the reduced thiol could greatly affect the cellular redox 
status and modulate the activity of several thiol dependent enzymes [204, 409].  
D-penicillamine (D-pen) is an aminothiol and a potent copper chelating agent. It is 
currently approved by the FDA (CUPRIMINE®, Merck) for the treatment of Wilson’s 
disease and rheumatoid arthritis. D-pen is known to remove excess copper accumulated 
in Wilson’s disease patients [39, 131].  The efficacy of D-pen in rheumatoid arthritis is 
more complicated as a variety of therapeutic mechanisms have been reported [24, 115, 
142]. D-pen binds Cu(II) and reduces it in the process of chelation to Cu(I) [23, 410]. D-
pen then binds to Cu(I) with a stability constant of 18.8 [47]. It has been proposed that 
the interaction between D-pen and copper results in the formation of a multivalent D-pen-
copper complex (Cu8ICu6II(D-pen)12Cl)5-, although its in-vivo presence is yet to be 
conclusively proven [143, 144]. Kato et al. demonstrated using in-vitro 1H-NMR studies 
that D-pen incubation with copper in the presence of glutathione resulted in the formation 
of a multivalent D-pen-glutathione-copper complex [144]. It has been proposed that in 
the D-pen copper complex, Cu(II) is in equilibrium with the surrounding aqueous 
medium while Cu(I) is removed from equilibrium [144].  Thus, the continued presence of 
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Cu(II) leads to the potential of Cu(II) being available for catalyzing thiol oxidation. 
Therefore, the process of D-pen chelation with Cu(II) and subsequent reduction of Cu(II) 
to Cu(I) may catalyze oxidation that leads to the generation of reactive oxygen species 
(ROS) such as superoxide radicals, H2O2, and hydroxyl radicals (Figure 4.1).  These ROS 
can induce damage to proteins and DNA and cause membrane peroxidation as previously 
described [211, 212, 411]. 
Although D-pen can generate H2O2, it can also react with the generated H2O2. The 
pKa of thiol group of D-pen is known to play a critical role in its reaction with H2O2 
[154, 412]. The thiol group of D-pen has a pKa of is 7.9 compared to that of 8.3 and 8.75 
for cysteine and glutathione, respectively. Since the rate of thiol reaction with H2O2 
increases with decreasing pKa [154, 412], there is more competition with D-pen between 
the production of H2O2 and reaction with H2O2 in the biological environment.   
Previous studies in the literature investigating the metal catalyzed thiol oxidation 
have employed a wide variety of techniques to detect or quantify H2O2 including 
horseradish peroxidase plus scopoletin [413], the use of an oxygen electrode [414], or by 
its inhibition with catalase [415]. The loss of thiol is commonly measured with Ellman’s 
reagent while the final product of oxidation, the respective disulfide, is generally not 
measured. These methods employed to quantify D-pen and H2O2 are relatively insensitive 
and non-specific. Newer techniques that can simultaneously quantify the disappearance 
of D-pen and the appearance of D-pen disulfide and H2O2 would greatly enhance the 
understanding of copper catalyzed D-pen oxidation mechanisms. One of the major 
difficulties in D-pen assay development has been to maintain D-pen in its reduced state 
and prevent its spontaneous oxidation in air to D-pen disulfide. It is notable that D-pen 
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disulfide is highly resistant to reduction even in the presence of DTT, TCEP and other 
commonly used reducing agents [185, 186].  
The aim of the present studies was to provide experimental evidence that 
concentration dependent H2O2 is generated in-vitro as a result of copper catalyzed D-pen 
oxidation. A simple, sensitive and rapid HPLC assay was developed that simultaneously 
detected and quantified D-pen, D-pen disulfide and H2O2 in a single run. The mechanism 
of copper catalyzed D-pen oxidation and simultaneous H2O2 production was investigated 
as a function of time, concentration of cupric sulfate or ferric chloride, temperature, pH, 
anaerobic condition and chelators such as EDTA and bathocuproinedisulfonic acid 
(BCS). The biological implications of cytotoxic H2O2 generation as a result of chelation 
of D-pen with copper was examined against MCF-7 human breast cancer cells and 
compared to the cytotoxic effects of D-pen, cupric sulfate and H2O2.     
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4.3 Materials and methods 
Reagents 
D-penicillamine, D-penicillamine disulfide, cupric sulfate (CuSO4), ferric chloride 
(FeCl3), hydrogen peroxide (H2O2) solution 30% w/w, bathocuproinedisulfonic acid 
(BCS) disodium salt, catalase (bovine liver), ethylenediaminetetraacetic acid  (EDTA) 
disodium salt, tris (2-carboxyethyl) phosphine (TCEP), dithiothreitol (DTT) were 
purchased from Sigma Chemical Co. (St. Louis, MO). Acetonitrile and o-phosphoric acid 
(85%) were HPLC grade and purchased from Fisher Scientific Co. (Pittsburg, PA).  
MCF-7 cell line, fetal bovine serum (FBS), penicillin-streptomycin antibiotic solution, 
trypsin-EDTA solution and MTT assay kit were purchased from the American Type 
Culture Collection (Rockville, MD). RPMI-1640 media was purchased from Gibco 
(Carlsbad, CA). 2’-7’-dichlorodihydrofluorescein diacetate (H2DCFDA) was purchased 
from Molecular Probes (Eugene, OR). 
 
High Performance Liquid Chromatography (HPLC) 
The HPLC system (Spectra System® (ThermoSeparation Products)) consisted of the 
following: a pump (model Spectra System® P4000; ThermoSeparation Products) with a 
flow rate of 1 mL/min; an autosampler (model Spectra System® AS3000; 
ThermoSeparation Products), an UV detector (model Spectra system® UV6000; 
ThermoSeparation Products) set at 214 nm (rise time 2 s) and a data acquisition system 
(Chromoquest® software Version. 2.5); an analytical column (YMC ProPack C18 with 5-
µm beads; 150 mm x 4.6 mm; Waters Corp. Milford, MA). The mobile phase (50% - 
50% v/v mixture of solvent A (50 mM phosphoric acid) and solvent B (50 mM 
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phosphoric acid + 5% acetonitrile)), the pH of both solvents was adjusted to pH 2.5 and 
were pumped at a flow rate of 1 mL/min, which led to a typical backpressure of 1600 psi. 
H2O2, D-pen disulfide and D-pen were detected by UV absorption at 214 nm with 
retention times of 1.69, 2.8 and 3.07 min, respectively. Sample concentrations (µM) were 
obtained from the regression line of peak area versus standard concentrations (µM).  
These were calculated using a ten-point calibration curve of H2O2, D-pen disulfide and D-
pen standards. Water used in the mobile phase was deionized and further purified with 
Milli-Q® Synthesis A10 Ultra Pure Water System, Millipore Ltd. (Billerica, MA).    
 
Evidence of hydrogen peroxide generation as a result of D-pen oxidation  
D-pen oxidation was investigated in deionized water as follows: either I) D-pen (50, 
100 and 500 µM) was incubated alone, or II) D-pen (50, 100 and 500 µM) was incubated 
with cupric sulfate (4 µM), or III) D-pen (50, 100 and 500 µM) was incubated with 
cupric sulfate (4 µM) and catalase (100 U/mL) for 15 min at 25 ˚C.  The percentage of D-
pen oxidized was calculated as:  D-pen oxidized (%) = (D-pen disulfide (µM) / D-pen 
(µM)) × 100. 
 
Effect of incubation time and cupric sulfate concentration on copper catalyzed D-
pen oxidation 
To investigate the effect of incubation time on copper catalyzed D-pen oxidation, 
solutions containing D-pen (100 µM) and cupric sulfate (4 µM) were incubated at 25˚C. 
The oxidation reaction was stopped with the addition of EDTA (1 mM) and samples 
where analyzed at predetermined time points between 0 and 20 min. These studies were 
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performed in deionized water. To compare the copper catalyzed D-pen oxidation profile 
with that of another transition metal, the above studies were repeated under similar 
experimental conditions with ferric chloride (4 µM).  
To investigate the effect of increasing cupric sulfate concentration on copper 
catalyzed D-pen oxidation, D-pen (100 µM) was incubated with a range of cupric sulfate 
concentrations of 0.1 to 20 μM for 20 min followed by addition of EDTA (1 mM).   
Samples were analyzed for the disappearance of D-pen and the appearance of D-pen 
disulfide and H2O2 using the developed HPLC assay. 
 
Effect of chelators, pH, and temperature on copper catalyzed D-pen oxidation 
EDTA and a Cu(I) specific chelator (BCS) were used to investigate the effect of 
other chelating agents on copper catalyzed D-pen oxidation. A solution containing D-pen 
and cupric sulfate (4 µM) was incubated with varying concentrations (0-50 mM) of either 
EDTA or BCS for 1 h.    
The effect of pH was investigated in the presence of cupric sulfate (3 µM), ferric 
chloride (3 µM), cupric sulfate (3 µM) + ferric chloride (12 µM), cupric sulfate (3 µM) + 
ferric chloride (3 µM) and cupric sulfate (12 µM) + ferric chloride (3 µM). These studies 
were performed in phosphate buffer (0.1 M) at pH 6.0 and 7.0.  
The effect of temperature was investigated by incubating D-pen (850 µM) with 
cupric sulfate (4 µM) at 4, 25 and 37°C at pH 7.4 in phosphate buffer (0.1 M). As a 
negative control, D-pen was also incubated without cupric sulfate at 25°C at pH 7.4 in 
phosphate buffer (0.1 M). Concentration (µM) versus time curves for the disappearance 
of D-pen and the appearance of D-pen disulfide at 4, 25 and 37ºC was fitted to a first-
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order model using non-linear least squares regression analysis (SCIENTIST®, Micromath 
Inc., St Louis, MO). 
 
Cell cytotoxicity studies with breast cancer cells (MCF-7)  
 MCF-7 cells were cultured in RPMI media supplemented with 10% FBS at 37°C in 
5% CO2. Cells were transferred to a 96-well plate and seeded at 1×105 cells/well and 
allowed to attach for 24 h before the commencement of the experiment. Cell cytotoxicity 
was determined using an MTT assay kit and reported as the % viable cells compared to 
control cells after 48 h. Cells were incubated with D-pen alone (10, 100 and 1000 µM), 
cupric sulfate alone (10 µM), H2O2 alone (50, 250, 500 and 1000 µM), and D-pen (100, 
500 and 1000 µM) + cupric sulfate (10 µM), D-pen (1000 µM) + cupric sulfate (10 µM) 
+ catalase (1000 U/mL). 
 
Determination of intracellular reactive oxygen species (ROS) with 2’-7’ 
dichlorodihydrofluorescein diacetate (H2DCFDA)  
MCF-7 cells (4×105 cells/well) were incubated with 10 µM 2’-7’ 
dichlorodihydrofluorescein diacetate (H2DCFDA) in PBS (pH 7.4) for 40 min at 37ºC to 
load the cells with the intracellular reactive oxygen species marker.  This was followed 
by washing the cells twice with fresh PBS to remove excess H2DCFDA. Complete RPMI 
media containing cupric sulfate (10 µM), D-pen (1000 µM), and D-pen (1000 µM) + 
cupric sulfate (10 µM) was added and cells were incubated for 2, 4 and 6 h, and the cell-
associated fluorescence was measured using a Biotek FL600 Spectrophotometer 
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(Winooski, VT) (excitation 485 nm, emission 530 nm) and compared to that of untreated 
but H2DCFDA loaded MCF-7 cells. 
 
Statistical analysis  
Statistical analysis on Figure 4.4 was performed with one-way analysis of variances 
(ANOVA) followed by Dunnett’s multiple comparison post-test.  Statistical analysis on 
Figures 4.5 and 4.7 was performed using a two-way ANOVA followed by Bonferroni 
post test. Statistical analysis on Figure 4.6 was performed using a one-way ANOVA with 
Newman-Keuls multiple comparison post-test with GraphPad Prism® 4 software (San 
Diego, CA). 
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4.4 Results and discussion  
Determination of D-pen, D-pen disulfide and hydrogen peroxide 
In earlier published reports investigating thiol oxidation [23, 413], the 
disappearance of thiol was solely analyzed by Ellman’s reagent (DTNB) which reacts 
with free sulfhydryl (-SH) groups to form a yellow colored compound. The appearance of 
H2O2 was analyzed by non-specific or insensitive methods [413-415] while the 
concentration of D-pen disulfide was not analyzed. Although HPLC methods to separate 
and quantify thiols and their disulfides have been published earlier by a few groups [416, 
417], we were not aware of a method that could separate and quantify D-pen and D-pen 
disulfide. The majority of the earlier published HPLC methods for detecting D-pen 
mostly involved an initial step of derivatization of D-pen [165, 171] mainly through 
Michael’s addition with the thiol group. This derivatization led to efficient and sensitive 
detection of D-pen, but it also meant that D-pen could be detected only in its reduced 
form. An HPLC assay was sought that could detect D-pen, D-pen disulfide and H2O2 
simultaneously in the same run. Luo et al. [418] previously described a simple HPLC 
method that detected cysteine, its respective disulfide, and H2O2 in a single run. Due to 
apparent structural similarities between cysteine and D-pen, we decided to modify the 
method of Luo et al. to achieve the separation, detection and quantification of D-pen, D-
pen disulfide and H2O2. A representative chromatogram of simultaneous H2O2, D-pen 
disulfide and D-pen elution is shown in Figure 4.2. The retention times for H2O2, D-pen 
disulfide and D-pen were 1.69 ± 0.01 min, 2.8 ± 0.01 min and 3.07 ± 0.01 min, 
respectively. Although D-pen disulfide and D-pen eluted close to one another, there was 
excellent resolution to separate and quantify both compounds. D-pen disulfide and H2O2 
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were stable if stored at 4°C; however, D-pen had to be analyzed immediately due to its 
oxidation to form D-pen disulfide. The limit of quantification (LOQ) for D-pen, D-pen 
disulfide and H2O2 was 5 µM. The coefficient of variation (C.V.) for intra-run and inter-
run for H2O2, D-pen disulfide and D-pen ranged between 1-3%, respectively. A linear 
concentration range of 5 to 1000 µM for H2O2, D-pen disulfide and D-pen was 
established. The C.V. for response factors in the linear range between 5 to 1000 µM was 
8-9%, 4-4.5% and 3–3.4% for H2O2, D-pen disulfide and D-pen, respectively. 
Although this assay for D-pen is not as sensitive as other fluorescence or 
electrochemical HPLC methods [417], it has the advantages of i) being easier than the 
previous assay requiring derivatization of D-pen and, ii) being able to simultaneously 
detect H2O2, D-pen disulfide and D-pen.. 
 
Evidence of hydrogen peroxide generation as a result of D-pen oxidation 
D-pen oxidation was preliminarily investigated in deionized water at 25°C for 15 
min. D-pen (50, 100 and 500 µM) was incubated alone, with cupric sulfate (4 µM), or D-
pen was incubated with cupric sulfate (4 µM) and catalase (100 U/mL). When D-pen was 
incubated alone at concentrations of 50, 100 and 500 µM, D-pen was fully recovered 
giving, 50.1 ± 1.3, 97.5 ± 7.0 and 500 ± 15.9 µM D-pen. However, when cupric sulfate (4 
µM) was added to D-pen at concentrations of 50, 100 and 500 µM, D-pen was 
completely oxidized to D-pen disulfide resulting in detectable D-pen disulfide 
concentrations at 15 min of 25.7 ± 0.4 µM, 51.4 ± 1.0 µM and 252.4 ± 6.3 µM, 
respectively, with the simultaneous production of H2O2 at concentrations of 21.1 ± 0.9 
µM, 43.4 ± 1.4 µM and 116.5 ± 8.6 µM, respectively. To confirm that H2O2 was being 
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generated, the same experiment was repeated in the presence of catalase (100 U/mL). D-
pen at concentrations of 50, 100 and 500 µM, was completely oxidized to D-pen disulfide 
to produce final concentration of D-pen disulfide of 24.8 ± 0.1 µM, 57.4 ± 0.6 µM and 
254 ± 0.7 µM, respectively, with no H2O2 being detected. It was also noted that the molar 
ratio of H2O2 generated to D-pen oxidized was approximately 1:2 mol/mol at lower 
concentration of D-pen (50 and 100 µM) which is in agreement with the mechanism 
proposed by Starkebaum et al. [23] for copper catalyzed D-pen oxidation and subsequent 
H2O2 generation (Figure 4.1). However, at higher D-pen concentration (500 µM), only 
116.5 ± 8.6 µM of H2O2 was detected. This was presumably due to the loss of H2O2 as 
well as further oxidation and loss of D-pen due to reaction of D-pen with H2O2.        
 
Effect of time of incubation and concentration of cupric sulfate on the copper 
catalyzed D-pen oxidation 
As shown in Figure 4.3a, when D-pen (100 µM) was incubated with cupric sulfate 
(4 µM), D-pen oxidation was complete after 10 min resulting in the generation of 45.7 ± 
1.7 µM H2O2, which is in agreement with the 1:2 molar ratio of H2O2 to D-pen 
mentioned above. After D-pen oxidation was complete, the H2O2 generated remained 
constant until the end of the experiment demonstrating that H2O2 generation was directly 
related to the availability of D-pen.     
D-pen (100 µM) was then incubated with a range of cupric sulfate concentration 
(0.1-20 µM) at 25°C for 20 min. This was followed by the addition of EDTA (1 mM) to 
stop further D-pen oxidation. Samples were analyzed to determine the D-pen 
disappearance and the appearance of H2O2 and D-pen disulfide. As shown in Figure 4.3b, 
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a maximum of 42 ± 4.3 µM H2O2 was generated using 4 µM cupric sulfate. It should be 
noted that almost all copper in-vivo is bound to the copper carrying protein ceruloplasmin 
and/or albumin and that the concentration of free copper is very low. Each ceruloplasmin 
binds about 6-7 copper atoms although it has been suggested that at least one of the 
copper atoms is loosely bound and therefore could be available for catalyzing D-pen 
oxidation [419, 420]. The binding of albumin to copper is much weaker compared to 
ceruloplasmin; thus, the ability of D-pen to remove excess copper in wilson’s disease 
could be due to its ability to interact with albumin and remove albumin bound copper 
[420-422]. In any case, it can be seen from the present experiments that ≤1000 nM cupric 
sulfate was able to oxidize D-pen and generate H2O2 which then suggests that even 
nanomolar concentrations of copper is  enough for significant H2O2 generation.    
When increasing concentrations of ferric chloride (0.1-20 µM) was incubated with 
D-pen (100 µM) under similar experimental conditions, it resulted in only ~6-8% 
oxidation of D-pen confirming earlier published reports [423-425] that iron catalyzed 
oxidation rates for thiols are significantly less than that of copper catalyzed (data not 
shown).   
 
Effect of ETDA and BCS on copper catalyzed D-pen oxidation 
When D-pen was incubated with cupric sulfate (4 µM) in the presence of EDTA 
and BCS at concentrations from 0.5-50 mM, D-pen was completely protected from 
oxidation due to the chelation of copper (data not shown). The possible explanation 
would be that EDTA is known to chelate Cu (II) compared to D-pen which reduces 
Cu(II) first to Cu(I) before chelation. Therefore, EDTA was able to protect D-pen from 
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oxidation in the presence of Cu(II). The mechanism proposed by Starkebaum et al.  
(Figure 4.1) of D-pen oxidation suggests that the first step involves the reduction of Cu 
(II) to Cu(I) by D-pen. As confirmed in these studies, the reduction of Cu(II) to Cu(I) is 
the initial step in H2O2 production, and thus a Cu(I) specific chelator is able to block any 
D-pen oxidation and subsequent generation of H2O2.  
 
Effect of copper and iron concentration on D-pen oxidation at pH 6 and 7 
The effect of pH and the presence of either cupric sulfate or ferric chloride alone or 
in combination on D-pen oxidation was investigated. The experiments were performed in 
phosphate buffer (0.1 M) at either pH 6 or 7 at 25°C for 2 h. When D-pen (450 µM) was 
incubated with cupric sulfate (3 µM) alone, complete oxidation (p<0.01) was observed at 
both pH 6 and 7. When ferric chloride (3 µM) was employed, only ~25% and ~20% 
(p<0.01) oxidation was observed at pH 6 and 7, respectively (Figure 4.4). When a 
combination of ferric chloride and cupric sulfate (12 µM + 3 µM, 3 µM + 3 µM and 3 
µM + 12 µM) were employed complete D-pen oxidation was observed (p<0.01) at both 
pH 6 and 7. This suggested that the rate of D-pen oxidation is dominated by the presence 
of copper. Finally, when D-pen was incubated with cupric sulfate (3 µM) in the absence 
of oxygen, only ≤ 10% D-pen was oxidized at both pH 6 and 7 (p<0.01) suggesting that 
oxygen is essential for the oxidation of D-pen.  
 
Effect of additional D-pen on copper catalyzed D-pen oxidation  
As shown in Table 4.1, D-pen (90 µM) was initially incubated with cupric sulfate (4 
µM) in phosphate buffer (0.1 M) at either pH 6.2 and 7.4 for 1 h at 25°C. Samples were 
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analyzed and complete D-pen oxidation was confirmed with the formation of 38.2 ± 4.2 
µM and 38.7 ± 2.3 µM of D-pen disulfide at pH 6.2 and 7.4, respectively. The state of 
copper after it has completely oxidized D-pen was investigated. Specifically, additional 
D-pen (90 µM) was added and samples were again incubated for 1 h followed by 
analysis. It was found that D-pen oxidation was complete as 81.7 ± 4.3 µM and 86.9 ± 
6.7 µM of cumulative D-pen-disulfide was formed at pH 6.2 and 7.4, respectively. 
Additional D-pen (90 µM) was added and samples were incubated for 2 h followed by 
analysis. Complete D-pen oxidation resulted in the cumulative formation of 126 ± 1.5 
µM and 134.7 ± 5.4 µM of D-pen disulfide at pH 6 and 7, respectively. Finally, D-pen 
(90 µM) was added one additional time and incubated for 10 h followed by analysis. All 
of the available D-pen was oxidized resulting in the formation of 181.9 ± 3.5 µM and 
186.4 ± 2.7 µM of D-pen disulfide at pH 6 and 7, respectively.  Thus, after each addition 
of D-pen and subsequent incubation there was a consistent formation of D-pen disulfide 
indicating that copper had retained its catalytic activity after initial interaction with D-
pen. These data strongly suggests that the formed D-pen copper complex is still able to 
oxidize available D-pen.      
 
Effect of temperature on copper catalyzed D-pen oxidation  
Copper catalyzed D-pen oxidation was strongly influenced by temperature as 
shown in Figure 4.5. After 5 h incubation of D-pen (850 µM) with cupric sulfate (4 µM), 
49% D-pen was oxidized at 4°C (p<0.01), 78% D-pen was oxidized at 25°C (p<0.001) 
and 99% D-pen was oxidized at 37°C (p<0.001). In the absence of cupric sulfate, only 
18% D-pen was oxidized after 5 h at 25°C. The first-order D-pen oxidation rate constants 
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in the presence of cupric sulfate (4 µM) at 4ºC, 25ºC and 37ºC were 0.131 ± 0.001 h-1, 
0.273 ± 0.002 h-1, and 0.459 ± 0.012 h-1, respectively. In contrast, in the absence of cupric 
sulfate, the oxidation rate constant at 25ºC was 0.036 ± 0.001 h-1. The rate constants 
generated through curve fitting at 4, 25 and 37ºC were well described by the Arrhenius 
Equation as a plot of (1/K x 103) (x-axis) versus k (y-axis) yielded an r2 value of 0.9921 
with an activation energy (Ea) of 20.57 kJ/mol (data not shown). 
 
Cytotoxicity studies with breast cancer cells (MCF-7)      
The in-vitro cell cytotoxicity of D-pen supplemented with cupric sulfate was 
investigated using MCF-7 human breast cancer cells                         
to ascertain the potential biological effect of H2O2 generation. Cell viability was 
investigated at 48 h using the MTT assay. Cell incubation with D-pen alone resulted in no 
significant cytotoxicity, with 94.1 ± 5.5%, 91.2 ± 5.6% and 97.9 ± 4.6% cells remaining 
viable after 48 h incubation with D-pen at concentrations of 10, 100 and 1000 µM, 
respectively. Likewise, cupric sulfate incubation at a concentration of 10 µM did not 
result in significant cytotoxicity, with 98 ± 2.1% cells surviving after 48 h incubation. 
Cell viability was 92 ± 0.6%, 98 ± 4 %, 97 ± 1.6% and 77.3 ± 6.2% after incubation with 
H2O2 concentrations of 50, 250, 500 and 1000 µM for 48 h, respectively. However when 
MCF-7 cells were incubated with a combination of D-pen (100, 500 and 1000 µM) + 
cupric sulfate (10 µM), the cell viability was 84 ± 2.8%, 86.7 ± 2.4% and 83.9 ± 5.6%, 
respectively, after 48 h incubation. The reason for a lack of dose-dependent response is 
currently under investigation. However, the current hypothesis is that since the membrane 
permeability of Cu, D-pen, and the D-pen/Cu complex are very low, a sufficiently high 
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extracellular concentration of these species is required by Fick’s law to drive the 
diffusion of these species into the cell. 
As shown in Figure 4.6, the cytotoxicity resulting from incubation MCF-7 cells 
with a combination of D-pen (1000 µM) + cupric sulfate (10 µM) was significantly lower 
than either D-pen (1000 µM) and cupric sulfate (10 µM) alone (p<0.05). It is to be noted 
that there was no significant difference between the cytotoxicity resulting from the 
incubation of the combination of D-pen (1000 µM) + cupric sulfate (10 µM) and H2O2 
(1000 µM) (p>0.05). To confirm that the cytotoxicity resulting from the incubation of D-
pen + cupric sulfate was directly related to H2O2 generation, catalase (1000 U/mL) was 
added to D-pen (1000 µM) plus cupric sulfate (10 µM) and the above experiment was 
repeated, a complete recovery of cell viability was observed (Figure 4.6) compared to D-
pen (1000 µM) + cupric sulfate (10 µM) (p<0.01) confirming the direct involvement of 
H2O2 in cell cytotoxicity.  
H2O2 has been shown to be generated in-vitro in cell cytotoxicity studies when D-
pen plus copper were incubated with ductal carcinoma cell line [426], murine 
plasmocytoma cells [427], endothelial cells [6, 23], T-lymphocytes [141, 428] and human 
fibroblast [142].  Samoszuk et al. [427] demonstrated that a combination of D-pen plus 
copper exhibited a significant antiproliferative effect on tumor cells in-vitro and the fact 
that this effect was inhibited by the presence of catalase clearly demonstrated that H2O2 
was responsible for the cytotoxicity.                                                                               
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Generation of intracellular oxidant species as determined with H2DCFDA   
H2DCFDA readily enters the cell and is hydrolyzed by esterases to the non-
fluorescent 2’-7’ dichlorodihydrofluorescein (H2DCF).  H2DCF undergoes subsequent 
conversion to the fluorescent 2’-7’ dichlorofluorescein (DCF) upon reaction with oxidant 
species [429-431]. To further provide proof that H2O2 and other reactive oxygen species 
were in fact being generated as a result of D-pen oxidation, D-pen (1000 µM) + cupric 
sulfate (10 µM) were incubated with H2DCFDA loaded MCF-7 cells and cell-associated 
fluorescence was measured at 2, 4, and 6 h. As shown in Figure 4.7, while D-pen (1000 
µM) and cupric sulfate (10 µM) alone did not show statistically significant cell-
associated fluorescence compared to control at 2, 4 and 6 h, D-pen and cupric sulfate 
incubated together at the concentrations above caused a 2 fold increase in the cell-
associated fluorescence at 2, 4 and 6 h. This confirmed that copper catalyzed D-pen 
oxidation leads to the generation of reactive oxygen species within the cells.   These data 
strongly suggest that the production of hydrogen peroxide led to the formation of 
intracellular reactive oxygen species that caused cell cytotoxicity.  However, additional 
studies are on-going to provide conclusive evidence. 
D-pen is currently being investigated as an anti-angiogenic agent [4, 8, 86], mainly 
due to its copper chelating efficacy.  However, the present work suggests that D-pen in 
the presence of copper is also capable of generating cytotoxic concentrations of H2O2. It 
has been reported that the serum and tumor levels of copper and ceruloplasmin are higher 
in diverse malignant conditions such as breast [59, 60], leukemia [432], lung [72], and 
gynecological carcinomas [71]. Additionally, the copper and ceruloplasmin levels have 
been shown to relate to the stage and kind of malignancy, with maximum rise in copper 
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levels in poorly differentiated variety [59].  Thus, these reports combined with the results 
obtained in this study warrant further examination of the possibility of employing D-pen 
as dual (anti-angiogenic and cytotoxic) anti-cancer agent.      
 
Conclusions 
The current work describes an experimental evidence of H2O2 generation as a result 
of copper catalyzed D-pen oxidation. A simple, sensitive and rapid HPLC assay was 
developed to simultaneously detect D-pen, its major oxidation product D-pen disulfide 
and H2O2 in a single run. The HPLC assay was employed to study effect of several 
factors on the copper catalyzed D-pen oxidation. It was shown that D-pen supplemented 
with copper resulted in the formation of reactive oxygen species within breast cancer 
cells and in-vitro cytotoxicity.  
 
Table of abbreviations 
D-penicillamine (D-pen)  
D-pen disulfide (D-pen-S-S-D-pen) 
Hydrogen peroxide (H2O2)  
Bathocuproinedisulfonic acid (BCS) 
Reactive oxygen species (ROS)  
Dithiothreitol (DTT) 
Tris (2-carboxyethyl)phosphine (TCEP) 
Cupric sulfate (CuSO4)   
Ferric chloride (FeCl3)  
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Ethylenediaminetetraacetic acid (EDTA)  
2’-7’-dichlorodihydrofluorescein diacetate (H2DCFDA)  
2’-7’dichlorodihydrofluorescein (H2DCF) 
2’-7’-dichlorofluorescein (DCF) 
5,5’-Dithio-bis(2-nitro-benzoic acid) (DTNB)  
 
 
*The content of this chapter were published in Journal of Inorganic Biochemistry, 
Gupte, A., Mumper, R. J., An investigation into copper catalyzed D-penicillamine 
oxidation and subsequent hydrogen peroxide generation, 2007;101:594-602. Copyright 
2008 with permission from Elsevier.   
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Table 4.1 Effect of D-pen added in succession on the copper catalyzed D-pen 
oxidation at pH 6.2 and 7.4. 
 
 
 
Time 
(h) Sample 
 
 
pH 6.2 
D-pen disulfide 
(μM) 
 
 
 
pH 7.4 
D-pen disulfide 
(μM) 
 
1  D-pen (90 μM) + CuSO4 (4 μM) 
38.2 ± 4.2 38.7 ± 2.3 
2  + D-pen (90 μM) 81.7 ± 4.3 86.9 ± 6.7 
4 + D-pen (90 μM) 126 ± 1.5 134.7 ± 5.4 
14  + D-pen (90 μM) 181.9 ± 3.5 186.4 ± 2.7 
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2PSH + 2Cu2+ 2PS. + 2Cu+ + 2H+ Initial reaction: formation of thiyl radical
Cu+ + O2 Cu2+ + O2
. - Maintenance reaction: Regeneration of Cu2+
Cu+ + O2
. - + 2H+ Cu2+ + H2O2 Maintenance of radical chain reaction and
generation of hydrogen peroxide
PS. + PS. PSSP                           Chain termination
2PSH + O2 PSSP + H2O2                       Overall reaction
 
 
Figure 4.1 Mechanism of copper catalyzed D-pen oxidation. The mechanism was 
initially proposed by Starkebaum [23]. PSH = D-penicillamine, PSSP = D-penicillamine 
disulfide, H2O2 = hydrogen peroxide, PS. = D-penicillamine (thiyl) radical, PS- = D-
penicillamine anion, O2.- = oxygen radical. 
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H2O2
D-pen 
disulfide
D-pen
 
 
Figure 4.2 HPLC chromatogram showing elution of H2O2, D-pen disulfide and  
D-pen. H2O2 (1.69 min), D-pen disulfide (2.80 min) and D-pen (3.07 min). 
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Figure 4.3 Copper catalyzed D-pen oxidation to D-pen disulfide and the generation  
of H2O2 at 25°C. a) Effect of incubation time: CuSO4 (4 µM) was incubated with D-pen  
(100 µM) for 0-20 min. b) Effect of cupric sulfate concentration: CuSO4 (0.1-20 µM)  
was incubated with D-pen (100 µM) for 20 min. Data represents the mean ± SD (n = 3).  
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Figure 4.4 Effect of pH and copper and iron concentration on D-pen oxidation to D- 
pen disulfide. D-pen (450 µM) incubated in phosphate buffer (0.1 M) at pH 6.0 or 7.0 in  
the presence of cupric sulfate (3 µM), ferric chloride (3 µM) and cupric sulfate + ferric  
chloride (4:1, 1:1, and 1:4) for 2 h at 25°C. Data represents the mean ± SD (n = 3).  
**p<0.01 compared to the control group of 0.1 M phosphate buffer. 
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Figure 4.5 Effect of temperature on copper catalyzed D-pen oxidation. D-pen (850  
µM) was incubated alone at 25°C and with cupric sulfate (4 μM) in phosphate buffer (0.1  
M) at 4°C, 25°C or 37°C. Data represents mean ± SD (n = 3). *p<0.05, **p<0.01,  
***p<0.001 compared to the control group of no cupric sulfate at 25°C. The first-order  
rate constant, k, for each condition is shown above each plot. 
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Figure 4.6 Cytotoxicity of the copper catalyzed D-pen oxidation. The cytotoxicity of  
D-pen and cupric sulfate was compared to H2O2 after 48 h. Free D-pen and free cupric  
sulfate were used as controls.  In addition, an additional sample contained catalase (1000  
U/mL) to quench generated H2O2. Data represents the mean ± SD (n = 3). *group c was  
statistically different compared to groups a and b (p<0.01) and group e (p<0.001).   
**group d was statistically different compared to groups a and b (p<0.05) and group e  
(p<0.01). There was no statistical difference between groups c and d. 
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Figure 4.7 Copper catalyzed D-pen oxidation results in the generation of 
intracellular reactive oxygen species. The intracellular ROS was measured using 2’-7’-  
dichlorodihydrofluorescin diacetate(H2DCFDA) loaded MCF-7 cells.  D-pen (1000 µM),  
CuSO4 (10 µM), and D-pen (1000 µM) + CuSO4 (10 µM) were added to cells and the  
cell-associated fluorescence was measured after 2, 4, and 6 h. *** p<0.001 for D-pen  
(1000 µM) + CuSO4 (10 µM) compared to D-pen (1000 µM) and CuSO4 (10 µM) alone. 
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Chapter 5 
 
Copper chelation by D-penicillamine generates reactive oxygen species that are 
cytotoxic to human leukemia and breast cancer cells 
 
5.1 Summary 
 Serum and tumor copper levels are significantly elevated in a variety of 
malignancies including breast, ovarian, gastric, lung cancer and leukemia. D-
penicillamine (D-pen), a copper chelating agent, at low concentrations in the presence of 
copper generates concentration dependent cytotoxic hydrogen peroxide (H2O2). The 
purpose of these studies was to investigate the in-vitro cytotoxicity, intracellular reactive 
oxygen species (ROS) generation, and the reduction in intracellular thiol levels due to 
H2O2 and other ROS generated from copper catalyzed D-pen oxidation in human breast 
cancer cells (BT474, MCF-7) and human leukemia cells (HL-60, HL-60/VCR, HL-
60/ADR). D-pen (≤ 400 µM) in the presence of cupric sulfate (10 µM) resulted in 
concentration dependent cytotoxicity. Catalase was able to completely protect the cells, 
substantiating the involvement of H2O2 in cancer cell cytotoxicity. A linear correlation 
between the D-pen concentration and the intracellular ROS generated was shown in both 
breast cancer and leukemia cells. D-pen in the presence of copper also resulted in a 
reduction in intracellular reduced thiol levels. The H2O2-mediated cytotoxicity was 
greater in leukemia cells compared to breast cancer cells. These results support the 
hypothesis that D-pen can be employed as a cytotoxic copper chelating agent based on its 
ROS generating ability.    
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5.2 Introduction 
D-penicillamine (D-pen) is an aminothiol and a potent copper chelating agent [39, 
117]. D-pen is currently approved for the treatment of Wilson’s disease and rheumatoid 
arthritis. Based on its ability to effectively chelate and remove copper, it has also been 
investigated as an anti-angiogenic agent [4, 8, 52, 117]   
Copper has been established as a key co-factor required by a number of pro-
angiogenic molecules including fibroblast growth factor (FGF) [433], vascular 
endothelial growth factor (VEGF) [105], and interleukin-1 [105]. Several in-vitro studies 
have shown that high copper concentrations facilitate the proliferation of cancer cells [52, 
90, 434]. Serum and tumor copper levels have been shown to be significantly elevated in 
breast cancer [60, 83, 435], lung cancer [69, 72], leukemia [70], and gynecological cancer 
[71]. Thus, anti-copper therapy has been investigated as an anti-angiogenic strategy for 
cancer treatment [4, 8] and include copper chelating agents, tetrathiomolybdate [105, 
433], clioquinol [102, 436], and D-pen [4, 8, 52].  
In the process of chelating copper, D-pen reduces Cu(II) to Cu(I) leading to the 
generation of hydrogen peroxide (H2O2) and other ROS [6, 23, 427].  D-pen has been 
shown to inhibit human endothelial cell proliferation in-vitro and neovascularization in-
vivo [6], and suppress human fibroblast proliferation [142] in the presence of copper. 
Auto-oxidation of other thiols (cysteamine, homocysteine) in the presence of copper has 
also been shown to generate H2O2 and cause cytotoxicity [425, 437].  
Thiol containing compounds are known to be cytotoxic at moderate concentrations 
but not at low and high concentrations [438, 439]. At low thiol concentration, very small 
levels of ROS are produced and the cells possess sufficient anti-oxidant capacity to 
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defend themselves against this ROS stress [152]. At high concentrations, thiols react with 
the generated H2O2 and other ROS and thus act as anti-oxidants [152]. It has been shown 
that the rate of thiol reaction with H2O2 and superoxide is inversely related to its pKa 
[154]. Therefore, thiol toxicity depends on the interplay between the rate of transition 
metal (copper, iron) catalyzed thiol oxidation and the rate of thiol reaction with H2O2 and 
other ROS generated during thiol oxidation [439]. Thiolate ion plays a critical role in 
metal catalyzed thiol oxidation [23]. The pKa of thiol group of D-pen is 7.9, therefore, 
the degree of ionization for D-pen at physiological pH would be higher than that 
compared to cysteamine (pKa 8.6), and homocysteine (pKa 8.9). In addition, D-pen has 
been shown to be oxidized at higher rates in the presence of copper compared to other 
thiols (e.g. cysteine, n-acetylcysteine, glutathione) [439]. Thus, we hypothesized that D-
pen at low concentration would generate H2O2 and ROS in the presence of copper and 
cause cytotoxicity against cancer cells, in contrast to high D-pen concentrations, wherein 
D-pen is more likely to act as an anti-oxidant against excess ROS.        
Cancer cells differ from typical cells as they exhibit increased intrinsic ROS stress 
due to a number of factors including the oncogenic stimulation, increased metabolic 
activity, and mitochondrial malfunction [19, 316, 440]. As a result, cancer cells under 
sustained ROS stress conditions tend to heavily utilize adaptation mechanisms and may 
exhaust ROS-buffering capacity while normal cells have low levels of ROS stress and 
reserve a higher capacity to cope with further oxidative insults [316, 440]. Therefore, the 
generation of ROS can be exploited therapeutically in the treatment of cancer [316].  
Several anticancer agents currently employed in cancer treatment including 
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anthracyclines, bleomycin, and cisplatin are known to either generate cellular ROS or to 
impair the cellular redox buffering [19, 244].  
We have recently investigated the mechanism of copper catalyzed D-pen oxidation 
and simultaneous H2O2 production as a function of time, concentration of cupric sulfate 
or ferric chloride, temperature, pH, anaerobic conditions, and in the presence of chelators 
such as EDTA and bathocuproinedisulfonic acid (BCS) [187]. It was demonstrated that 
H2O2 was generated in a concentration dependent manner as a result of D-pen oxidation 
in the presence of cupric sulfate. Chelators such as EDTA and BCS were able to inhibit 
D-pen oxidation [187]. Additionally, it was shown that  the in-vitro copper catalyzed D-
pen oxidation generates H2O2 in a 2:1 mole ratio at low D-pen concentrations (<500 µM) 
[187]. Therefore, the purpose of these studies was to, 1) examine the cytotoxicity due to 
the ROS generating ability of D-pen, and 2) if the cytotoxicity of D-pen in the presence 
of copper correlated to the in-vitro non-cell based molar ratio of D-pen and H2O2. Breast 
cancer cell lines differing in HER2 expression (MCF-7 (HER2 negative) and BT474 
(HER2 positive)), and leukemia cell lines differing based on their anthracycline 
sensitivity (HL-60 (wild type), HL-60/VCR (P-gp) and HL-60/ADR (MRP-1)) were used 
in these studies to ascertain differences in H2O2 and ROS cytotoxic effects.  
The specific aim of the current study was to assess whether D-pen at low 
concentration (≤ 400 µM) in the presence of copper would cause intracellular generation 
of ROS and result in cytotoxicity in cancer cells. Indeed, in the current studies, it is 
demonstrated that D-pen generates concentration dependent ROS only in the presence of 
copper and exhibits concentration dependent cytotoxicity in cancer cells.   
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5.3 Materials and methods 
Cell lines and culture conditions  
The human breast cancer cell lines BT474 (HER2 positive and ER+), and MCF-7 
(HER2 negative and ER+) and human leukemia cell line, HL-60, were purchased from 
American Type Cell Culture Collection (ATCC, Rockville, MD). Resistant leukemia cell 
lines, HL-60/VCR (P-gp) and HL-60/ADR (MRP-1) were kindly provided by Dr Baer 
(Roswell Park Cancer Institute, Buffalo, NY). Cells were routinely cultured in RPMI-
1640 media (Invitrogen, Carlsbad, CA) supplemented with 100 U/mL penicillin, 100 
µg/mL streptomycin and 10% Fetal Bovine Serum (FBS) (ATCC, Rockville, MD) and 
maintained at 37ºC in a humidified 5% CO2 incubator. Plasmocin (5 µg/mL) (InvivoGen, 
San Diego, CA) was added to the cell culture media as a prophylactic measure to prevent 
mycoplasma contamination. Cell viability was regularly determined by trypan blue 
exclusion test.  
 
Reagents 
D-penicillamine (D-pen), hydrogen peroxide (H2O2) 30% w/w and cupric sulfate 
(CuSO4), catalase (2860 U/mg), glutathione, 5,5’-dithiobis (2-nitrobenzoic acid) 
(DTNB), EDTA, were purchased from Sigma-Aldrich Inc. (St. Louis, MO). Coomassie 
Plus Protein Assay kit was purchased from Pierce Biotech Inc. (Rockford, IL). 
Dimethylsulfoxide (DMSO) was purchased from Fisher Scientific (Pittsburg, PA). Cell 
cytotoxicity was assessed with the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide) (MTT) assay, phosphate buffer saline (PBS), pH 7.4 cell culture grade was 
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purchased from ATCC (Rockville, MD), 2’-7’-dichlorodihydrofluorescein diacetate 
(H2DCFDA), and hydroethidine were purchased from Invitrogen Inc (Carlsbad, CA). 
 
Assessment of cell viability 
Cell viability was measured using the 3-(4,5-dimethyl-2-yl)-2,5-diphenylteraolium 
bromide (MTT) assay. The adherent breast cancer cells (MCF-7 and BT474) were seeded 
at an initial concentration of 3×104 cells/well 24 h prior to the commencement of the 
experiments to allow them to attach, while the suspension leukemia cells, HL-60, HL-60-
/VCR and HL-60/ADR were seeded at 3×104 cells/well on the same day of the 
experiment in a 96 well plate. Cells were then treated with H2O2 (1-200 µM), D-pen (1-
400 µM), cupric sulfate (1-50 µM), D-pen (1-400 µM) + cupric sulfate (10 µM), and D-
pen (1-400 µM) + cupric sulfate (10 µM) + catalase (500 U/mL). The MTT assay was 
performed at 48 h and absorbance was measured with the microplate reader (Biotek ELx 
800, Biotek Instruments, Winooski, VT) at a wavelength of 595 nm. Data is reported as 
cell viability (% control) and corresponds to the percent viable cells compared to 
untreated cells.   
 
Determination of intracellular reactive oxygen species (ROS) 
2’-7’-dichlorodihydrofluorescein diacetate (H2DCFDA) was used as an indicator of 
intracellular ROS generation. H2DCFDA is a cell permeable probe, it enters the cell and 
is deacetylated to a non-fluorescent product, 2’-7’-dichlorodihydrofluorescein (H2DCF) 
by cellular esterases and is oxidized by ROS to a fluorescent product, 2’-7’-
dichlorofluorescein (DCF). MCF-7 and HL-60 cells were loaded with H2DCFDA and 
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were seeded in a 96 well plate at a concentration of 3×104 cells/well. Briefly, cells were 
incubated with PBS buffer containing 5 µM H2DCFDA (dissolved in DMSO) for 30 min 
at 37ºC. H2DCFDA was then removed and cells were washed twice with fresh PBS to 
remove excess H2DCFDA. Cells were then incubated with either drug in media or media 
alone (positive control). Non-H2DCFDA loaded cells were used as negative control. The 
fluorescence of control and sample wells was recorded at excitation 485 ± 20 nm, 
emission 530 ± 25  nm with Biotek FL600 (Biotek Instruments, Winooski, VT) at 30, 60, 
and 90 min. Then data is reported as DCF fluorescence (fold increase vs. control) 
corresponding to the increase of fluorescence associated with the sample cells compared 
to that of untreated cells.  
 
Intracellular levels of thiols (-SH)    
The intracellular reduced glutathione levels were measured with 5, 5’-dithiobis-(2-
nitrobenzoic acid) (DTNB). Briefly, HL-60 cells (5×106) were seeded in a 12 well plate 
and incubated for 4 and 48 h with or without D-pen (50 and 200 µM) plus cupric sulfate 
(10 µM). Cells were collected, washed with ice-cold PBS buffer and then suspended in 
pH 7.4 lysis buffer comprised of 25 mM Tris-HCl + 1 mM EDTA + 0.5% Triton X-405.  
Cells were then lysed in the buffer with a homogenizer (Tissue Tearor, Model 985370 
Variable Speed, Biospec Products Inc, Bartlesville, OK). 25 µL of standard (glutathione) 
or samples (cell lysate) + 25 µL DTNB (0.4 mg/mL) + 150 µL of 50 mM HEPES buffer, 
pH 7.4 with 5 mM EDTA were incubated for 10 min at room temperature and read at 405 
nm on a microplate reader.  
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Protein assay 
The total protein content of the cell lysate was analyzed with Coomassie Plus® 
Bradford Protein Assay using Glutathione as a standard.  
 
Statistical analysis 
Data are represented as the mean ± standard error (SE). Each experimental group 
consisted of n = 6 and experiments were repeated two times. Statistical analysis was 
performed with two-way analysis of variance (ANOVA) followed by Bonferroni post test 
where significance was set at p<0.05 with GraphPad Prism® 4 Software (GraphPad 
software Inc. San Diego, CA). The IC50 was calculated with GraphPad Prism® non-linear 
regression program.  
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5.4 Results  
In-vitro cytotoxicity of D-pen plus cupric sulfate and H2O2   
Leukemia cells 
HL-60, HL-60/VCR and HL-60/ADR cells were treated with H2O2 (1, 10, 25, 50, 
100 and 200 µM) and D-pen (1, 50, 100, 150, 200 and 400 µM) plus cupric sulfate (10 
µM). Cells were also treated with cupric sulfate alone as control (0.1, 1, 10, 25 and 50 
µM). The concentrations of H2O2 and D-pen were chosen based on our previous in-vitro 
non-cell based studies [187], where it was determined that at low D-pen concentrations (< 
500 µM) copper catalyzed D-pen oxidation resulted in H2O2 generation in the molar ratio 
of 2:1 (D-pen: H2O2). Therefore, we wanted to compare the cytotoxicity in these present 
studies using H2O2 alone and versus H2O2 generated from D-pen plus cupric sulfate 
wherein the theoretical H2O2 generated corresponded to a 2:1 molar ratio of D-pen to 
H2O2. 
Figure 5.1 shows the concentration dependent cytotoxicity of H2O2 alone (Figure 
5.1a) and D-pen plus cupric sulfate (Figure 5.1b), respectively, in leukemia cells (HL-60, 
HL-60/VCR and HL-60/ADR). HL-60 and HL-60/VCR cells were highly sensitive to 
H2O2 with IC50 of 20 ± 1.0 µM and 31.5 ± 1.1 µM, respectively. The IC50 of D-pen plus 
cupric sulfate in these two leukemia cell lines was 102.1 ± 1.0 µM and 123.7 ± 1.0 µM, 
which was approximately 5-fold and 4-fold more than corresponding IC50 of H2O2 alone 
in these two cell lines. The HL-60/ADR cells were shown to be less sensitive to the 
cytotoxic effects of both H2O2 and D-pen plus cupric sulfate with IC50 of H2O2 of 162.5 ± 
1.1 µM, while the IC50 of D-pen plus cupric sulfate was beyond the concentration range 
of D-pen used in the present studies. Cupric sulfate alone (0.1-50 µM) did not result in 
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any appreciable loss in cell viability (data not shown). The purpose of employing the 
resistant leukemia cells, HL-60/VCR (p-gp) and HL-60/ADR (MRP-1), was to compare 
the effect of H2O2 and D-pen plus cupric sulfate cytotoxicity on these cells versus the 
HL-60 cells. The order of sensitivity of leukemia cells to both H2O2 and D-pen plus 
cupric sulfate cytotoxicity was HL-60 > HL-60/VCR > HL-60/ADR and correlated with 
the sensitivity of these cells to anti-cancer agents. These results support the relationship 
between ROS and drug resistance [19].  
 
Breast cancer cells 
The cytotoxicity of H2O2 and D-pen plus cupric sulfate in breast cancer cells is 
shown in Figure 5.2. The IC50 of H2O2 was 115.5 ± 1.6 µM and 96.1 ± 1.1 µM for MCF-7 
and BT474 breast cancer cells (Figure 5.2a). In comparison, as shown in Figure 5.2b, the 
IC50 of D-pen plus cupric sulfate was 246.1 ± 1.1 µM and 287.4 ± 1.1 µM for MCF-7 and 
BT474 cells, respectively. The IC50 of H2O2 was approximately 2-fold and 3-fold lower 
than the IC50 of D-pen plus cupric sulfate in MCF-7 and BT474 cells, respectively. 
  
Catalase protects MCF-7 and HL-60 cells from D-pen plus cupric sulfate 
cytotoxicity 
Figure 5.3 demonstrates that catalase (500 U/mL) was able to completely protect 
both MCF-7 (Figure 5.3a) and HL-60 cells (Figure 5.3b) from D-pen plus cupric sulfate 
cytotoxicity.  
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Intracellular reactive oxygen species (ROS) generation in MCF-7 and HL-60 cells 
Figure 5.4 shows that intracellular ROS was produced in both MCF-7 (Figure 5.4a) 
and HL-60 cells (Figure 5.4b) in the presence of D-pen (200 µM) plus cupric sulfate (10 
µM). D-pen alone (200 µM) or cupric sulfate alone (10 µM) failed to produce any ROS, 
supporting the fact that copper interaction with D-pen is essential and is responsible for 
the generation of ROS.  Further, a 4-fold increase in ROS production was shown in D-
pen plus cupric sulfate treated HL-60 cells vs. H2DCFDA loaded untreated HL-60 control 
cells compared to a 2-fold increase in ROS production for D-pen plus cupric sulfate 
treatment of MCF-7 vs. H2DCFDA loaded untreated MCF-7 control cells. In addition, the 
presence of catalase (500 U/mL) with D-pen plus cupric sulfate completely inhibited 
ROS generation, demonstrating that H2O2 was the major ROS generated. As shown in 
Figure 5.4 (A and B), when H2O2 alone (100 µM) was incubated with HL-60 and MCF-7 
cells, 5-fold greater ROS was generated in each cell line (compared to D-pen plus cupric 
sulfate) which agrees very well with the 5-fold reduced IC50 calculated for H2O2 
compared to D-pen plus cupric sulfate in HL-60 cells.   
In separate cell studies, hydroethidine was used as a quantitative marker for 
intracellular superoxide anion production. Hydroethidine is freely permeable into cells 
and can be directly oxidized to a fluorescent compound by intracellular superoxide anion. 
These studies showed that there was no statistical difference in the intracellular 
superoxide anion at up to 90 min post-incubation between all treatment and control 
groups (data not shown), suggesting that the observed cytotoxicity was not caused by 
superoxide anion but by hydrogen peroxide.  
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Figure 5.5 shows the linear relationship between D-pen (50, 100 and 200 µM) in the 
presence of cupric sulfate and the increase in the DCF fluorescence (indicator of 
intracellular ROS) in both MCF-7 (Figure 5.5a) and HL-60 (Figure 5.5b). The correlation 
between D-pen concentration and DCF fluorescence was shown to increase over time, as 
indicated by the r2 values becoming higher over time and closer to r2 = 1.     
 
Intracellular reduced thiols  
Figure 5.6 shows the levels of intracellular thiols (mainly glutathione) in HL-60 
cells after incubation with D-pen (50 and 200 µM) plus cupric sulfate (10 µM) for 4 and 
48 h. The levels of reduced thiols was shown to be significantly decreased (p<0.05) after 
incubation with D-pen (200 µM) plus cupric sulfate compared to control at 4 h. After 48 
h incubation, intracellular thiol levels were significantly lower (p<0.01) after D-pen plus 
cupric sulfate incubation compared to control.  
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5.5 Discussion  
Therapeutic selectivity (cancer cells versus normal cells) and drug resistance are 
two important factors that greatly affect the chances for success of cancer therapy. 
Therefore, it is important to explore key biochemical differences between cancer cells 
and normal cells and develop strategies that could potentially use these differences to 
improve therapeutic selectivity and/or overcome drug resistance [19]. Oxidative stress 
occurs when the production of ROS exceeds their removal with anti-oxidant compounds 
or enzymes [440]. Cellular defenses against ROS include anti-oxidants scavengers such 
as glutathione, ascorbate, thioredoxin and enzymes like catalase, superoxide dismutase, 
and glutathione peroxidase [19]. Strong evidence from studies in literature suggests that 
cancer cells differ from normal cells in being under persistent ROS stress [208, 441-443]. 
Additionally, it has been suggested that the ability of a cell to defend itself against ROS 
could be associated with resistance against chemotherapy [203, 316]. Several chemically 
diverse compounds have been shown to generate ROS and exhibited anti-cancer activity 
alone or in combination with other chemotherapeutic agents [340, 444, 445].   
D-pen is a potent copper chelating agent that has been investigated in the recent 
years as a potential anti-angiogenic agent based on its efficient copper chelating and 
removing abilities [8, 86]. However, D-pen interaction with copper during chelation has 
been shown to generate H2O2 and other ROS [23, 187, 427]. A few reports have also 
shown that D-pen in the presence of copper causes the inhibition of human fibroblasts 
proliferation [142], and inhibition of human endothelial cells proliferation in-vitro and 
their in-vivo neovascularization [6].  
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Starkebaum et al. [23] proposed a free radical mechanism of copper catalyzed D-
pen oxidation to D-pen disulfide and the subsequent generation of H2O2. The mechanism 
involves an initial reduction of Cu(II) to Cu(I) by D-pen. This is followed by the 
generation of superoxide anion and finally of H2O2 during the spontaneous oxidation of 
Cu(I) to Cu(II). We have recently further investigated the mechanism proposed by 
Starkebaum et al. as a function of time, concentration of cupric sulfate or ferric chloride, 
temperature, pH, anaerobic conditions and in the presence of chelators [187]. We have 
shown with a novel HPLC assay that H2O2 was indeed generated in a concentration 
dependent fashion as a result of D-pen oxidation in the presence of cupric sulfate.    
In the present studies, it was hypothesized that D-pen at low concentrations (≤ 400 
µM) in the presence of cupric sulfate would generate cellular H2O2 and ROS and result in 
cytotoxicity. The anthracycline sensitive HL-60 and the mildly resistance HL-60/VCR 
leukemia cells were found to be highly susceptible to D-pen plus cupric sulfate 
cytotoxicity. The IC50 of H2O2 alone was approximately 5-fold and 4-fold lower 
compared to D-pen plus cupric sulfate in HL-60 and HL-60/VCR cells, respectively. The 
ROS assay showed that approximately 5-fold higher cellular ROS was generated in HL-
60 cells due to incubation with H2O2 alone compared to D-pen plus cupric sulfate, which 
was remarkably similar to the measured 5-fold higher cytotoxicity with H2O2 alone 
compared to D-pen. H2O2 was also established to be the major ROS species, as the 
presence of catalase completely inhibited D-pen plus cupric sulfate cytotoxicity. Breast 
cancer cells (MCF-7 and BT474) were less sensitive to both H2O2 and D-pen 
cytotoxicity, with 5-fold higher IC50 compared to leukemia cells.  The IC50 of H2O2 was 
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approximately 2-fold and 3-fold lower compared to D-pen plus cupric sulfate in MCF-7 
and BT474 cells, respectively.                   
In conclusion, these studies demonstrated that low concentration of D-pen (≤ 400 
µM) in the presence copper resulted in a concentration dependent H2O2-mediated 
cytotoxicity in both breast cancer and leukemia cells. D-pen in the presence of copper 
also was shown to generate concentration dependent cellular ROS and to decrease 
cellular reduced thiol content in cancer cells. Further, it was shown that leukemia cells 
were highly sensitive to D-pen plus cupric sulfate cytotoxicity. A four-fold increase in 
ROS generation was shown in leukemia cells after D-pen plus cupric sulfate treatment 
compared to untreated control. It was demonstrated that D-pen has effective ROS 
generating ability in the presence of copper. Since copper levels are significantly elevated 
in the serum and tumor tissue in a variety of malignancies, these findings provides a 
novel and exciting opportunity to exploit D-pen as an anti-cancer agent having both anti-
angiogenic and cytotoxic mechanism of action.   
 
Abbreviations:  
D-pen: D-penicillamine 
CuSO4: cupric sulfate 
ROS: reactive oxygen species 
H2O2: Hydrogen peroxide 
H2DCFDA: 2’-7’-dichlorodihydrofluorescein diacetate 
DTNB: 5,5’-dithiobis (2-nitrobenzoic acid)  
PBS: phosphate buffer saline 
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GSH: reduced glutathione 
P-gp: P-glycoprotein 
 
 
*The contents of this chapter were published in Free Radical Biology and Medicine, 
Gupte, A., Mumper, R. J., Copper catalyzed D-penicillamine generated reactive oxygen 
species that are cytotoxic to human leukemia and breast cancer cells, 2007;43:1271-1278. 
Copyright 2008 with permission from Elsevier.  
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Figure 5.1 The concentration dependent in-vitro cytotoxicity of H2O2 alone 
compared to D-pen plus cupric sulfate in HL-60, HL-60/VCR and HL-60/ADR 
leukemia cells. a) H2O2 alone and b) D-pen plus cupric sulfate.  
Cells (3 ×104 cells/well) were treated with increasing concentrations of H2O2 alone and 
D-pen plus cupric sulfate (10 µM) for 48 h in media. Cell viability was determined with 
the MTT assay. Absorbance was measured at 595 nm and adjusted to the absorbance of 
untreated cells. Data represent mean ± SE; n = 12 (two independent experiments 
performed in n = 6). Inhibitory concentrations (IC50) were reported as the mean ± SE in 
the figure legend. 
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Figure 5.2 The concentration dependent in-vitro cytotoxicity of H2O2 alone 
compared to D-pen plus cupric sulfate in MCF-7 and BT474 breast cancer cells.  
a) H2O2 alone. b) D-pen plus cupric sulfate.  
Cells (3×104 cells/well) were treated with increasing concentration of H2O2 and D-pen  
plus cupric sulfate for 48 h in media. Cell viability was determined with MTT assay.  
Absorbance was measured at 595 nm and adjusted to the absorbance of untreated cells.  
Data represent mean ± SE; n = 12 (two independent experiments performed in n = 6).  
Inhibitory concentration (IC50) was reported as mean ± SE. 
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Figure 5.3 Catalase inhibits the D-pen plus cupric sulfate cytotoxicity in breast 
cancer and leukemia cells.  
a) MCF-7 cells b) HL-60 cells.  
Cells (3×104/well) were treated with D-pen, D-pen plus cupric sulfate (10 µM) and D-pen 
plus cupric sulfate (10 µM) plus catalase (500 U/mL) for 48 h in media. Cell viability was 
determined with MTT assay. Absorbance was measured at 595 nm and adjusted to the 
absorbance of untreated cells. Data represent the mean ± SE; n = 12 (two independent 
experiments performed in n = 6). *p<0.05 and ***p<0.001 for D-pen plus cupric sulfate 
compared to D-pen alone and D-pen plus cupric sulfate plus catalase. 
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Figure 5.4 D-pen in the presence of cupric sulfate generates intracellular ROS in  
breast cancer and leukemia cells.  
a) MCF-7 cells (3×104/well) were loaded with ROS probe H2DCFDA (5 µM). *p<0.05  
for D-pen plus cupric sulfate (10 µM) compared to D-pen alone.***p<0.001 for H2O2 
compared to D-pen alone.  
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b) HL-60 cells (3×104/well) were loaded with ROS probe H2DCFDA (5 µM).  **p<0.01  
D-pen plus cupric sulfate compared to D-pen alone.  
***p<0.001 for H2O2 compared to D-pen alone. Cells were incubated without (positive  
control) or with H2O2, H2O2 plus catalase, cupric sulfate, D-pen, D-pen plus cupric sulfate,  
D-pen plus cupric sulfate plus catalase in media. Unloaded cells were used as negative  
control. The cell associated fluorescence was measured at 30, 60, 90 min at excitation  
and emission of 485 ± 20 nm and 530 ± 25 nm, respectively. Data are reported as the  
DCF fluorescence (fold increase versus control). Data represent mean ± SE; n = 12 (two  
independent experiments performed in n = 6).  
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Figure 5.5 The correlation between D-pen concentration and the intracellular ROS  
generation in breast cancer and leukemia cells. a) MCF-7 cells (3×104/well) were  
loaded with ROS probe H2DCFDA (5 µM). b) HL-60 cells (3×104/well) were loaded  
with ROS probe H2DCFDA (5 µM).  
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Cells were incubated without (positive control) or with 50, 100 and 200 µM D-pen plus  
cupric sulfate (10µM) in media. Unloaded cells were used as negative control. The cell  
associated fluorescence was measured at 30, 60, 90 and 120 min at excitation and   
emission of 485 ± 20 nm and 530 ± 25 nm, respectively. Data are reported as   
Fluorescence Units or the raw fluorescence of DCF. Data represent the mean ± SE;  
n = 12 (two independent experiments performed in n = 6). 
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Figure 5.6 D-pen in the presence of cupric sulfate causes the reduction in 
intracellular thiol levels in leukemia cells. HL-60 cells (5×106/well) were plated in a 12 
well plate and treated with D-pen plus cupric sulfate (10 µM) for 4 and 48 h. Cells were 
counted with trypan blue assay, washed with PBS buffer and homogenized in lysis 
buffer. Cells were centrifuged and the supernatant was used for total intracellular protein 
and thiol assay.  Data represent the mean ± SE; n = 6 (two independent experiments 
performed in triplicate). *p<0.05 and **p<0.01 for D-pen (200 µM) plus cupric sulfate 
(10 µM) compared to control. 
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Supplemental Study (not included in the manuscript published in Free Radical Biology 
and Medicine) 
 
Intracellular superoxide radical generation 
Hydroethidine from Invitrogen (Carlsbad, CA) was used as a quantitative marker for 
superoxide anion.  Hydroethidine is freely permeable into cells and can be directly 
oxidized by superoxide anion produced inside the cells [446]. It has been reported that 
hydrogen peroxide, hydroxyl radical, nitric oxide derived oxidants do not react with 
hydroethidine [447]. Therefore, the oxidation of hydroethidine was employed as the 
intracellular superoxide anion marker. Briefly, HL-60 cells were incubated with 
hydroethidine (10 µM) for 30 min at 37ºC. Cells were plated at 30,000/well in a 96 well 
plate. Cells were incubated with media alone (control) or D-pen (200 µM), CuSO4 (10 
µM), D-pen (200 µM) + CuSO4 (10 µM), D-pen (200 µM) + CuSO4 (10 µM) + SOD (10 
U), and H2O2 (100 µM). Cells not treated with hydroethidine were used as negative 
control. Fluorescence was read at 30, 60 and 90 min at 485 ± 10 nm and 610 ± 20 nm. 
Superoxide anion being a charged species cannot enter the cell. Therefore, the 
intracellular oxidation of Hydroethidine would exclusively detect the intracellular 
generated superoxide anion. As shown in the Figure below there was no statistical 
difference after incubation of D-pen + cupric sulfate compared to control cells at any time 
points indicating that superoxide anion did not play a role in the of the intracellular ROS 
being produced from D-pen + cupric sulfate incubation with breast cancer and leukemia 
cells. Xanthine and Xanthine oxidase was used as a positive control for the superoxide 
production (not shown in the figure).  
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Figure 5.7 Intracellular superoxide anion generations in HL-60 cells. Cells were 
incubated in media alone (control), cupric sulfate, D-pen, D-pen + cupric sulfate, D-pen 
+cupric sulfate + superoxide dismutase, and hydrogen peroxide.  
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Chapter 6 
 
Enhanced intracellular delivery of the reactive oxygen species (ROS)-generating 
copper chelator D-penicillamine via a novel gelatin-D-penicillamine conjugate  
 
 
6.1 Summary 
 
 D-penicillamine (D-pen) is an established copper chelator. We have recently shown 
that the copper catalyzed D-pen oxidation generates concentration dependent hydrogen 
peroxide (H2O2). Additionally, D-pen co-incubated with cupric sulfate resulted in 
cytotoxicity in human leukemia and breast cancer cells due to the extracellular generation 
of reactive oxygen species (ROS). The inherent physicochemical properties of D-pen 
such as its short in-vivo half life, low partition coefficient and rapid metal catalyzed 
oxidation limit its intracellular uptake and the potential utility as an anti-cancer agent in-
vivo. Therefore, to enhance the intracellular delivery and to protect the thiol moiety of D-
pen, we designed, synthesized, and evaluated a novel gelatin-D-pen conjugate. D-pen 
was covalently coupled to gelatin with a biologically reversible disulfide bond with the 
aid of a heterobifunctional crosslinker, (N-succinimidyl-3-(2-pyridyldithio)-propionate) 
(SPDP). Additionally, fluorescein labeled gelatin-D-pen conjugate was synthesized for 
cell uptake studies. D-pen alone was shown not to enter leukemia cells. In contrast, the 
qualitative intracellular uptake of the conjugate in human leukemia cells (HL-60) was 
shown with confocal microscopy. The conjugate exhibited slow cell uptake (over the 
period of 48 to 72 h). The gelatin amino groups were modified with SPDP and 
conjugated with D-pen. A novel HPLC assay was developed to simultaneously quantify 
both D-pen and glutathione in a single run. The conjugate was shown to completely 
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release D-pen in the presence of glutathione (1 mM) in approximately 3 h in PBS buffer, 
pH 7.4. The gelatin-D-pen conjugate resulted in significantly greater cytotoxicity 
compared to free D-pen, gelatin alone and a physical mixture of gelatin and D-pen in 
human leukemia cells. Further studies are warranted to assess the potential of D-pen 
conjugate in the delivery of D-pen as a ROS generating anti-cancer agent.    
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6.2 Introduction 
 
D-penicillamine (D-pen) is a copper chelating agent that is currently approved by 
the FDA for the treatment of Wilson’s disease and rheumatoid arthritis. In recent years 
there has been immense interest in the use of copper chelators including D-pen as anti-
angiogenic agents [4, 8]. This is due to the now established role of copper in 
angiogenesis. Copper is known to act as a co-factor for a variety of important endogenous 
pro-angiogenic compounds such as fibroblast growth factor (FGF) and vascular 
endothelial growth factor (VEGF) [4]. Thus, it has been proposed that the copper 
chelation by D-pen could lead to an anti-angiogenic effect. It is also known that the 
interaction of D-pen with copper during chelation leads to the generation of hydrogen 
peroxide (H2O2) and other reactive oxygen species (ROS) [8, 23, 24]. We have recently 
both qualitatively and quantitatively confirmed that the copper catalyzed D-pen oxidation 
generated concentration dependent H2O2 [187]. In addition, we have shown that D-pen 
co-incubated with cupric sulfate resulted in concentration dependent cytotoxicity in both 
human breast cancer (MCF-7, BT474) and leukemia cells (HL-60, HL-60/VCR) in 
culture [190].  
As copper levels have been reported to be significantly elevated in the serum [60, 
70] and the tumor tissue [9, 59, 84] of cancer patients, we believe that our studies in the 
investigation of D-pen cytotoxicity in the presence of copper have significant potential. 
Therefore, we hypothesized that novel formulation strategies that could increase the 
intracellular delivery of D-pen would potentially lead to the use of D-pen as a dual anti-
cancer agent via, 1) cytotoxicity, through the intracellular generation of H2O2 and other 
ROS, 2) anti-angiogenesis, through the well known copper chelation process. The 
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physicochemical properties of D-pen would limit the anti-cancer efficacy of D-pen in-
vivo. These limiting properties include, i) extreme hydrophilicity (Log P: -0.39) [448] 
thus limiting its intracellular uptake in cancer cells [114, 123] ii) rapid elimination from 
the blood exhibiting biphasic kinetics [116, 449], and iii) sensitivity to oxidation. The 
thiol group of D-pen is critical to both copper chelation and H2O2 generation; however, 
D-pen is prone to oxidation resulting in inactive D-pen disulfide or mixed disulfides. 
Therefore, the efficacy of D-pen as an anti-cancer agent would depend on its successful 
delivery to cancer cells in its reduced form or a modified form which could then be 
reversibly converted intracellularly to bioactive D-pen.  
We have previously reported on a novel D-pen-nanoparticle formulation for metal 
chelation therapy [450]. Also, Chvapil et al. recently reported on the synthesis of a hexyl-
D-pen-ester that converted D-pen to a more lipophilic form (Log P: 1.61), but resulted in 
very slow D-pen release [448, 451]. The ester prodrug strategy for the D-pen delivery 
would potentially have other problems such as i) the lack of protection of the critical thiol 
group, and ii) the slow rate of D-pen release from the lipophilic ester prodrug. This could 
result in less than effective free D-pen concentrations in-vivo. To overcome these 
potential problems, we designed a novel conjugate of D-pen wherein D-pen was linked to 
a macromolecular polymer via a biologically reversible disulfide bond. In the recent 
years, the covalent conjugation of low molecular weight drugs with soluble 
macromolecular carriers (peptides, protein and polymers) has been the focus of 
considerable research [390, 452].     
Gelatin is a partially hydrolyzed form of collagen [452]. Gelatin has been used in 
oral delivery technologies such as hard and soft capsules and is recently being examined 
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as a carrier in novel drug delivery [384]. Gelatin has been reported to be both 
biocompatible and biodegradable [384, 389]. These and other desirable physiochemical 
properties of gelatin make it a suitable carrier for the delivery of genes [453-455], 
chemotherapeutic agents formulated as: conjugates [390, 392, 395, 452], as nanoparticles 
[384, 388, 396, 456, 457], as complex coacervates [454], and as microspheres [384, 455]. 
Both the carboxyl and the amino groups of gelatin have been modified to directly 
conjugate drugs [389, 392].  
In the present studies, we describe the synthesis of a soluble gelatin-D-pen 
conjugate through the modification of gelatin with the aid of a heterobifunctional cross-
linker, sulfosuccinimidyl 6-(3´(2-pyridyldithio)-propionamido) hexanoate (sulfo-LC-
SPDP) (water soluble derivative of SPDP). Gelatin was coupled to D-pen with the aid of 
SPDP to form a potentially biologically reversible disulfide bond. The disulfide bond was 
an attractive strategy for D-pen delivery due to, i) enhanced protection of the thiol group 
of D-pen from oxidation before it reaches the site of action, ii) its potential for 
intracellular reversibility (due to the presence of ~1-11 mM of glutathione inside the 
cells) [371, 458, 459] and iii) its reported relative stability in plasma [460].  
The overall objectives of the present studies were to: 1) synthesize and characterize 
a novel disulfide gelatin-D-pen conjugate, 2) evaluate the in-vitro release of D-pen from 
the gelatin-D-pen conjugate as a function of glutathione concentration, time of incubation 
with glutathione and pH, 3) evaluate the qualitative intracellular uptake of fluorescein 
labeled gelatin-D-pen conjugate in human leukemia cells (HL-60), and 4) investigate the 
in-vitro cytotoxicity of gelatin-D-pen conjugate in HL-60 cells compared to free D-pen, 
gelatin alone and the physical mixture of gelatin with D-pen. 
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6.3 Materials and methods  
Materials 
Type B gelatin (75 bloomstrength) with 100-115 mmol of carboxylic acid per 100 g 
of protein, an isoelectric point of 4.7-5.2, and an average molecular weight of 20,000-
25,000 Da was purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). D-
penicillamine (D-pen), D-penicillamine disulfide, Glutathione, Glutathione disulfide, 
Dithiothreitol (DTT) was also purchased from Sigma-Aldrich. Sulfosuccinimidyl 6-(3´(2-
pyridyldithio)-propionamido) hexanoate (Sulfo-LC-SPDP), 2,4,6-trinitrobenzene sulfonic 
acid (TNBS) reagent, N-hydroxysuccinimide-Fluorescein (NHS-Fluorescein), M-PER 
mammalian cell extraction reagent were purchased from Pierce Biotech Inc. (Rockford, 
IL). Acetonitrile, o-phosphoric acid (85%) were purchased from Fisher Sci. (Pittsburg, 
PA). Microcon® (YM-10, MWCO: 10 kDa) centrifugal filter devices were purchased 
from Millipore (Billerica, MA). All aqueous solutions were prepared in deionized 
distilled water (MilliQ®, Millipore Inc.).  
 
Cell lines and culture conditions 
The human leukemia cell line (HL-60) was purchased from American Type Cell 
Culture Collection (ATCC, Rockville, MD). Cells were routinely cultured in RPMI-1640 
media (Invitrogen, Carlsbad, CA) supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin and 10% Fetal Bovine Serum (FBS) (ATCC, Rockville, MD) and 
maintained at 37ºC in a humidified 5% CO2 incubator. Plasmocin (5 µg/mL) (InvivoGen, 
San Diego, CA) was added to the cell culture media as a prophylactic measure to prevent 
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mycoplasma contamination. Cell viability was regularly determined by trypan blue dye 
(0.4% in phosphate buffered saline) (ATCC, Rockville, MD). 
 
Synthesis and purification of the gelatin-D-pen conjugate 
A heterobifunctional cross-linker (sulfo-LC-SPDP) was employed to conjugate D-
pen with gelatin. Sulfo-LC-SPDP has an amine reactive N-hydroxysuccinimide (NHS) 
and a thiol reactive 2-pyridylthio group. The conjugate synthesis was performed in two 
steps. Briefly, gelatin (2 mg/mL) was incubated with SPDP for 2 h at room temperature 
in PBS, pH 7.4. After incubation, excess SPDP was separated from gelatin with microcon 
centrifugation devices (MWCO: 10 kDa). As described below, the pyridine-2-thione and 
the TNBS assays were performed to determine the degree of SPDP modification of 
gelatin. The SPDP-modified gelatin was then incubated with excess D-pen. The gelatin-
D-pen conjugate was separated from the unconjugated D-pen with microcon centrifugal 
devices. The HPLC assay as described below was performed on the filtrate and retentate 
to determine the amount of D-pen conjugated to gelatin.         
 The complete and efficient separation of gelatin from unreacted SPDP or D-pen 
was performed with microcon centrifugation filter devices (MWCO: 10 kDa). Briefly, 
500 µL of reaction mixture was added to the microcon, the mixture was centrifuged at 
14,000 g for 30 min at room temperature. The filtrate was then collected and the retentate 
was washed twice with 400 µL of fresh PBS buffer. The retentate was finally collected 
by centrifuging at 3,000 g for 5 min. Gelatin and D-pen concentration both in the filtrate 
and the retentate were quantified.  
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Synthesis and purification of the fluorescein labeled gelatin-D-pen conjugate  
The fluorescent labeling of the conjugate was performed with the aid of an amine 
reactive fluorescent probe, NHS-fluorescein. Briefly, NHS-fluorescein was added to 
gelatin in a 1:1 mole ratio and the mixture was incubated with constant shaking for 1 h at 
room temperature. The unreacted free fluorescein was separated from fluorescein-gelatin 
using the microcon centrifugal filter devices. The fluorescein-gelatin was washed three 
times with PBS, pH 7.4 until the free fluorescein was completely removed. The 
fluorescein-gelatin was then used to synthesize the conjugate as described above.  
 
Characterization of the gelatin-D-pen conjugate 
Amino content determination 
2, 4, 6-trinitrobenezene sulfonic acid (TNBS) is a rapid and sensitive assay reagent 
employed for the determination of free amino groups. Briefly, 50 µL of 0.01% (w/v) 
TNBS was added to 100 µL of either gelatin or SPDP-modified gelatin in PBS buffer, pH 
7.4 and was incubated for 2 h at 37ºC. Twenty five (25) µL of 1 N HCl was added to stop 
the reaction. The resulting absorbance was recorded at 335 nm with the SynergyTM 2 
Multi-Detection Microplate Reader (Biotek, Winooski, VT). A standard curve for amino 
groups was generated using known concentrations of D-pen. The primary amino group 
was expressed as the amount of TNBS reactive amino groups in 1 g of gelatin. The % 
amino groups conjugated were calculated as follows: % amino groups conjugated = 
(amino group of SPDP modified gelatin / amino groups in gelatin alone) × 100%.  
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Gelatin determination 
The gelatin concentration was analyzed using the Coomassie Plus assay.  Briefly, 
10 µL of standard or sample was added to 150 µL of Coomassie Plus Protein Assay 
Reagent (Pierce Biotech, Rockford, IL), mixed and incubated for 10 min at room 
temperature and the absorbance was read at 595 nm with the SynergyTM 2.  
 
Determination of the level of SPDP modification 
The degree of SPDP modification of gelatin was determined by quantifying the 
release of pyridine-2-thione group after exposure of the SPDP-modified gelatin with 
DTT. Briefly, 100 µL purified SPDP-modified gelatin was diluted to 1 mL with PBS 
buffer, pH 7.4. Ten (10) µL DTT (15 mg/mL) was added and samples were incubated for 
exactly 15 min and the absorbance was recorded at 343 nm with the SynergyTM 2. The 
molar ratio of SPDP to gelatin modification as follows = (ΔA × 8080) × (Average M.W. 
of gelatin × mg/mL of gelatin), where the value 8080 reflects the extinction coefficient 
(8.08 x 103 M-1cm-1) for pyridine-2-thione at 343 nm.  
 
HPLC determination of D-pen and glutathione  
D-pen and glutathione were simultaneously analyzed with a modification of our 
previously reported HPLC method [187]. Briefly, a HPLC system (Finnigan™ Surveyor 
System (Thermo Electron Corp., San Jose, CA) was used and the data was analyzed with 
the ChromQuest™ software version 4.2. The mobile phase employed was a 50:50% v/v 
mixture of solvent A (50 mM phosphoric acid) and solvent B (50 mM phosphoric acid + 
5% acetonitrile), both adjusted to pH 2.5, and pumped at a flow rate of 1 mL/min. Both 
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D-pen and glutathione were detected by UV absorption at 214 nm with retention time of 
3.1 ± 0.01 and 2.79 ± 0.01 min, respectively. Sample concentrations (µM) were obtained 
from the regression line of peak area versus standard sample concentration (µM).  These 
were calculated using a ten-point calibration curve of D-pen and glutathione dissolved in 
PBS buffer, pH 7.4.  
 
D-pen release from the conjugate under reducing conditions  
To evaluate the amount of D-pen released from the conjugate under reducing 
conditions, the gelatin-D-pen conjugate was incubated in PBS buffer, pH 6.2 and 7.4 with 
increasing concentrations of glutathione (0, 0.1, 1 and 10 mM) for 2 h at 37°C. 
Additionally, D-pen release from the conjugate at various time was also determined in 
PBS at pH 6.2 and 7.4 after incubation in the presence of 1 mM of glutathione at 37°C.  
 
Cancer cell uptake studies 
Quantitative cell uptake of free D-pen 
The quantitative cell uptake of free D-pen was investigated in HL-60 cells. Briefly, 
D-pen (100 µM) was incubated with HL-60 (1×106) cells in PBS, pH 7.4 at 37ºC in a 5% 
CO2 incubator. Cells were incubated for 1-4 h. At pre-determined time the cells were 
separated by centrifugation and the supernatant was analyzed for the remaining 
concentration of D-pen as present as either free D-pen or D-pen disulfide using the HPLC 
assay previously described [187].    
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Intracellular uptake of the conjugate 
The uptake of the fluorescein-gelatin-D-pen conjugate was determined qualitatively 
using confocal microscopy. HL-60 cells (1×105) were suspended in a 24 well plate in the 
medium alone (control), or containing either fluorescein-gelatin (fluorescein labeled 
gelatin) (control) or fluorescein-gelatin-D-pen conjugate. At 4, 24, 48 72 h post-
treatment, cells were transferred to a centrifuge tube, washed twice with PBS and 
resuspended in 200 µL fresh media. Cells were transferred onto a slide for visualizing 
using Zeiss 510 Meta Laser Scanning Confocal Microscope (Carl Zeiss, Thornwood, 
NY). Differential Interference Contrast (DIC) images, fluorescence images and the 
overlapped images taken from the microscope were visualized using the Zeiss AIM 
Viewer (Carl Zeiss, Thornwood, NY).     
Additionally to support the qualitative cell uptake of the conjugate we measured the 
lysate fluorescence of the fluorescence-gelatin-D-pen conjugate treated HL-60 cells. 
Briefly, after treatment and washing with PBS as described above the HL-60 cells were 
lysed with M-PER mammalian cell extraction reagent. Fluorescence of the cell lysate was 
measured at 485 ± 20 nm (excitation) and 520 ± 25 nm (emission). 
 
Gelatin-D-pen conjugate cytotoxicity  
HL-60 cells were plated in 48 well plates at a concentration of 20,000 cells/well. 
The cells were treated with the gelatin-D-pen conjugate (1 mg/mL), D-pen (100 µM), 
gelatin (1 mg/mL), a physical mixture of gelatin (1 mg/mL) plus D-pen (100 µM). The 
medium was replaced every two days, and no further dose of any treatment group was 
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added. Cytotoxicity was determined over a period of 10 days (on the 2, 4, 6, 8, and 10 
day) using the MTT assay.    
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism® 4 Software (GraphPad 
software Inc. San Diego, CA). Figure 6.7 was analyzed with two-way analysis of 
variance (ANOVA) followed by Berfontini’s post test, where significance was set at 
p<0.05. 
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6.4 Results and discussion 
Synthesis of gelatin-D-pen conjugate  
The gelatin-D-pen conjugate was prepared by a simple two step reaction as shown 
in Figure 6.1: i) gelatin was modified with the heterobifunctional cross-linker (sulfo-LC-
SPDP); ii) D-pen was conjugated to the modified gelatin (SPDP-gelatin) with simple 
thiol exchange. The choice of the amine-thiol reactive heterobifunctional cross-linker 
(sulfo-LC-SPDP) was based on two important properties: i) availability of amino groups 
in gelatin for chemical modification, ii) the protection of the thiol group of D-pen, 
through a reversible bond between polymer (gelatin) and the drug (D-pen). A disulfide 
bond compared to the irreversible (maleimide) bond provides potential biological 
reversibility.  
As shown in Figure 6.2 the amino group content of gelatin was reduced to 
approximately 50% of the original gelatin as the ratio of SPDP added to gelatin increased 
to 0.23% w/w. To confirm and quantify the amount of SPDP modification of gelatin in 
the process of loss of amino groups, the SPDP modified gelatin was incubated with DTT 
to release the pyridine-2-thione group. Figure 6.2 shows that approximately 3 moles of 
SPDP were conjugated per mole of gelatin as SPDP added to gelatin increased to 0.23% 
w/w. This corresponded to 20.5 ± 0.5 to 102.4 ± 1.4 µmol D-pen/g gelatin or 3.1 ± 0.07 
to 15.2 ± 0.2 mg D-pen/g gelatin as the ratio of SPDP to gelatin was increased from 0.02-
0.23% w/w (shown in Table 6.1).  
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Synthesis of fluorescein labeled gelatin-D-pen conjugate 
A fluorescein-gelatin-D-pen conjugate was synthesized for cell uptake studies. The 
degree of labeling of fluorescein on gelatin was 0.1 mole of fluorescein per mole of 
gelatin. Gelatin was labeled with fluorescein through the reaction of the NHS-Fluorescein 
with gelatin to form fluorescein labeled gelatin. The fluorescein-gelatin was then 
conjugated to D-pen as described above to form the fluorescein-gelatin-D-pen conjugate. 
Fluorescein-gelatin alone was used as a control for cell uptake studies.  
     
D-pen release in the presence of glutathione 
The stability of the disulfide bond between D-pen and gelatin was probed using 
glutathione, an endogenous reducing molecule. The intracellular glutathione 
concentration has been reported to range from 1-11 mM [459]. Therefore, in-vitro release 
studies were performed in the presence of both low (1 mM) and high (10 mM) 
concentrations of glutathione. The pH 7.4 and 6.2 were based on the reported pH of the 
early endosomal and cytosolic conditions. In the presence of 1 mM glutathione in pH 7.4, 
D-pen was completely released in 4 h, while only ~50% D-pen was released at pH 6.2 
(Figure 6.3a). As shown in Figure 6.3b, the 2 h incubation of the conjugate with 
glutathione (0.1-10 mM) at pH 7.4 resulted in the release of approximately 30%, 80% 
and 100% of D-pen in presence of 0.1, 1, and 10 mM glutathione, respectively. In 
contrast, D-pen release at pH 6.2 was approximately 5%, 20% in the presence of 0.1, 1, 
and 10 mM glutathione, respectively. D-pen and glutathione were simultaneously 
quantitated as shown in Figure 6.4. These studies underline the significance of interaction 
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of the conjugate at favorable pH and local concentration of glutathione for successful D-
pen release and the subsequent cytotoxicity.  
 
Intracellular uptake of free D-pen 
Lodemann et al. reported the inability of D-pen to cross cell membrane of 
mammalian cells [126]. The inability to be transported is likely explained by the three 
highly ionizable functional groups of D-pen. The novel HPLC assay developed provides 
accurate determination of both D-pen and D-pen disulfide. As shown in Figure 6.5 when 
the supernatant was analyzed for remaining D-pen in the supernatant at 1, 2, 3 and 4 h 
post-incubation, approximately 100% D-pen was recovered. These results support the 
previously reported studies by Lodermann et al. [126] and signify the need for developing 
a novel delivery system for D-pen to enhance intracellular delivery.    
 
Gelatin-D-pen conjugate uptake  
The intracellular uptake of the gelatin-D-pen conjugate was studied using confocal 
laser scanning microscopy in HL-60 cells. The fluorescein-gelatin-D-pen conjugate 
uptake into HL-60 cells was a slow process with maximum uptake seen at the 72 h 
(Figure 6.6a) compared to 4 h (Figure 6.6b). The conjugate was shown to accumulate in 
the cytoplasm and the distribution of the conjugate was uniform throughout the 
cytoplasm. We have confirmed the cell uptake of the conjugate by measuring the cell 
lysate fluorescence of the conjugate treated HL-60 cells (data not shown). Ofner et al. 
previously showed a similar cellular distribution and slow uptake (over 96 h) of 
fluorescein-labeled gelatin in HL-60 cells [390].  
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Conjugate cytotoxicity in HL-60 cells  
We have reported that D-pen alone in the presence of cupric sulfate was more 
cytotoxic in leukemia cells compared to breast cancer cells [190]. The data suggest that 
this may be due to the higher innate copper levels in the cultured leukemia cells 
compared to breast cancer cells (unpublished data). Therefore, the cytotoxicity of the 
conjugate was evaluated in human leukemia cells (HL-60). The cells were treated with 
gelatin and D-pen alone, a physical mixture of gelatin plus D-pen and the gelatin-D-pen 
conjugate. As the conjugate was shown to enter the cells, the differences in cytotoxicity 
of the conjugate was compared with the free gelatin and D-pen and the physical mixture 
of gelatin plus D-pen in the presence of innate levels of intracellular copper in HL-60 
cells. During the studies, media was replaced every two days. As shown in Figure 6.7, the 
conjugate exhibited significantly increased cytotoxicity compared to all the controls 
(p<0.001 on day 4 and 10 and p<0.01 on day 6 and 8, respectively). As we have reported 
earlier, the mechanism of D-pen cytotoxicity is due to the generation of H2O2 and other 
ROS in presence of copper [187, 190]. Thus, the intracellular efficacy of D-pen is 
dependent upon two important processes: i) the interaction of the conjugate with 
glutathione and the subsequent release of D-pen and ii) the interaction of the released D-
pen with the intracellular innate copper present in leukemia cells to produce its cytotoxic 
effect. We are presently investigating the intracellular D-pen release from the conjugate 
and the localization of intracellular copper to improve the conjugate anti-cancer effect.  
Other conjugates are being designed and synthesized that may increase the rate and 
extent of uptake and subsequent D-pen release. 
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6.5 Conclusions 
A novel method for the synthesis and characterization of a novel gelatin-D-pen 
conjugate is described. The disulfide bond between gelatin and D-pen in the conjugate 
provides protection of D-pen from oxidation. Additionally, the disulfide bond in the 
conjugate was shown to be biologically reversible through the complete release of D-pen 
only in the presence of biologically relevant concentration of glutathione. It was shown 
that free D-pen does not enter cells. The delivery of D-pen as a novel gelatin-D-pen 
conjugate was shown to increase the intracellular accumulation of conjugate in cancer 
cells over time, and this directly led to enhanced cytotoxicity in human leukemia cells. 
The cytotoxicity was of the conjugate in leukemia cells was sustained and significant 
compared to the physical mixture of gelatin and D-pen indicating to the importance of 
disulfide bond between gelatin and D-pen. 
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Table 6.1 
 
The effect of SPDP/gelatin concentration on the amount of D-pen conjugated to gelatin   
 
0.02                          20.5 ± 0.5                  3.1 ± 0.07
0.06                          52.8 ± 2.0                  7.8  ± 0.3
0.1                            58.8 ± 0.9                  8.7  ± 0.14
0.18                          84.3 ± 9.1                  12.6  ± 1.3
0.23                         102.4 ± 1.4                 15.3  ± 0.2
D-pen (µmol)/
gelatin (g) ± S.D
D-pen (mg)/
gelatin (g) ± S.D
SPDP/gelatin
(% w/w)
 
      Each value represents the mean ± SD (n = 3). 
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Figure 6.1 
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Figure 6.1 Schematic illustration of gelatin-D-pen conjugate synthesis.  
The amino group of gelatin was modified with the amine reactive N-hydroxysuccinimide 
(NHS) portion of sulfo-SPDP and D-pen was conjugated to the SPDP modified gelatin by 
reacting with sulfhydryl reactive 2-pyridothione 
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Figure 6.2 
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Figure 6.2 Effect of increasing SPDP concentration on the modification of gelatin.  
The amine groups and moles of SPDP conjugated to gelatin. The pyridine-2-thione assay 
was used to determine the SPDP modification of gelatin. The TNBS assay was used to 
determine the level of SPDP modification of gelatin. Each value represents mean ± SD  
(n = 3).   
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Figure 6.3 
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Figure 6.3 Release of D-pen from the gelatin-D-pen conjugate under reducing 
conditions.  
a) The gelatin-D-pen conjugate was incubated with glutathione (1 mM) at 37°C in 
phosphate buffer saline (PBS, pH 7.4 and pH 6.2) and the release of D-pen was analyzed 
with HPLC. Each value represents mean ± SD. (n = 3).  
b) The gelatin-D-pen conjugate was incubated with increasing concentration of 
glutathione (0, 0.1, 1, 10 mM) at 37°C for 2 h. D-pen release was analyzed with HPLC.  
Each value represents mean ± SD (n = 3).    
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Figure 6.4 
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Figure 6.4 HPLC chromatogram showing glutathione and D-pen elution. 
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Figure 6.5 
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Figure 6.5 Cell uptake of D-pen. D-pen (100 µM) was added to HL-60 (1×106) cells in 
PBS (pH 7.4) in a 24-well plate at 37°C in 5% CO2 incubator. Cells were separated by 
centrifugation and the supernatant was analyzed by HPLC assay for D-pen concentration. 
Data represents mean ± SD (n = 4). 
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Figure 6.6 
 
a) 
 
 
 
b) 
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Figure 6.6 Intracellular uptake of gelatin-D-pen conjugate. HL-60 cells were 
incubated with the Fluorescein labeled gelatin-D-pen conjugate at 37°C for a) 4 and b) 
72 h. Cells were washed twice with PBS and cells then suspended in phenol red free 
RPMI media. Cells were imaged by Confocal Laser Scanning Microscopy. Fluorescence 
(left), Differential Contrast (DIC) (right) and overlapped Images (bottom).  
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Figure 6.7 
 
 
 
2 4 6 8 10 2 4 6 8 10 2 4 6 8 10 2 4 6 8 10
50
75
100
125
Gelatin
Gelatin + D-pen
Gelatin-D-pen Conjugate
D-pen
***
** **
***
Time (d)
C
el
l V
ia
bi
lit
y 
(%
 c
on
tr
ol
)
C
el
l V
ia
bi
lit
y 
(%
 c
on
tr
ol
)
 
 
 
Figure 6.7 Cytotoxicity of the gelatin-D-pen conjugate in HL-60 cells. Cells (2×104)  
were incubated with gelatin alone (1 mg/mL), D-pen alone (100 µM), gelatin (1 mg/mL) 
plus D-pen (100 µM), and gelatin-D-pen conjugate (1 mg/mL) After every 2 day interval 
media was replaced with fresh media. MTT assay was performed on day 2, 4, 6, 8 and 10. 
Data represents mean ± SD (n = 6). **p<0.01 and ***p<0.001 compared to gelatin plus 
D-pen. 
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Chapter 7 
 
Copper pre-treatment of human leukemia cells augments the cytotoxicity resulting 
from D-penicillamine chelation of copper 
 
 
 
7.1 Summary  
 
The aim of present research was to investigate the effect of cupric sulfate (CuSO4) 
pre-treatment on D-penicillamine (D-pen) and gelatin-D-pen conjugate cytotoxicity in 
human leukemia cells (HL-60). The CuSO4 pretreatment resulted in reduced thiol level 
and significantly increased cellular copper content compared to untreated cells. Whereas 
both free D-pen and gelatin-D-pen conjugate lacked cytotoxicity in un-treated cells, they 
both caused concentration dependent cytotoxicity in CuSO4 pre-treated leukemia cells. 
D-pen was more cytotoxic compared to the conjugate under the conditions tested. These 
findings warrant further investigation into the role of copper (amounts and intracellular 
distribution) on D-pen mediated cytotoxicity.          
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7.2 Introduction  
 
Copper is an essential trace metal needed for the normal physiological functions in 
the body [2]. Copper acts as a co-factor for many important enzymes such as cytochrome 
c oxidase, lysyl oxidase, and superoxide dismutase [2, 3]. The human body regulates the 
copper homeostasis through a complex system of uptake and excretory pathways [36]. 
Copper influx into cells is known to be accomplished by the human copper transporter 
(hCTR1) although the exact mechanism remains to be determined [30]. hCTR1 is present 
in the plasma membrane and its ability to import copper has been reported to depend on 
temperature, pH and potassium ion concentration [461]. Once inside the cell copper binds 
to a number of pathway specific copper metallochaperones such as ATOX1, COX17 and 
CCS [30]. The metallochaperones deliver copper to various sub-cellular sites [30, 462]. 
The copper efflux from the cells is mediated by P-type ATPases, ATP7A and ATP7B 
[30]. Wilson’s disease and Menke’s disease are genetic disorders associated with 
abnormal copper homeostasis [2]. Copper has also been postulated to play a role in the 
etiology of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative 
disorders [48].  
The role of copper in cancer has been extensively investigated in the past two to 
three decades [86, 87]. Copper is now known to act as a co-factor for a number of 
important endogenous angiogenic compounds such as vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF) [86, 87]. As the importance of copper in 
angiogenesis was shown, subsequent strategies have been developed for copper targeting. 
The copper chelating agents such as D-penicillamine (D-pen) [8, 188], 
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tetrathiomolybdate [86, 87], and clioquinol [86] are at the forefront as investigative anti-
angiogenic drugs for cancer therapy.  
The serum and tumor copper levels have been shown to be significantly elevated in 
various malignancies including in leukemia patients [70, 76, 78]. Copper levels in the 
serum of patients with acute leukemia, acute lymphoid leukemia (ALL), acute 
nonlymphoid leukemia (ANLL) and chronic myelogeneous leukemia (CML) have been 
reported to be 1.3 ± 0.5 µM (p<0.01), 1.3 ± 0.5 µM (p<0.01), 1.4 ± 0.5 µM (p<0.001), 
and 1.1 ± 0.5 µM (p<0.05), respectively compared to 0.9 ± 0.2 µM in healthy individuals 
[70]. Additionally the levels of ceruloplasmin, the major copper carrying protein, have 
also been shown to be elevated in some malignancies [65]. These elevated copper levels 
have also been shown to correlate to progression and severity of malignancy [91].  
However, cancer cells in culture do not accumulate the same levels of copper as that 
of cells in-vivo [463]. Therefore, to simulate increased copper levels in cultured leukemia 
cells, HL-60 cells were pre-treated with a copper salt, cupric sulfate. Daniel and Dou 
have previously described similar cupric sulfate pre-treatment with breast cancer cells to 
study the effect of copper chelator clioquinol as an apoptosis inducer [436, 463, 464].  
Cancer cells are known to be under persistent oxidative stress [204, 294]. An 
interactive relationship between leukemia and oxidative stress has been shown [293, 
305]. Significantly increased levels of ROS such as superoxide radical and H2O2 
production has been measured in both the serum and the leukemic cells of leukemia 
patients. Significant alterations in the levels of antioxidant enzymes such as SOD, 
glutathione peroxidase, glutathione reductase, and catalase have also been reported [293, 
305]. Additionally, the increased oxidative stress has been shown to be limited to cancer 
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cells and not present in the surrounding normal cells [296]. Even though the presence of 
elevated copper levels and the increased oxidative stress in leukemia cells is well known, 
their exact interplay in the etiology of the disease still remains largely unclear. However 
these apparent differences in oxidative stress in cancer compared to normal cells may be 
exploited for selective anti-cancer therapy.  
D-pen is an extremely hydrophilic (log P: -0.39) copper chelating agent [451]. The 
intracellular uptake of D-pen is proposed to be limited due to the presence of three 
ionizable functional groups, the amino (pKa: 10.8), the carboxyl (pKa: 1.8) and the thiol 
(pKa: 7.9) [116, 123]. At physiological pH of 7.4, D-pen is expected to exist as a highly 
polar zwitterion, which would limit its intracellular uptake. We [187] have recently 
shown with the aid of a novel HPLC assay that D-pen produces hydrogen peroxide 
(H2O2) and other reactive oxygen species (ROS) through a copper catalyzed oxidation to 
D-pen disulfide. Subsequently, we also showed that the ROS produced during the copper 
catalyzed oxidation of D-pen can cause in-vitro cell cytotoxicity in human breast cancer 
and leukemia cells [190]. A direct correlation between ROS and D-pen cytotoxicity was 
also shown [190]. In these previous D-pen cytotoxicity studies [190], cupric sulfate was 
externally added with D-pen to the breast cancer and leukemia cells to examine D-pen 
cytotoxicity in presence of copper. This does not simulate the in-vivo condition of copper 
being already present either intracellularly or in the extracellular tumor 
microenvironment at elevated levels in leukemia cells. Thus, in the present studies, HL-
60 cells were pre-treated with cupric sulfate in order to simulate the elevated copper 
concentrations in-vivo and provide an improved model for examining the cytotoxic effect 
of free D-pen and of gelatin-D-pen conjugate. The novel disulfide gelatin-D-pen 
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conjugate cannot bind copper before being reduced to release D-pen. The conjugate was 
designed in order increase the intracellular D-pen concentration and to compare the 
cytotoxicity to that of free D-pen.  
Therefore, the aims of these studies were: i) pre-treat human leukemia cells (HL-60) 
for pre-determined time with cupric sulfate, ii) assess the increase in cell number, change 
in the intracellular thiol status and cellular copper concentration after the cupric sulfate 
pre-treatment, iii) assess the in-vitro cytotoxicity of free D-pen and the novel disulfide 
gelatin-D-pen conjugate in naïve cells compared to the cupric sulfate pretreated human 
leukemia cells.  
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7.3 Materials and methods 
 
Materials 
D-penicillamine, cupric sulfate, glutathione, Type B gelatin (75 bloom strength with 
100-115 mmol of carboxylic acid per 100 g of protein, an isoelectric point of 4.7-5.2, and 
an average molecular weight of 20,000-25,000 Da) were purchased from Sigma-Aldrich 
Chemical Co. (St. Louis, MO). Sulfosuccinimidyl 6-(3´(2-pyridyldithio)-propionamido) 
hexanoate (Sulfo-LC-SPDP), Coomassie Plus® Bradford Protein Assay reagent, M-PER 
mammalian cell extraction reagent, Ellman’s reagent was purchased from Pierce Biotech 
Inc. (Rockford, IL). A copper standard (1000 µg/mL) for inductively coupled plasma 
atomic absorption spectroscopy (ICP-AAS) was purchased from Fisher Scientific Co. 
(Pittsburg, PA).  Phosphate buffer saline (PBS), pH 7.4 cell culture grade was purchased 
from ATCC (Rockville, MD). All aqueous solutions were prepared in deionized distilled 
water (MilliQ®, Millipore Inc.). 
 
 Cell line and culture conditions  
The human leukemia cell line (HL-60) was purchased from American Type Cell 
Culture Collection (ATCC, Rockville, MD). Cells were routinely cultured in RPMI-1640 
media (Invitrogen, Carlsbad, CA) supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin and 10% Fetal Bovine Serum (FBS) (ATCC, Rockville, MD) and 
maintained at 37ºC in a humidified 5% CO2 incubator. Plasmocin (5 µg/mL) (InvivoGen, 
San Diego, CA) was added to the cell culture media as a prophylactic measure to prevent 
mycoplasma contamination.  
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Synthesis and purification of a gelatin-D-pen conjugate 
A Gelatin-D-pen conjugate was designed and synthesized to increase the 
intracellular concentrations of D-pen. The synthesis was performed in two steps. Briefly, 
gelatin (10 mg/mL) was incubated with increasing amounts of Sulfo-LC-SPDP for 2 h at 
room temperature in PBS, pH 7.4. Excess SPDP was separated from gelatin with 
microcon centrifugation devices (MWCO: 10 kDa). The SPDP-modified gelatin was then 
incubated with D-pen. The gelatin-D-pen conjugate was separated from the unconjugated 
D-pen with microcon centrifugal devices.          
 
Pre-treatment of human leukemia cells with cupric sulfate  
HL-60 cells were seeded at a density of 3.75×105 cells/mL in 10 mL (3.75 million 
cells) in triplicate in a 6-well plate. Cells were either incubated in media alone (un-
treated) or media containing various concentrations of cupric sulfate (10, 25, 50, and 100 
µM) for 96 h. After 96 h incubation, both naïve and the cupric sulfate treated cells were 
collected, washed twice with PBS, and then resuspended in fresh copper free media.      
 
Cellular copper determination 
 The amount of cell associated copper was analyzed as described below. Briefly, 
cells were collected, centrifuged to remove the copper containing media, and then washed 
twice with PBS, pH 7.4. The cell suspension was then suspended in 5% HNO3 and heated 
at 80ºC for 48 h under continuous stirring. The cell suspension at the end of the extraction 
process turned clear indicating that cell lysate has been completely digested. Copper 
concentration was determined by inductively coupled plasma-atomic absorption 
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spectroscopy (ICP-AAS, Varion Inc.). Yttrium was used as an internal standard. Copper 
and yttrium were analyzed at a wavelength of 327.39 and 371.03 nm, respectively. An 
eight point (10-250 ng/mL) copper standard curve was used to quantify copper 
concentration in cancer cells. Water used in the mobile phase was deionized and further 
purified with Milli-Q® Synthesis A10 Ultra Pure Water System, Millipore Ltd. (Billerica, 
MA). The 5% HNO3 dilution vehicle for the cells was used as blank in the copper 
analysis. Additionally, several known amounts of copper were spiked into leukemia cell 
lysate and copper analysis was performed to validate the extraction process. Data 
represents mean ± SD (n = 3). 
 
Cell number determination 
The number of cells was determined with trypan blue exclusion assay. Cells were 
diluted with trypan blue exclusion dye introduced into the hemacytometer for counting. 
    
Intracellular levels of thiols (-SH)    
The intracellular reduced glutathione levels were measured with 5, 5’-dithiobis-(2-
nitrobenzoic acid) (DTNB). Briefly, cupric sulfate pre-treated or naïve cells were 
collected, washed twice with ice-cold PBS buffer, and then suspended in the M-PER 
mammalian cell extraction reagent. Twenty five (25) µL of standard (glutathione) or 
samples (cell lysate) + 25 µL DTNB (0.4 mg/mL) + 150 µL of 50 mM HEPES buffer, pH 
7.4 were incubated for 10 min at room temperature and absorbance was measured at 
wavelength of 412 nm with the SynergyTM 2 multi-detection microplate reader (Biotek, 
Winooski, VT).  
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Protein assay 
The total protein content of the cell lysate was analyzed with Coomassie Plus® 
Bradford Protein Assay using glutathione as a standard.  
 
Cell viability determination 
Cell viability was measured using the 3-(4,5-dimethyl-2-yl)-2,5-diphenylteraolium 
bromide (MTT) assay. Un-treated (naïve) or cupric sulfate pre-treated HL-60 cells were 
plated at concentration of 3×104cells/well (n = 3) in a 96 well plate. Cells were treated 
with free D-pen, gelatin, gelatin plus D-pen, and gelatin-D-pen conjugate for 48 h. The 
MTT assay was performed at 48 h and absorbance was measured at a wavelength of 570 
nm with the SynergyTM 2 Multi-Detection Microplate Reader (Biotek, Winooski, VT). 
Data are reported as cell viability (% control) and corresponds to i) the percent viable 
cells after 48 h compared to the untreated (naïve) cells or ii) the percent viable cells after 
48 h compared to the cupric sulfate pre-treated cells.  
 
Statistical analysis 
Data represents mean ± standard deviation (SD) (n = 3). Statistical analysis was 
performed with two-way analysis of variance (ANOVA) followed by Bonferroni post test 
where significance was set at p<0.05 with GraphPad Prism® 4 Software (GraphPad 
software Inc. San Diego, CA).  
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7.4 Results 
The HL-60 cells were pre-treated with increasing concentrations of cupric sulfate 
(10, 25, 50 and 100 µM) for 96 h. The cupric sulfate pre-treatment groups (50 and 100 
µM) showed significantly lower (p<0.01) cell number compared to the untreated (naïve) 
HL-60 cells. As shown in Table 7.1, the fold increase in cell number was significantly 
lower (p<0.01) in 50 and 100 µM pre-treated cells (2.3 ± 0.2 and 2.2 ± 0.1) compared to 
the naïve cells (3.3 ± 0.3). The total cellular thiol content showed significant reduction 
(p<0.01) on all the cupric sulfate pre-treatment groups (Figure 7.1). The total cellular 
thiol concentration after 96 h was 103 ± 4.2 nmol/mg protein in naïve cells compared to 
85.9 ± 5.6, 84.9 ± 3.7, 88.3 ± 9.0, and 77.4 ± 10.1 nmol/mg protein for the 10, 25, 50 and 
100 µM cupric sulfate pre-treatment group, respectively. Whereas the total cellular 
copper content significantly increased from the baseline levels after 96 h of 45.6 ± 12.1 
ng in naïve cells to 131.9 ± 58.8 ng (p<0.01), 92.7 ± 12.6 ng, 220.5 ± 61.2 ng (p<0.001), 
335.1 ± 28.0 ng (p<0.001) in the 10, 25, 50 and 100 µM cupric sulfate pre-treatment 
groups, respectively. After 96 h pre-treatment, when the ratio of the amount of cellular 
copper was normalized against the total number of both naïve and pre-treated cells as 
shown in Figure 7.1, the copper (ng) per million cells in 50 and 100 µM pre-treatment 
groups were shown to have significantly higher (p<0.01) copper levels compared to the 
naïve cells. It should be noted that the studies with all the pre-treatment groups including 
the naïve cells were performed after washing the cells twice with PBS to remove any 
external copper associated with cells and suspending the cells in fresh copper free media.   
The naïve and the copper pre-treated leukemia cells were then incubated with 
increasing concentrations of either free D-pen (Table 7.2a), D-pen plus cupric sulfate 
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(Figure 7.2), the gelatin-D-pen conjugate (Table 7.3a) and a physical mixture of gelatin 
plus D-pen (Table 7.3b). Cytotoxicity assay was performed after 48 h. The free D-pen did 
not cause any significant toxicity in naïve HL-60 cells (Table 7.2a). This was most likely 
due to the inability of D-pen to enter the cancer cells, and thus failure to bind any 
endogenous intracellular copper [126]. It should be noted that endogenous copper was 
analyzed in the culture media used in these studies and was found to be undetectable 
(below the detection limit of copper with atomic absorption spectroscopy of 10 ng/mL). 
In contrast, when increasing concentrations of free D-pen was incubated with cupric 
sulfate pre-treated cells, concentration dependent cytotoxicity was observed in all pre-
treated groups (Table 7.2a). The IC50 for free D-pen in cupric sulfate (10 µM) pre-treated 
HL-60 cells was 131.8 ± 3.0 µM. These results were contrary to expectations as free D-
pen would still not be able to interact with elevated level of intracellular copper. 
However, the results could be explained with the copper efflux phenomena to the copper 
free media once the copper pre-treatment media is substituted with the copper free media. 
When free D-pen is added to the cells, it interacts with this effluxed copper and results in 
the extracellular H2O2 generation which causes the observed cytotoxicity. The copper 
efflux phenomenon from cancer cells has been verified once they are removed from 
copper containing media (data not shown). To confirm that D-pen would be cytotoxic in 
presence of cupric sulfate present in culture media, cupric sulfate (10 µM) was 
simultaneously added with increasing concentrations of D-pen to naïve HL-60 cells. As 
shown in Figure 7.2, this resulted in concentration dependent cytotoxicity in naïve HL-60 
cells with D-pen IC50 of 102.1 ± 1.0 µM. As copper acts as a catalyst in the process of 
ROS generation from D-pen oxidation, the D-pen cytotoxicity can be proposed to be 
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independent of copper concentration. The cytotoxicity would be dependent on two 
factors: D-pen concentration and the availability of copper to catalyze the oxidation. This 
was experimentally supported by the comparable D-pen IC50 in cupric sulfate pre-treated 
cells of 131.8 ± 3.0 µM and 102.1 ± 1.0 µM in the cells when cupric sulfate was 
simultaneously added with D-pen.  
To improve the intracellular uptake of D-pen, a Gelatin-D-pen conjugate was 
successfully synthesized and characterized for D-pen release in the presence of 
glutathione [465]. The conjugate has a disulfide bond between gelatin and D-pen. Due to 
the lack of appreciable levels of glutathione (major biological reducing agent) in the 
culture media, the reduction of the conjugate in media was not expected. The conjugate 
has been shown to enter the cells slowly over a period of 48 to 72 h time period [465]. In 
the present studies the effect of treatment of gelatin-D-pen conjugate, gelatin alone and 
the physical mixture of gelatin plus D-pen (which contains gelatin and D-pen 
concentrations equivalent to the conjugate) in naïve and cupric sulfate pre-treated HL-60 
cells was examined. As shown in the Table 7.3a and b, free D-pen, gelatin-D-pen 
conjugate and gelatin plus D-pen showed no cytotoxicity in the naïve HL-60 cells. While 
gelatin alone had no cytotoxic effect in either the naïve and the cupric sulfate pre-treated 
group (data not shown), the conjugate exhibited modest cytotoxicity of ~55% at the 
highest gelatin concentrations (2000 µg/mL) for almost all the pre-treated groups (except 
100 µM cupric sulfate pre-treated cells) (Table 3a), while the gelatin plus D-pen 
treatment resulted in the considerable cytotoxicity in all pre-treated groups (Table 3b) 
which was comparable to that seen with free D-pen. These data suggest that gelatin alone 
is not cytotoxic under the conditions tested.          
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7.5 Discussion 
Leukemia patients have been reported to have significantly elevated copper levels 
compared to normal individuals [70, 76]. Additionally, the leukemia cells from patients 
have been shown to have increased level of H2O2, superoxide anion and enhanced levels 
of antioxidants such as superoxide dismutase and glutathione peroxidase which are 
hallmarks of cells being under increased oxidative stress [293]. This cellular imbalance 
between the oxidant-antioxidant species in the favor of oxidant environment in cancer 
cells supports the current emerging interest in the use of reactive oxygen species (ROS) 
in selective treatment in cancer [19, 316].  
We have previously shown that copper chelator D-pen in the presence of cupric 
sulfate caused a concentration dependent cytotoxicity in leukemia cells [190] We have 
also shown that leukemia cells were more sensitive to the D-pen plus cupric sulfate 
cytotoxicity compared to breast cancer cells (MCF-7, BT474) [190]. Copper was 
externally added in the above studies because: 1) D-pen cannot cross cell membranes and 
thus cannot interact with intracellular copper, and 2) cancer cells in culture are known not 
to accumulate to similar levels of copper as observed in-vivo [436, 463]. Therefore, in 
these present studies we pre-treated the HL-60 cells with cupric sulfate in order to 
simulate the in-vivo condition of elevated copper levels. The effect cupric sulfate pre-
treatment on the sensitivity of HL-60 to D-pen induced ROS mediated cytotoxicity was 
investigated. The cupric sulfate pre-treatment of cancer cells has been previously reported 
to simulate in-vivo levels [19]. Additionally, it has been reported that when cells in 
culture are exposed to copper salts they effectively take up copper; however, the cells 
were also shown to efflux certain fraction of copper when copper salts were removed 
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[466]. Katano et al. showed that copper was effluxed from ovarian cancer cell lines in 
culture after they were removed from copper containing media [467]. This process of 
copper efflux from cultured cells has not been extensively studied. However, it has been 
proposed to depend on two important factors: the copper concentration employed during 
the pre-treatment studies and the cell type. The process of copper efflux could explain the 
cytotoxicity of free D-pen in the present studies. This would allow free D-pen to quickly 
chelate copper and cause the H2O2 mediated cytotoxicity, as we have elucidated 
previously [190]. Copper acts as a catalyst in the mechanism of ROS generation which 
leads to the D-pen cytotoxicity [187, 190]. Therefore, D-pen cytotoxicity should be solely 
dependent on D-pen concentration and copper availability for catalysis although 
independent of the copper concentration. This was clearly supported by the comparable 
IC50 of D-pen in HL-60 cells when D-pen was added with cupric sulfate and D-pen added 
to the cupric sulfate pre-treated HL-60 cells. However, the copper concentration in cupric 
sulfate pre-treated cells was more than 100-fold less compared to when cupric sulfate was 
added with D-pen. 
The moderate cytotoxicity of the disulfide gelatin-D-pen conjugate may be 
explained as follows: i) slow uptake of the conjugate into the leukemia cells (data not 
shown), and ii) an additional step of disulfide bond reduction to release D-pen for 
biological activity, iii) the inability of the gelatin-D-pen conjugate to bind copper [465]. 
Thus, the moderate conjugate cytotoxicity seen against the HL-60 cells is perhaps an 
indication of a slower process compared to free D-pen. In order to support these 
differences in the cytotoxicity of free D-pen versus the conjugate we are currently 
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investigating the intracellular accumulation, cellular localization and the intracellular D-
pen release from the conjugate.  
In conclusion, these results show that cellular copper levels in the cultured leukemia 
cells could be elevated with pre-treatment with copper salts. The copper levels in cultured 
leukemia cells were shown to be significantly lower than the cupric sulfate pre-treated 
cells.  In the present study under the conditions of cupric sulfate pre-treatment the copper 
chelator D-pen was shown to be cytotoxic selectively in the cupric sulfate pre-treated but 
not in the naïve leukemia cells indicating the need for copper availability for its 
cytotoxicity. The current copper pre-treatment method needs optimization so that more 
biologically relevant in-vitro model of copper uptake could be developed.     
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Table 7.1 The effect of cupric sulfate pretreatment on HL-60 cells. The changes in 
cell number, total cellular thiol status, total copper levels are compared between the un-
treated (naïve) and the cupric sulfate pre-treated HL-60 after 96 h incubation. Data 
represents mean ± SD (n = 3). **p<0.01 and ***p<0.001 compared to untreated (naïve) 
cells. 
 
 
 
  
CuSO4 
(µM) 
 
Fold increase in 
cell number     
(millions) 
 
Cellular thiol 
(nmol/mg cellular 
protein) 
 
Cellular Copper 
(ng) 
  
 0 
 
 3.25 ± 0.34 
 
103.4  ±  4.16 
 
45.6  ±  12.1 
 
10 
 
2.7 ± 0.42 
 
85.9  ±  5.6** 
 
131.9  ±  58.8** 
 
25 
 
2.6 ± 0.49 
 
84.9  ±  3.7** 
 
92.7  ±  12.6 
 
50 
 
2.33 ± 0.17** 
 
88.3  ±  9.05** 
 
220.5 ±  61.2*** 
 
100 
 
2.15 ± 0.13** 
 
77.44  ±  10.1** 
 
335.1 ± 28.0*** 
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Table 7.2 In-vitro cytotoxicity of D-pen in HL-60 cells. Un-treated (naïve) and cupric 
sulfate (10, 25, 50, 100 µM) pre-treated cells were plated at concentration of 3×104 
cells/well. Cells were treated with D-pen (2-200 µM) for 48 h. Data represents mean ± 
SD (n = 3) *p<0.05, **p<0.01, ***p<0.001 compared to un-treated cells for the 
corresponding D-pen concentration. 
 
 
 
  % viability HL-60 cells (mean ±  SD) 
D-pen 
(µM) 
 
Un-treated 
(naïve) 
 
CuSO4 
(10 µM) 
Pre-treated
CuSO4 
(25 µM) 
pre-treated 
CuSO4 
(50 µM) 
pre-treated 
CuSO4 
(100 µM) 
Pre-treated
2 111.2 ± 29 86.2 ± 18.2 85.4 ± 11.2 73.3 ± 9.4** 97.2 ± 3.5 
10 90.7 ± 24 69.6 ± 9.4 79.4 ± 5.7 70.0 ± 12.3  86.8 ± 28.0 
50 91.1 ± 12.6 65.6 ± 6.9 60.0 ± 5.0* 58.2 ± 2.4* 86.2 ± 13.0 
100 99.7 ± 16.8 52.2 ± 6.9*** 48.2 ± 7.5*** 45.6 ± 3.9*** 75.5 ± 5.2 
200 85.7 ± 10.7 39.9 ± 1.5*** 22.6 ± 8.0*** 35.2 ± 3.6*** 43.5 ± 2.0***
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Table 7.3 a) In-vitro cytotoxicity of the gelatin-D-pen conjugate in HL-60 cells. a)   
naïve and cupric sulfate (10, 25, 50, 100 µM) pre-treated HL-60 cells were plated at a 
concentration of 3×104 cells/well. Cells were treated with gelatin-D-pen conjugate (20-
2000 µg/mL) for 48 h. Data represents mean ± SD (n = 3). *p<0.05 compared to un-
treated cells for the corresponding gelatin-D-pen conjugate concentration. 
                       
 
  % viability HL-60 cells (mean ± SD) 
 
Gelatin-D-pen 
conjugate 
(µg/mL) 
 
Un-treated
(naïve) 
 
CuSO4  
(10 µM)  
pre-treated  
 
CuSO4  
(25 µM) 
Pre-treated 
 
CuSO4  
(50 µM) 
pre-treated 
 
CuSO4  
(100 µM) 
pre-treated
2 84.5 ± 19.7 91.9 ± 14.0  85.1 ± 23.0 94.3 ± 4.5 99.6 ± 4.1 
10 82.4 ± 20.8 74.5 ± 10.2 78.2 ± 17.4 88.1 ± 9.8 99.1 ± 5.1 
50 83.3 ± 17.7 74.0 ± 7.6 68.8 ± 9.6 75.4 ± 7.4 87.9 ± 4.5 
100 85.9 ± 10.6 70.1 ± 9.6 57.0 ± 11.2* 76.2 ± 7.4 82.2 ± 6.5 
200 79.9 ± 3.9 53.9 ± 10.2* 53.7 ± 4.9* 52.6 ± 1.3* 76.8 ± 1.3 
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Table 7.3 b)   Naïve and cupric sulfate (10, 25, 50, 100 µM) pre-treated HL-60 cells were 
plated at a concentration of 3×104 cells/well. Cells were treated with gelatin (20-2000 
µg/mL)  plus D-pen (2-200 µM) for 48 h. Data represents mean ± SD (n = 3). *p<0.05, 
**p<0.01 and ***p<0.001 compared to the un-treated cells for corresponding gelatin plus 
D-pen concentration. 
 
 
 
 
 
 
  % viability HL-60 cells (mean ± SD) 
D-pen (µM) 
+ Gelatin 
(µg/mL) 
Un-treated 
(naïve) 
CuSO4  
(10 µM)  
pre-treated  
CuSO4  
(25 µM) 
pre-treated 
CuSO4  
(50 µM) 
pre-treated  
CuSO4  
(100 µM) 
pre-treated
2 + 20  97.1 ± 2.7 69.9 ± 20.7** 73.8 ± 3.4* 73.7 ± 10.9 100.2 ± 7.6 
10 + 100   86.5 ± 0.4 80.4 ± 9.2 78.2 ± 5.5 70.3 ± 20.2 95.9 ± 6.7 
50 + 500  90.6 ± 18.4 65.9 ± 13.3** 58.4 ± 2.9*** 58.6 ± 3.9*** 79.8 ± 6.2 
100 + 1000  93.3 ± 5.7 47.2 ± 7.6*** 38.3 ± 1.5*** 45.0 ± 3.0*** 63.0 ± 5.4***
200 + 2000   93.7 ± 8.7 40.9 ± 4.2*** 19.8 ± 2.5*** 21.2 ± 1.9*** 35.9 ± 4.8***
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Figure 7.1 The intracellular copper and thiol status after cupric sulfate pre-
treatment. Total cellular thiol content/mg protein as a result of cupric sulfate pre-
treatment and copper (ng) per million cells as a result of cupric sulfate pre-treatment. 
Data represents mean ± SD (n = 3). **p<0.01 compared to untreated (naïve) cells 
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Figure 7.2 In-vitro cytotoxicity of D-pen plus cupric sulfate in HL-60 cells Naïve HL-
60 cells were plated at a concentration of 3×104 cells/well. Cells were treated with D-pen 
(1-200 µM) plus cupric sulfate (10 µM) for 48 h. Data represents mean ± SD (n = 3). 
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Chapter 8 
 
Summary and conclusions 
 
The focus of these studies was to 1) investigate the cytotoxic anti-cancer properties 
of the copper chelating agent D-penicillamine (D-pen) through the generation of 
hydrogen peroxide (H2O2) and other reactive oxygen species (ROS), and 2) to develop 
novel delivery strategies for enhancing its intracellular uptake in order to potentially 
improve its in-vivo therapeutic efficacy as an anti-cancer agent. Therefore, the hypotheses 
driving this research were: 1) Copper catalyzed D-pen oxidation will lead to the 
concentration dependent generation of H2O2 2) H2O2 generated from D-pen in the 
presence of copper will cause oxidative stress in human cancer cells and result in 
cytotoxicity 3) A novel polymer-D-pen conjugate could be synthesized and the conjugate 
would be able to deliver D-pen intracellularly and cause cytotoxicity in cancer cells and 
4) Copper pre-treatment of human cancer cells in culture would simulate the elevated in-
vivo copper status and augment the cytotoxicity of D-pen. 
To test the generation of H2O2 as a result of D-pen oxidation a novel simple, 
sensitive and rapid HPLC assay was developed to detect and quantitate D-pen, its major 
oxidation product D-pen disulfide and H2O2 simultaneously in a single run. With the aid 
of the HPLC assay it was conclusively shown that in the presence of cupric sulfate, D-
pen was oxidized to D-pen disulfide while simultaneously generating H2O2. The ratio of 
D-pen oxidized to H2O2 generated was shown to be 2:1 mole/mole at low D-pen 
concentrations (<500 µM). At higher concentrations (1 mM), D-pen was shown to react 
with H2O2 being produced and thus the ratio of D-pen oxidized to H2O2 generated was 
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much lower. The formation of H2O2 due to D-pen oxidation was confirmed with the H2O2 
specific enzyme, catalase. Cupric sulfate at a range of concentrations (nanomolar to 
micromolar) was shown to catalyze D-pen oxidation. Also, it was shown that the rate of 
copper catalyzed D-pen oxidation was greater than that compared to iron catalyzed D-pen 
oxidation. Further, the rate of D-pen oxidation was shown to increase with temperature, 
with the rate of D-pen oxidation at 37ºC > 25ºC > 4ºC. D-pen oxidation was inhibited in 
the absence of oxygen (anaerobic) conditions even if cupric sulfate was added at 
micromolar concentrations. Copper chelator such as EDTA and the Cu(I) specific 
chelator, BCS, were shown to inhibit copper catalyzed D-pen oxidation. The inhibition of 
the oxidation in the presence of BCS suggests that Cu(II) added to the reaction in the 
form of cupric sulfate was converted to Cu(I) during its interaction with D-pen.  
To investigate the potential cytotoxicity of H2O2 being produced as a result of D-
pen oxidation, D-pen was incubated in the presence of cupric sulfate with human cancer 
cells. Breast cancer cell lines differing in their expression of HER2 protein were 
employed in these studies (MCF7: HER2 negative and BT474: HER2 positive) and 
leukemia cell lines differing in their sensitivity to anthracycline drugs (HL-60: wild type 
and resistant cell lines, HL-60/VCR (P-gp) and HL-60/ADR: (MRP1) were employed. 
Increasing concentrations of D-pen (1-400 µM) in the presence of cupric sulfate (10 µM) 
resulted in concentration dependent cytotoxicity in the wild type HL-60 cells and also in 
the mildly resistant HL-60/VCR cells, but was not cytotoxic in the highly resistant HL-
60/ADR cells. This was interesting as it suggested a relationship between the ROS 
mediated cytotoxicity and the mechanism of action of cytotoxic agents such as 
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anthracyclines. These results support the hypothesis that H2O2 and other ROS might be 
involved in the mechanism of cytotoxicity of chemotherapeutic drugs.  
Similar concentrations of D-pen in the presence of cupric sulfate were less 
cytotoxic in human breast cancer cells. The involvement of H2O2 was indirectly 
confirmed, since in the presence of catalase, D-pen mediated cytotoxicity was inhibited. 
Additionally, direct proof of intracellular H2O2 and ROS generation was shown with the 
aid of the intracellular oxidation of cell permeable, non-fluorescent H2DCFDA into 
deacetylated, oxidized, fluorescent DCF. Significantly higher DCF was shown to be 
formed in D-pen plus cupric sulfate treated cells compared to D-pen, cupric sulfate and 
un-treated cells. Additionally, a direct correlation between the intracellular ROS 
generation and the increasing D-pen concentration was also shown and this correlation 
was shown to improve over time. The total cellular thiol levels were significantly lower 
after treatment with D-pen plus cupric sulfate compared to either D-pen or cupric sulfate 
alone. It should be pointed out that the incubation of cancer cells with either D-pen or 
cupric sulfate alone did not result in any of the above cytotoxic effects. This result 
indicated that the cytotoxicity was due to the interaction of D-pen with copper.  
To improve the intracellular D-pen concentrations, a novel disulfide gelatin-D-pen 
conjugate was synthesized and characterized. D-pen is highly hydrophilic and is reported 
to be not taken up by cells. Therefore, to increase its intracellular levels, we synthesized a 
gelatin-D-pen conjugate with the aid of heterobifunctional cross-linker SPDP. The 
synthesis was performed in two steps; gelatin was modified with SPDP followed with 
conjugation with D-pen. In-vitro release of D-pen from the conjugate was examined in 
the presence of glutathione. These studies demonstrated that the disulfide bond between 
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gelatin and D-pen is biologically reversible as glutathione (10 mM) was able to release 
D-pen in 2 h. A novel modified assay was developed to analyze glutathione and D-pen 
simultaneously. While D-pen alone was shown not to be taken up by cancer cells, the 
intracellular uptake of the conjugate was clearly exhibited with confocal microscopy. The 
fluorescein-gelatin-D-pen conjugate exhibited a slow in-vitro uptake in the human 
leukemia cells, with progressive uptake seen from 48 h to 72 h. The process of cell 
uptake was similar to a fluid phase or pinocytosis process rather than the punctuate 
endocytosis observed with particulate delivery systems. However, the intracellular 
localization of the conjugate was not determined in these studies.        
To simulate the enhanced copper levels in cancer cells, human leukemia cells (HL-
60) were pre-treated with cupric sulfate for 96 h. The total cellular copper amount, cell 
number, total thiol status were evaluated after the copper pre-treatment. Copper levels 
were shown to be significantly higher after cupric sulfate treatment compared to un-
treated (naïve) cells. The copper pre-treated leukemia cells were then incubated with 
either free D-pen or gelatin-D-pen conjugate. The studies demonstrated that both the free 
D-pen and the D-pen conjugate alone were able to cause cytotoxicity selectively in the 
copper pre-treated cells and not in the naïve leukemia cells. D-pen alone exhibited 
concentration dependent cytotoxicity, while the conjugate was shown to have only 
moderate cytotoxicity. The concentration dependent cytotoxicity of free D-pen was 
explained with the aid of copper exchange between the intracellular and extracellular 
media, once the copper containing media is removed. The moderate conjugate 
cytotoxicity was explained with the aid of previously described above was slowly taken 
up in the cells and after uptake has to be reduced to release D-pen     
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In conclusion, these studies demonstrated the potential application of D-pen as 
cytotoxic anti-cancer agent. The proof of concept of D-pen to produce H2O2 both in the 
presence of cupric sulfate and in cupric sulfate pre-treated cancer cells combined with the 
successful intracellular delivery of D-pen into cancer cells with the aid of polymer 
conjugate were promising results when combined with the well documented higher 
copper levels known to be present in various malignancies. Therefore, these studies 
provide a proof of concept as well as an excellent opportunity to selectively target cancer 
cells with D-pen resulting in both copper chelation and subsequent cytotoxic effect with 
the aid of H2O2 generation as a result of the copper chelation by D-pen. 
The studies presented in the dissertation have established the mechanism of action 
of D-pen for its use as an anti-cancer agent and provided novel delivery strategies to 
improve its therapeutic effectiveness. Along these lines, future studies would focus on 
selection of improved biocompatible polymers such as poly-glutamic acid or chitosan for 
enhanced D-pen delivery. Furthermore, the mechanism of intracellular uptake and 
localization of the polymer conjugate also needs to be characterized in order to, 1) 
optimize the release and release rate of D-pen from the conjugate, and 2) the interaction 
of the released D-pen with protein-bound intracellular copper. Ultimately, in-vivo studies 
would be necessary to assess the improvement in the half-life and biological activity of 
the D-pen formulation compared to free D-pen. Combined these additional studies may 
revel further improvements or alternative formulation approaches in the delivery of D-
pen as an anti-cancer agent.    
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Appendices 
 
 
 
This section contains the following additional experiments:  
 
 
 
• Appendix A: Chemical structures of compounds employed in this dissertation 
• Appendix B: Development of a HPLC-Fluorescence assay for the determination 
of D-pen in biological samples 
• Appendix C: Preparation and characterization of D-pen nanoparticles 
• Appendix D: Synthesis of monostearyl ester of D-pen disulfide, a prodrug 
approach for the potential D-pen delivery 
• Appendix E: Preparation and characterization of the Herceptin-D-pen 
immunoconjugate  
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Appendix A 
 
 
 
Glutathione
m.w. 307.3
D-penicillamine
m.w. 149.2
D-penicillamine disulfide
m.w. 296.4
Glutathione Disulfide
m.w. 612.6  
 
 
Figure A1. Structure of thiols and disulfides employed in the studies.  
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DL-Dithiothreitol (DTT)
m.w. 154.2 Tris(2-carboxyethyl)phosphine hydrochloride(TCEP)
m.w. 286.6
Ethylenediaminetetraacetic acid
(EDTA) 
m.w. 292.2
Bathocuproinedisulfonic acid disodium salt
m.w. 564.5  
 
 
Figure A2. Structure of chelators and reducing agents used in these studies.  
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a) 
 
 
 
 
b) 
 
 
 
PDP-PE 
 
 
 
Figure A3. Structure of cross-linker and lipid used in these studies. 
a) Structure of the heterobifunctional cross-linker, Sulfosuccinimidyl 6-(3´(2-
pyridyldithio)-propionamido) hexanoate (Sulfo-LC-SPDP) m.w: 527.57, spacer arm 
Length: 15.6 Å and 
b) the functionalized phospholipid, 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine- 
N-(3-(2-pyridyldithio)propionate) (Sodium Salt) (PDP-PE) m.w: 911.2 
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a) 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
Figure A4. Mechanism of Ellman’s and TNBS assay.  
a) Mechanism of Quantification of sulfhydryl groups with 5,5'-Dithio-bis (2-nitrobenzoic 
acid) DTNB, and b) Mechanism of quantification of amino groups with trinitrobenzene 
sulfonate (TNBS) assay. 
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a) 
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b) 
 
 
 
Figure A5. Mechanism of intracellular ROS and superoxide radical assay.  
a) Mechanism of quantification of intracellular reactive oxygen species (ROS) generation 
with 2’, 7’-dichlorodihydrofluorescein diacetate (H2DCFDA) m.w: 487.3. H2DCFDA is 
deacetylated and oxidized in the presence of ROS to dichlorodihydrofluorescein (DCF) 
(λexic: 485 λemis: 525 nm) and b) the mechanism of intracellular superoxide (O2.-) 
generation with Hydroethidine (HE) (λexic: 365 λemis: 420 nm) 
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Figure A6. Structure of the amino reactive fluorescein, (NHS-Fluorescein).   
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Appendix B 
 
 
Development of a HPLC-Fluorescence assay for the determination of D-pen in 
biological samples 
 
Despite its wide use in the treatment of Wilson’s disease and rheumatoid arthritis, 
the pharmacokinetics of D-pen in humans is not well established. This is partly due to the 
lack of suitable detection methods [115, 116]. There have been a number of reports over 
the years regarding development of suitable assay for D-pen utilizing gas, cation 
exchange chromatography and radioimmunoassay [165, 171, 184, 468]. Sensitivity, 
reproducibility, time consuming are some of the limitations of these assays.  
Yusof et al. previously described an assay where D-pen was conjugated with N-
pyrenyl maleimide (NPM) through a Michael’s reaction to form a stable fluorescent D-
pen-NPM adduct (Figure B1) [171]. We have modified the assay described by Yusof et 
al. The assay we developed consisted of a HPLC system (Thermoquest) comprised of a 
model P4000, spectra pump, injection valve with 100 μL loop and a FL3000, fluorometer 
operating at an excitation/emission wavelength of 330/380 nm. The HPLC column (YMC 
Pack Pro 150 × 4.6 mm i.d.) contains 5 μm particles of C18 packing material. Peaks were 
quantified with Chromoquest®, Chromatography Workstation software. The mobile phase 
consists of 60% water, 40% acetonitrile and 1 mL/L of acetic acid, 1 ml/L ο-phosphoric 
acid. The sample injection volume is 20 μL and is eluted at a flow rate of 0.5 mL/min. 
Both the samples and standards were pre-column derivatized to form the NPM-D-
pen adduct as follows. Tris-EDTA buffer (240 μL) and 1 mM NPM (750 μL) was added 
to diluted samples (10 μL). The resulting solution was vortexed and incubated at room 
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temperature for 30 min after which it is acidified with 5 μL of 1/6 M HCl to stop the 
reaction. Samples are then filtered through 0.2 μm acrodisc and subsequently injected in 
the HPLC column. The NPM-D-pen adduct peak (retention time: 2.90 min) was 
effectively separated from NPM hydrolysis peaks (retention time: 5.75, 6.59 and 7.38 
min) within a short runtime of 12 min (Figure B2a).  
A calibration curve of D-pen was constructed by injecting 20 μL of NPM 
derivatized standards. Excellent linearity was observed when the standard curve was 
performed in either water or in rat brain homogenate. Linearity was observed over the 
entire range of concentration (15-400 ng/mL), r2 = 0.9992 and 0.9998 in water and rat 
brain homogenate, respectively (Figure B2b). The lower limit for detection was 
established to be 2 ng/mL (S/N = 3) while the lower quantitation limit was 15 ng/mL 
(S/N = 10). Inter-day and intra-day variations for the assay were <3%. Spike recovery 
studies of D-pen in rat brain homogenate were also performed in the concentration range 
of 15-400 ng/mL. Additionally, the stability of the NPM-D-pen adduct stored at 4ºC was 
investigated. Adduct was observed to be stable for at least 4 weeks with RSD <3% for all 
the concentrations analyzed (Figure B3a). Additionally, the time needed for 
derivatization reaction to be complete was confirmed as follows, D-pen was incubated 
with NPM and Tris buffer for 10, 15, 20, 30 and 40 min and reaction was stopped using 
10 µL of 1/6 M HCl, as shown in Figure B3b, the reaction was complete in 30 min.   
Although, this assay has been validated for D-pen, a discrete assay development 
for a thiol like D-pen should ideally incorporate reduction of drug from its disulfides or 
any relevant mixed disulfide to account for total D-pen. This holds true for D-pen, as it 
will most likely be present in the form of a mixed disulfide (with cysteine and/or 
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glutathione) or as D-pen disulfide in the biological samples. Therefore, reduction of D-
pen-disulfide was investigated with strong reducing agents such as Dithiothreitol (DTT) 
and Tri (2-carboxyethyl) phosphine (TCEP). DTT is a thiol containing reducing agent as 
compared to TCEP which is a non-thiol reducing agent. However, DTT and TCEP are 
known to interfere with reactions involving maleimide chemistry (derivatization of D-pen 
with NPM). TCEP was found to interfere with the derivatization reaction at all ranges 
(500 µM-50 mM) compared to DTT, which interfered only at concentrations >10 mM.  
The reduction of D-pen in the presence of excess reducing agents such as DTT was found 
to be incomplete, as a maximum of 5-10% of D-pen-disulfide could be reduced. Further 
modifications in the assay are required to optimize the assay in order to detect and 
quantify D-pen disulfide simultaneously with D-pen and other mixed D-pen disulfides. 
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Figure B1. Structure of N-pyrenyl maleimide (NPM). Structure of NPM and the 
reaction of NPM with D-pen to form fluorescently tagged NPM-D-pen derivative (λexic: 
330 and λemis: 380 nm) 
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a) 
 
 
 
 
 
 
b) 
 
 
Sample concentration 
(nM) 
 
Relative Brain 
recovery   
(n =3) 
 
% Brain 
recovery 
(n =3) 
5 1.119 111.9 ± 1.7 
10 0.954 95.4 ± 3.0 
50 0.938 93.8 ± 8.47 
200 0.958 95.8 ± 0.6 
500 0.963 96.3 ± 3.7 
1000 1.049 104.9 ± 1.3 
2000 1.016 101.6 ± 13.2 
 
 
 
Figure B2. HPLC-Fluorescence assay of D-pen. a) HPLC chromatograph of NPM-D-
pen derivative elution. b) Recovery of D-pen spiked in brain homogenate.   
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Figure B3. Stability of NPM-D-pen adduct. a) Stability of D-pen-NPM adducts (14.9-
402.3 ng/mL) stored in solution at 4ºC for 4 weeks. Data represents mean ± SD (n = 3). 
b) Effect of incubation time of D-pen with NPM on to changes in peak area.      
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Appendix C 
 
Preparation and characterization of D-pen nanoparticles 
 
C1. Preparation of D-pen nanoparticles  
In the past decade, Dr Mumper’s lab has developed a novel technology to formulate 
stable nanoparticles from microemulsion precursors. These nanoparticles have been 
shown to be successfully employed for tumor targeting [469-472], brain targeting [473, 
474], and dendritic cell targeting [469, 475-477]. The technology is based on the 
spontaneous formation of a warm microemulsion that can be used as a template to form 
nanoparticles. The formulation involves melting a pharmaceutically acceptable matrix 
polymer emulsifying wax and a surfactant polyoxyl 20-stearyl ether (Brij 78) at 50-60oC 
to form a slurry of the melted material in water under constant stirring. Simple cooling of 
the heated microemulsion results in the formation of stable nanoparticles less than 100 
nm. NPs require no further purification, and once passed through a 0.2 micron filter for 
sterilization, are ready for injection.  
Thiol (sulfhydryl, -SH) activated liposomes have been employed previously to 
attach antibodies for cell targeting [478]. We employed a similar strategy to attach D-pen 
to sulfhydryl reactive NPs. D-pen has a free sulfhydryl group that may be conjugated to 
NPs that are made to have reactive thiol group at their surface. The resulting disulfide 
bond would be stable in normal physiologic conditions, but be reduced in the reducing 
environment of the cells. In preliminary studies, sulfhydryl reactive NPs (PDP-NPs) were 
prepared with functionalized lipid, PDP-PE (1,2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine-N-(3-(2-pyridylthio)propionate); (Avanti Polar Lipids, 
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Birmingham, AL). Briefly, various amounts of PDP-PE (0-25% w/w) were added during 
the formulation of empty nanoparticle (EPs) to incorporate PDP-PE in the NPs to 
formulate PDP-NPs. The PDP-PE is thought to be incorporated in NPs according to its 
specific orientation (the hydrophobic tail is embedded in the NP core and hydrophilic 
head group outside the NP) as shown in Figure C1 a and b. To maximize PDP-PE 
loading, while at the same time maintaining the NP size below 100 nm, the PDP-PE 
loading was optimized. As seen in Figure C2, the size of the NPs increased with 
increasing PDP-PE loading. Although PDP-PE loading of 15-25% resulted in particle 
sizes <100nm, but the results showed inconsistency from batch to batch. Therefore, a 
10% w/w PDP-PE loading was selected for future studies as it resulted in NPs size 
consistently below 100nm.  
D-pen was conjugated to PDP-NPs. Briefly; freshly prepared PDP-NPs were mixed 
with excess D-pen (1 mg/mL). The pH was adjusted to 8.0 with NaOH and the reaction 
was stirred under N2 for 2 h. After 2 h, NPs were separated from the unconjugated D-pen 
using Sepharose CL-4B (15 mm × 70 mm). Particle size was measured by photon 
correlation spectroscopy (PCS) using a Coulter N4 plus Particle Sizer at 90° for 200 s.  
 
C2. Separation of free D-pen from D-pen-NPs 
As described earlier, after the incubation of excess D-pen (1 mg/mL) with the PDP-
NPs for 2 h (deduced as the time at which reaction is essentially complete from earlier 
experiments) under N2 to conjugate D-pen on the surface of PDP-NPs, the unconjugated 
D-pen was removed with gel permeation chromatography (GPC). Fractions (0.5 mL 
each) were collected from the Sepharose CL-4B column; fractions were analyzed for 
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particle intensity in the Coulter N4 Plus Submicron Particle Size Analyzer and for the D-
pen concentration with HPLC assay described below. Based on particle intensity it was 
established that NPs were eluted in fractions 3-4 (as seen in Figure C3) while free D-pen 
eluted in fractions 6-20 (based on the HPLC assay of the fractions). Therefore a complete 
separation of bound and free drug was shown to be achieved with GPC. The experimental 
conjugation of D-pen (34.8 µg/mL) for Sepharose CL-4B was similar to the theoretical 
D-pen conjugation calculated based on the amount of PDP-PE added (e.g. for 10% w/w 
PDP-PE loading, the maximum theoretical D-pen conjugation would be 34 µg/mL).   
 
C3. Stability of nanoparticles 
The stability of D-pen-NPs was evaluated in biologically relevant media (Phosphate 
buffer saline (PBS), Fetal Bovine serum (FBS), sodium chloride (NaCl) and lactose) at 0 
and 30 min. As seen in Figure C4 the particle size of the NPs remain relatively 
unchanged between 0 and 30 min. The PDP-NPs and D-pen-NPs showed an increase in 
particle size when stored at 4ºC (Figure C5a.) for 7 days. 
To ascertain the stability of disulfide bond through which D-pen was bound to the 
NPs, the D-pen-NPs were incubated for 18 h at 25ºC with PBS buffer (5 mM), pH 6.0, 
7.0 and 8.0, about 96% 92% and 85%, respectively, were still conjugated to the NPs. 
However, D-pen was shown to be cleaved from the NPs when incubated in presence of 
DTT, about 62% of D-pen was conjugated to the NPs (Table C5b).       
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a)  
 
 
Oil Phase: Emulsifying Wax (EW)
Surfactant: Polyoxyethylene 20 stearyl 
ether (Brij 78)
EW  
+ 
Surfactant   
+ H20
+ PDP-PE 
(in CHCl3)
PDP-PE  
Nanoparticles
(PDP-PE-NPs)
Evaporate
CHCl3
Heat at 
55-60°C
Add 
water
and 
continue 
heating
Cool to 
20ºC
D-pen
D-pen
D-pen
D-pen
D-pen
D-pen
N2 at 
25ºC
D-pen-NPs
 
 
 
 
 
b) 
 
 
 
 
 
 
Figure C1. Formulation of D-pen nanoparticles. a) Schematic of the formulation of D-
pen nanoparticles, b) Schematic showing the conjugation of D-pen to PDP-NPs.   
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Figure C2. Effect of PDP incorporation on the size and PI of NPs.  
a) Effect of increasing PDP-PE (% w/w) loading on NPs size (nm). Data represents mean 
± SD (n = 3). b) Effect of increasing PDP-PE loading on particle size (nm) and 
Polydispersity index of three separate nanoparticle batches. 
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Figure C3. Gel permeation chromatography (GPC) separation of free D-pen from 
D-pen-NPs. Free D-pen (fractions 6-20) from D-pen associated with the NPs (fractions 
3-4). Data represents mean ± SD (n = 3). 
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Figure C4. The short term stability of D-pen-NPs in biological media. 
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Table C1. Stability of D-pen-NPs. a) The stability of PDP-NPs and D-pen-NPs after 
storing at either 4 or 25°C for 7 days. b) The stability of D-pen bound to NPs after 
exposure to DTT at various pH.  
a) 
 
6220.533Dithiothreitol
DTT) in water
8528.033pH 8.0
(5 mM PBS)
9230.433pH 7.0
(5 mM PBS)
9633pH 6.0
(5 mM PBS)
Remaining 
D-pen (µg/mL)
Original 
D-pen (µg/mL)
31.7
% 
remaining
 
 
 
 
b) 
 
PDP-NPs                                                      88 ± 35 0.430
PDP-NPs at 4ºC for 1 day                           105 ± 32
PDP-NPs at 4ºC for 7 days                          134 ± 40
PDP-NPs at 25ºC for 1 day                         137 ± 28 0.354 
PDP-NPs at 25ºC for 7 days                        265 ± 30 0.215
D-pen-NPs                                                  108 ± 40 0.424
D-pen-NPs at 4ºC for 1 day                        126 ± 45 0.324
D-pen-NPs at 4ºC for 7 days                       158 ± 36 0.242
Particle size (nm) ± SD
0.230
0.453 
Polydispersity index
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Appendix D 
 
 
Synthesis of a monostearyl ester of D-pen disulfide, a prodrug approach for the 
potential D-pen delivery  
 
 
D-pen is highly hydrophilic compound (log P: -0.35) [448], and thus its intracellular 
uptake is very limited [126]. Recently Chvapil et al. have reported on the synthesis of 
ester derivatives of D-pen to enhance its lipophilicity [448, 451]. We have investigated 
similar strategy to conjugate D-pen disulfide with stearyl alcohol to potentially form 
monostearyl ester of D-pen-disulfide. This lipophilic D-pen disulfide would then be 
entrapped in the emulsifying wax nanoparticles. Thus, the monostearyl ester of D-pen 
disulfide could be used as a potential lipophilic prodrug for D-pen delivery. 
Briefly, mole to mole of stearyl alcohol dissolved in tetrahydrofuran was added to 
D-pen disulfide, which was then dissolved in a mixture of tetrahydrofuran and water. The 
pH of the reaction mixture was adjusted to 2.8 with the aid of H2SO4. The reaction was 
carried for 2 h at 70°C. After cooling to room temperature, a white oily precipitate was 
formed. The product was then extracted with dichloromethane/water solution to remove 
any unreacted D-pen. The dichloromethane was then removed by under nitrogen. The 
product was further dried in a rotovap to remove any dichloromethane and 
tetrahydrofuran for 8 h at 70°C. The product was then cooled to room temperature. A 
white powder was obtained. The product was confirmed to be monostearyl ester of D-pen 
disulfide by mass spectroscopy with the molecular ion peak present at 571 m/z.       
However, our concurrent in-vitro studies to examine the reduction of D-pen 
disulfide to D-pen showed that the reduction was extremely slow even in the presence of 
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millimolar concentrations of DTT, TCEP and glutathione. This led us to reevaluate our 
approach of delivering D-pen disulfide as a prodrug for D-pen. It should be noted that in-
vivo the ester prodrug of D-pen disulfide would have to be converted to D-pen disulfide 
followed by its reduction to the bioactive form D-pen. This would certainly lead to the 
released D-pen concentrations to be below the minimum effective levels, and thus the 
strategy would not a good vehicle for D-pen delivery.  
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Figure D1. Schematic of the synthesis of monostearyl ester of D-pen disulfide 
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Figure D2. Mass spectrum of the purified monostearyl ester of D-pen-disulfide. The 
mass spectrum was obtained in a negative ion mode MALDI-TOFMS 
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Appendix E 
 
 
Preparation and characterization of Herceptin-D-pen immunoconjugate 
 
 
Herceptin (Trastuzumab, Genentech, Inc.) is a humanized monoclonal antibody that 
has been reported to selectively bind with high binding affinity (Kd = 5 nM) in cell based 
assays to the extracellular domain of the human epidermal growth factor receptor 2 
protein (HER2) [479, 480]. HER2 protein overexpression has been reported in about 20 
to 30% of breast cancer patients [479]. The binding of Herceptin to HER2 receptor 
restricts the binding of growth factors needed by the breast cancer cells for growth and 
development and thus has been described to lead to cytostatic effect [480]. Herceptin is 
currently indicated either alone or in combination with chemotherapeutic agent, 
paclitaxel in HER2 positive metastatic breast cancer patients with no previous 
chemotherapy.  
Immunoconjugate has been defined as monoclonal antibodies coupled to highly 
toxic agents, including radioisotopes and toxic drugs (ineffective when administered 
systemically alone) [481, 482]. The combination of the targeting specificity of 
monoclonal antibodies with the enhanced tumor-killing power of chemotherapeutic 
agents, immunoconjugate provide a selective treatment of malignant vs. normal tissue, 
resulting in fewer toxic side effects than most conventional chemotherapeutic drugs [481, 
482]. Two radioimmunoconjugates, Ibritumomab Tiuxetan (Zevalin®) and Tositumomab-
131I (Bexxar®), and one drug conjugate, Gemtuzumab Ozogamicin (Mylotarg®) are 
currently marketed immunoconjugates.  
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Mandler et al. [483, 484] reported on the synthesis of a novel Geldanamycin-
Herceptin immunoconjugate synthesized with the aid of thiolation of Herceptin followed 
by attachment of a cytotoxic agent, geldanamycin with an irreversible maleimide bond 
[483, 484]. Bernstein [485], Hamann [486] et al. examined the CD-33 monoclonal 
antibody for the purpose of immunoconjugate synthesis, anti-CD33 antibody-
calicheamicin conjugates have been described by the authors for effective targeting of the 
cytotoxic agent, calicheamicin and treatment of leukemia.   
We decided to employ a similar strategy for the synthesis of Herceptin-D-pen 
immunoconjugate. Due to the availability of primary amino groups in lysine present in 
the heavy chain of the antibody Herceptin, it was decided to thiolate these amine groups 
to form a disulfide bond between the thiol group of D-pen and the thiol group introduced 
in Herceptin. The hypothesis was that the disulfide bond employed would be biologically 
reversible and lead to the release of D-pen under reducing conditions.  
Herceptin was a kind gift from Genentech, Inc. (San Francisco, CA) as a part of 
their Research Contracts and Reagents Program. D-pen and traut’s reagent were 
purchased from Sigma Aldrich Co. (St Louis, MO). The Herceptin-D-pen 
immunoconjugate synthesis was performed in two separate steps. Briefly, in step I 
thiolation of Herceptin was accomplished and in step II D-pen conjugation to the 
thiolated Herceptin was performed. Briefly, traut’s reagent (133.3 µM) was incubated 
with Herceptin (13.3 µM, based on IgG molecular weight of 150 kDa) in PBS-EDTA (1 
mM) buffer, pH 7.4 for 1 hr at room temperature. Traut’s reagent was in 10 fold molar 
excess to assure that on average 2-3 antibody amine groups would be thiolated 
(information from traut’s reagent thiolation protocol). After 1 hr, reaction mixture was 
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eluted through a dextran desalting column (molecular weight cut off: 5000 Da) in the 
presence of PBS-EDTA (2 mM) buffer, pH 7.4 and 10 fractions were collected. Each of 
these fractions was analyzed by Ellman’s assay to quantify thiol groups. The purified 
thiolated Herceptin was reacted with excess D-pen overnight at room temperature. The 
reaction mixture was again eluted through dextran column to separate the free D-pen or 
D-pen disulfide from Herceptin. Fractions were analyzed by coomassie assay to 
determine the antibody concentration and an HPLC assay was conducted for the 
concentrations of D-pen or D-pen disulfide. The coomassie assay confirmed the presence 
of Herceptin, thiolated Herceptin, Herceptin-D-pen conjugate in fraction 4 (void volume) 
while the HPLC assay confirmed the presence of D-pen and D-pen disulfide in the 
fractions 7-10. It should be noted that no free D-pen or D-pen disulfide was eluted in 
fractions 1-4.  
The release of D-pen from the Herceptin-D-pen immunoconjugate was investigated 
in the presence and absence of DTT. Herceptin-D-pen immunoconjugate was lyophilized 
to obtain a concentrated sample for performing in-vitro release studies. This was done in 
order to achieve concentration of D-pen or D-pen disulfide released over the HPLC 
detection limits. The in-vitro release experiments were performed in PBS (phosphate 
buffer (100 mM), with NaCl (154 mM)) pH 7.4 at 37˚C. For reducing conditions, a final 
concentration of DTT (20 mM) was employed as reducing agent in PBS and PBS alone 
was used in non-reducing conditions. Briefly, lyophilized immunoconjugate was weighed 
and resuspended in PBS as follows:1) Immunoconjugate plus DTT (20 mM) (reducing 
conditions) in PBS, 2) Immunoconjugate in PBS (non-reducing conditions), 3) DTT (20 
mM) (background control) in PBS, 4) PBS (negative control). Ellman’s and Coomassie 
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assays were performed both before and after the experiment to quantitative any reduction 
or loss of protein respectively.   
Ellman’s assay before the reduction showed no free thiol, as expected. According to 
the coomassie assay the concentration of antibody was 2.9 mg/mL. This was equivalent 
to the presence of 19 μM of antibody in the lyophilized sample. If a theoretical 
conjugation of either 2:1 or 3:1 mole/mole is assumed between D-pen and Herceptin, 
then 38 and 57 μM of D-pen was expected to be conjugated to the antibody, respectively. 
The coomassie assay showed similar concentration of antibody presence as before 
reduction, thus indicating no loss of the antibody before and after reduction. The HPLC 
assay was then performed on both reduced and non-reduced immunoconjugate as well as 
DTT and PBS. D-pen concentration in the immunoconjugate sample subjected to 
reducing environment was calculated to be 36 ± 7 μM, while immunoconjugate incubated 
with PBS (non-reducing conditions) showed 0 μM of D-pen. This experiment confirmed 
that D-pen was conjugated to the antibody and the ratio of D-pen conjugated to the 
antibody was approximately 2:1 mole/mole. The studies also showed that the disulfide 
bond between D-pen and the antibody was reduced in the presence of reducing agent 
(DTT) and thus could be potentially biologically reversible in the presence of glutathione. 
Although, the approach of synthesis of Herceptin-D-pen immunoconjugate was 
successful, there are two major obstacles in the potential in-vivo success of this delivery 
system: 1) internalization of the conjugate in the HER2 positive breast cancer cells. This 
is essential for the reduction of the disulfide bond between the antibody and D-pen, but is 
highly unlikely in the extracellular environment where the glutathione concentrations 
have been described to be 100-fold lower than that of the intracellular glutathione 
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concentrations. Based on the recently reported in-vitro studies with the Geldanamycin-
Herceptin, it is known that the internalization of Herceptin is low, quantified to be 
between 10-30% therefore this would lead to extremely low reduction of D-pen and in 
turn lead to less than minimum effective concentration being released; 2) low drug 
loading on the antibody, as only two molecules of D-pen were conjugated per antibody. 
Higher loading, although possible, could limit the binding of the antibody to HER2 which 
would lead to loss of active targeting.    
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NHC(NH2)CH2CH2CH2S-S-C(CH3)2CH(NH2)(COOH)NHC(NH2)CH2CH2CH2SH
Herceptin Thiolated Herceptin Herceptin-D-pen Immunoconjugate
Traut’s Reagent
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Figure E1. Schematic of the synthesis of Herceptin-D-pen immunoconjugate. 
Herceptin is thiolated with the aid of traut’s reagent, followed by its conjugation with D-
pen to form a stable disulfide conjugate. 
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Figure E2. Gel Permeation column (GPC) separation of Herceptin, thiolated 
Herceptin or the Herceptin-D-pen immunoconjugate.  
a) Coomassie assay of fractions showing the elution of Herceptin in fraction 4.  
b) Ellman’s assay on all fractions, showing thiolated Herceptin elution in fraction 4.   
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Figure E3. In-vitro release of D-pen from the Herceptin-D-pen immunoconjugate in 
non-reducing conditions and reducing (in presence of DTT: 20 mM) conditions after 2 
h at room temperature. The D-pen concentration was analyzed with a HPLC assay.  
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